U.S. patent application number 16/172197 was filed with the patent office on 2019-05-09 for modulators of cellular adhesion.
This patent application is currently assigned to SARcode Bioscience Inc.. The applicant listed for this patent is SARcode Bioscience Inc.. Invention is credited to Kenneth BARR, Johan D. OSLOB, Wang SHEN, Min ZHONG.
Application Number | 20190134022 16/172197 |
Document ID | / |
Family ID | 34576803 |
Filed Date | 2019-05-09 |
View All Diagrams
United States Patent
Application |
20190134022 |
Kind Code |
A1 |
SHEN; Wang ; et al. |
May 9, 2019 |
MODULATORS OF CELLULAR ADHESION
Abstract
The present invention provides compounds having formula (I):
##STR00001## and pharmaceutically acceptable derivatives thereof,
wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as
described generally and in classes and subclasses herein, and
additionally provides pharmaceutical compositions thereof, and
methods for the use thereof for the treatment of disorders mediated
by the CD11/CD18 family of cellular adhesion molecules (e.g.,
LFA-1).
Inventors: |
SHEN; Wang; (San Mateo,
CA) ; BARR; Kenneth; (Boston, MA) ; OSLOB;
Johan D.; (Sunnyvale, CA) ; ZHONG; Min;
(Foster City, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SARcode Bioscience Inc. |
Brisbane |
CA |
US |
|
|
Assignee: |
SARcode Bioscience Inc.
Brisbane
CA
|
Family ID: |
34576803 |
Appl. No.: |
16/172197 |
Filed: |
October 26, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14939600 |
Nov 12, 2015 |
10124000 |
|
|
16172197 |
|
|
|
|
13969968 |
Aug 19, 2013 |
9216174 |
|
|
14939600 |
|
|
|
|
13223557 |
Sep 1, 2011 |
|
|
|
13969968 |
|
|
|
|
13020992 |
Feb 4, 2011 |
8071617 |
|
|
13223557 |
|
|
|
|
12537147 |
Aug 6, 2009 |
7928122 |
|
|
13020992 |
|
|
|
|
11934049 |
Nov 1, 2007 |
7790743 |
|
|
12537147 |
|
|
|
|
10982463 |
Nov 5, 2004 |
7314938 |
|
|
11934049 |
|
|
|
|
60560517 |
Apr 8, 2004 |
|
|
|
60517535 |
Nov 5, 2003 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 19/02 20180101;
C04B 35/632 20130101; A61P 37/00 20180101; A61P 31/18 20180101;
A61P 11/06 20180101; C07D 409/14 20130101; A61P 7/06 20180101; A61P
11/00 20180101; A61P 17/02 20180101; A61P 17/00 20180101; A61P
17/06 20180101; A61P 19/04 20180101; A61P 21/02 20180101; A61K
45/06 20130101; A61P 7/00 20180101; A61P 11/16 20180101; C07D
217/16 20130101; A61P 1/00 20180101; A61P 3/10 20180101; A61P 37/02
20180101; C07D 405/12 20130101; C07D 405/14 20130101; A61K 31/506
20130101; C07D 401/12 20130101; A61P 17/04 20180101; A61P 37/08
20180101; C07D 231/56 20130101; C07D 403/14 20130101; A61P 9/00
20180101; A61K 31/472 20130101; C07D 217/26 20130101; C07D 217/06
20130101; C07D 409/12 20130101; A61P 21/00 20180101; A61P 27/02
20180101; A61P 35/00 20180101; A61P 43/00 20180101; C07D 401/06
20130101; C07D 401/14 20130101; C07D 403/12 20130101; A61P 5/14
20180101; A61P 9/08 20180101; A61P 29/00 20180101; A61K 31/4725
20130101; A61K 31/517 20130101; A61P 35/04 20180101; A61P 25/00
20180101; A61P 1/04 20180101; A61P 31/04 20180101; A61P 21/04
20180101; A61P 37/06 20180101; C07D 405/06 20130101; A61P 9/10
20180101; A61P 25/28 20180101; A61P 31/06 20180101 |
International
Class: |
A61K 31/4725 20060101
A61K031/4725; A61K 31/517 20060101 A61K031/517; C04B 35/632
20060101 C04B035/632; C07D 401/06 20060101 C07D401/06; C07D 405/14
20060101 C07D405/14; C07D 217/16 20060101 C07D217/16; C07D 217/26
20060101 C07D217/26; A61K 31/472 20060101 A61K031/472; A61K 45/06
20060101 A61K045/06; C07D 409/14 20060101 C07D409/14; C07D 409/12
20060101 C07D409/12; C07D 405/12 20060101 C07D405/12; C07D 405/06
20060101 C07D405/06; C07D 403/14 20060101 C07D403/14; C07D 403/12
20060101 C07D403/12; C07D 401/14 20060101 C07D401/14; C07D 401/12
20060101 C07D401/12; C07D 231/56 20060101 C07D231/56; C07D 217/06
20060101 C07D217/06; A61K 31/506 20060101 A61K031/506 |
Claims
1-75. (canceled)
76. A method for treatment of an inflammatory or immune related
disorder in a subject comprising topically administering to said
subject in need thereof a formulation comprising an LFA-1
antagonist and a pharmaceutically acceptable excipient, wherein the
LFA-1 antagonist comprises a compound of Formula I or its
pharmaceutically acceptable salt or ester, wherein ##STR00217##
wherein R.sup.1 and R.sup.2 are each independently hydrogen,
--(CH.sub.2).sub.mOH, --(CH.sub.2).sub.maryl,
--(CH.sub.2).sub.mheteroaryl, wherein m is 0-6,
--CH(R.sup.1A)(OR.sup.1B), --CH(R.sup.1A)(NHR.sup.1B), U-T-Q, or an
aliphatic, alicyclic, heteroaliphatic or heteroalicyclic moiety
optionally substituted with U-T-Q, wherein U is absent, --O--,
---S(O).sub.0-2--, --SO.sub.2N(R.sup.1A), --N(R.sup.1A)--,
--N(R.sup.1A)C(.dbd.O)--, --N(R.sup.1A)C(.dbd.O)--O--,
--N(R.sup.1A)C(.dbd.O)--N(R.sup.1B)--, --N(R.sup.1A)--SO.sub.2--,
--C(.dbd.O)--, --C(.dbd.O)--O--, --O--C(.dbd.O)--, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, --C(.dbd.O)--N(R.sup.1A)--,
--O--C(.dbd.O)--N(R.sup.1A)--, --C(.dbd.N--R.sup.1E)--,
--C(.dbd.N--R.sup.1E)--O--, --C(.dbd.N--R.sup.1E)--N(R.sup.1A)--,
--O--C(.dbd.N--R.sup.1E)--N(R.sup.1A)--,
--N(R.sup.1A)C(.dbd.N--R.sup.1E)--,
--N(R.sup.1A)C(.dbd.N--R.sup.1E)--O--,
N(R.sup.1A)C(.dbd.N--R.sup.1E)--N(R.sup.1B)--,
-P(.dbd.O)(OR.sup.1A)--O--, or -P(.dbd.O)(R.sup.1A)--O--; T is
absent, an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety; and Q is hydrogen, halogen, cyano,
isocyanate, --OR.sup.1B, --SR.sup.1B; --N(R.sup.1B).sub.2,
--NHC(.dbd.O)OR.sup.1B, --NHC(.dbd.O)N(R.sup.1B).sub.2,
--NHC(.dbd.O)R.sup.1B, --NHSO.sub.2R.sup.1B,
--NHSO.sub.2N(R.sup.1B).sub.2, --NHSO.sub.2NHC(.dbd.O)OR.sup.1B,
--NHC(.dbd.O)NHSO.sub.2R.sup.1B, --C(.dbd.O)NHC(.dbd.O)OR.sup.1B,
--C(.dbd.O)NHC(.dbd.O)R.sup.1B,
--C(.dbd.O)NHC(.dbd.O)N(R.sup.1B).sub.2,
--C(.dbd.O)NHSO.sub.2R.sup.1B,
--C(.dbd.O)NHSO.sub.2N(R.sup.1B).sub.2,
--C(.dbd.S)N(R.sup.1B).sub.2, --SO.sub.2R.sup.1B,
--SO.sub.2--O--R.sup.1B, --SO.sub.2--N(R.sup.1B).sub.2,
--SO.sub.2--NHC(.dbd.0)OR.sup.1B,
--SO.sub.2--NHC(.dbd.O)--N(R.sup.1B).sub.2,
--SO.sub.2--NHC(.dbd.O)R.sup.1B, --O--C(.dbd.O)N(R.sup.1B).sub.2,
--O--C(.dbd.O)R.sup.1B, --O--C(.dbd.O)NHC(.dbd.O)R.sup.1B,
--O--C(.dbd.O)NH--SO.sub.2R.sup.1B, --O--SO.sub.2R.sup.1B, or an
aliphatic heteroaliphatic, aryl or heteroaryl moiety, or wherein
R.sup.1 and R.sup.2 taken together are an alicyclic or heterocyclic
moiety; wherein each occurrence of R.sup.1A and R.sup.1B is
independently hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl
moiety, --COR.sup.1C, or --CONR.sup.1CR.sup.1D; wherein each
occurrence of R.sup.1C and R.sup.1D is independently hydrogen,
hydroxyl, or an aliphatic, heteroaliphatic, aryl, heteroaryl,
alkylaryl or alkylheteroaryl moiety; and R.sup.1E is hydrogen, an
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety, --CN, --OR.sup.1C,
--NR.sup.1CR.sup.1D or --SO.sub.2R.sup.1C; R.sup.3 is
--C(.dbd.O)OR.sup.3A, --C(.dbd.O)H, --CH.sub.2OR.sup.3A,
--CH.sub.2O--C(.dbd.O)-alkyl, --C(.dbd.O)NH(R.sup.3A),
--CH.sub.2X.sup.0; wherein each occurrence of R.sup.3A is
independently hydrogen, a protecting group, an aliphatic,
alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl,
alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl moiety, or R.sup.3A, taken together with
R.sup.1 or R.sup.2, forms a heterocyclic moiety; wherein X.sup.0 is
a halogen selected from F, Cl, Br or I; R.sup.4, for each
occurrence, is independently hydrogen, halogen, --CN, --NO.sub.2,
an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety, or is -GR.sup.G1
wherein G is --O--, --S--, --NR.sup.G2--, --CO--, --SO--,
--SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--,
--OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic,
alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl,
alkylaryl or alkylheteroaryl moiety; n is an integer from 0-4;
AR.sup.1 is a monocyclic or polycyclic aryl, heteroaryl, alkylaryl,
alkylheteroaryl, alicyclic or heterocyclic moiety; A, B, D and E
are connected by single bonds; wherein D is N and each occurrence
of A, B, and E is independently CHR.sup.i wherein each occurrence
of R.sup.i is independently hydrogen, halogen, --CN, --NO.sub.2, an
aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety, or is -GR.sup.G1
wherein G is --O--, --S--, --NR.sup.G2--, --CO--, --SO--,
--SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--,
--OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic,
alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl,
alkylaryl or alkylheteroaryl moiety, or any two adjacent
occurrences of R.sup.i, taken together, represent an alicyclic,
heteroalicyclic, aryl, or heteroaryl moiety; p is an integer from
0-4; and L is C.dbd.O or a substituted or unsubstituted
C.sub.1-6alkylidene or C.sub.2-6alkenylidene chain wherein up to
two non-adjacent methylene units are independently optionally
replaced by --C(.dbd.O)--.
77. The method of claim 76, wherein the LFA-1 antagonist comprises
a compound of Formula I' or its pharmaceutically acceptable salt or
ester, having the following structure: ##STR00218## wherein
R.sup.4A and R.sup.4B are independently a halogen selected from F,
Cl, Br or I; and R.sup.B1, R.sup.B2 and R.sup.E are independently
hydrogen or substituted or unsubstituted lower alkyl.
78. The method of claim 77, wherein the LFA-1 antagonist has one of
the following formulae: ##STR00219## ##STR00220##
79. The method of claim 76, wherein the compound is present in an
amount effective to modulate adhesion between intracellular
adhesion molecules and the leukocyte integrin family of
receptors.
80. The method of claim 76, wherein the compound is present in an
amount effective to antagonize CD11/CD18 receptors associated with
leukocytes.
81. The method of claim 76, wherein the LFA-1 antagonist is a
sodium, potassium, lithium, magnesium, or calcium salt.
82. The method of claim 76, wherein the formulation is in the form
of an ointment, paste, cream, lotion, gel, powder, solution, spray,
inhalant, patch, suspension, emulsion, crystalline form, oil,
plaster, liposome, microemulsion, or buffered solution.
83. The method of claim 76, wherein the excipient is selected from
the group consisting of alcohols, quaternary amines, organic acids,
parabens, phenols, ascorbic acid, ascorbic acid esters, sodium
bisulfite, butylated hydroxytoluene, butylated hydroxyanisole,
tocopherols, chelating agents, glycerine, sorbitol, polyethylene
glycols, urea, propylene glycol, citric buffer, hydrochloric
buffer, lactic acid buffer, quaternary ammonium chlorides,
cyclodextrins, benzyl benzoate, lecithin, polysorbates, vitamin E
oil, allatoin, dimethicone, glycerin, petrolatum, zinc oxide, and
combinations thereof.
84. The method of claim 76, further comprising a topical
penetration enhancer.
85. The method of claim 84, wherein the penetration enhancer is
triglycerides, aloe compositions, ethyl alcohol, isopropyl alcohol,
octolyphenylpolyethylene glycol, oleic acid, polyethylene glycol
400, propylene glycol, N-decylmethylsulfoxide, fatty acid esters,
N-methylpyrrolidone, or combinations thereof.
86. The method of claim 76, further comprising at least one
additional therapeutic agent, wherein the additional therapeutic
agent is selected from the group consisting of an anti-inflammatory
agent, painkillers, antinausea medications, anti-sickness drugs, a
MAC-1 modulator, and an LFA-1 modulator.
87. The method of claim 76, wherein the formulation is topically
applied to skin or eyes.
88. The method of claim 76, wherein the inflammatory or immune
disorder is psoriasis, responses associated with inflammatory bowel
disease, Crohn's disease, ulcerative colitis, dermatitis,
meningitis, encephalitis, uveitis, eczema, asthma, conditions
involving infiltration of T-cells and chronic inflammatory
responses, skin hypersensitivity reactions, artherosclerosis,
autoimmune diseases, rheumatoid arthritis, systemic lupus
erythematosus (SLE), diabetes mellitus, multiple sclerosis,
Reynaud's syndrome, autoimmune thyroiditis, experimental autoimmune
encephalomyelitis, Sjorgen's syndrome, juvenile onset diabetes,
immune responses associated with delayed hypersensitivity mediated
by cytokines and T-lymphocytes, sarcoidosis, polymyositis,
granulomatosis, vasculitis, pernicious anemia, diseases involving
leukocyte diapedeses, CNS inflammatory disorder, multiple organ
injury syndrome secondary to septicaemia or trauma, autoimune
hemolytic anemia, myasthemia gravis, antigen-antibody complex
mediated diseases, transplantations, HIV, rhinovirus infection, or
pulmonary fibrosis.
89. The method of claim 79, wherein said intracellular adhesion
molecules are selected from ICAM-1, -2 and -3.
Description
PRIORITY
[0001] This application claims priority under 35 U.S.C. .sctn. 120
as a continuation of U.S. application Ser. No. 13/020,992, filed
Feb. 4, 2011 (pending), which is a continuation of U.S. application
Ser. No. 12/537,147, filed Aug. 6, 2009, issued as U.S. Pat. No.
7,928,122, which is a continuation of U.S. application Ser. No.
11/934,049, filed Nov. 1, 2007, issued as U.S. Pat. No. 7/790,743,
which is a divisional application of U.S. application Ser. No.
10/982,463, filed Nov. 5, 2004, issued as U.S. Pat. No. 7,314,938,
which claims the benefit under 35 U.S.C. .sctn. 119(e) of U.S.
Provisional Application Ser. Nos. 60/560,517, filed Apr. 8, 2004
and 60/517,535, filed Nov. 5, 2003; the contents of each
application are incorporated herein by reference in their
entirety.
BACKGROUND OF THE INVENTION
[0002] Research conducted over the last decade has helped elucidate
the molecular events attending cell-cell interactions in the body,
especially those events involved in the movement and activation of
cells in the immune system. See generally, Springer, T., Nature,
1990, 346, 425-434. Cell surface proteins, and especially the
Cellular Adhesion Molecules ("CAMs") and "leukointegrins",
including LFA-1, MAC-1 and gp150.95 (referred to as CD18/CD11a,
CD18/CD11b, and CD18/CD11c, respectively) have correspondingly been
the subject of pharmaceutical research and development having as
its goal the intervention in the processes of leukocyte
extravasation to sites of injury and leukocyte movement to distinct
targets. For example, it is presently believed that prior to the
leukocyte extravasation, which is a mandatory component of the
inflammatory response, activation of integrins constitutively
expressed on leukocytes occurs and is followed by a tight
ligand/receptor interaction between integrins (e.g., LFA-1) and one
or several distinct intercellular adhesion molecules (ICAMs)
designated ICAM-1, ICAM-2, ICAM-3 or ICAM-4 which are expressed on
blood vessel endothelial cell surfaces and on other leukocytes. The
interaction of the CAMs with the leukointegrins is a vital step in
the normal functioning of the immune system. It is believed that
immune processes such as antigen presentation, T-cell mediated
cytotoxicity and leukocyte extravasation all require cellular
adhesion mediated by ICAMs interacting with the leukointegrins. See
generally Kishimoto, T. K.; Rothlein, R. R. Adv. PharmacoL. 1994,
25, 117-138 and Diamond, M.; Springer, T. Current Biology, 1994, 4,
506-532.
[0003] Clearly, because of the role that the interaction of the
CAMs and the leukointegrins plays in the immune response, it would
be desirable to modulate these specific interactions to achieve a
desired therapeutic result (e.g., inhibition of the interaction in
the event of an overactive immune response). Significantly, it has
been demonstrated that the antagonism of the interaction between
the CAMs and the leukointegrins can be realized by agents directed
against either component. Specifically, blocking of the CAMs, such
as for example ICAM-1, or the leukointegrins, such as for example
LFA-1, by antibodies directed against either or both of these
molecules effectively inhibits inflammatory responses. In vitro
models of inflammation and immune response inhibited by antibodies
to CAMs or leukointegrins include antigen or mitogen-induced
lymphocyte proliferation, homotypic aggregation of lymphocytes,
T-cell mediated cytolysis and antigen-specific induced tolerance.
The relevance of the in vitro studies are supported by in vivo
studies with antibodies directed against ICAM-1 or LFA-1. For
example, antibodies directed against LFA-1 can prevent thyroid
graft rejection and prolong heart allograft survival in mice
(Gorski, A.; Immunology Today, 1994, 15, 251-255). Of greater
significance, antibodies directed against ICAM-1 have shown
efficacy in vivo as anti-inflammatory agents in human diseases such
as renal allograft rejection and rheumatoid arthritis (Rothlein, R.
R.; Scharschmidt, L., in: Adhesion Molecules; Wegner, C. D., Ed.;
1994, 1-38, Cosimi, C. B.; et al., J. ImmunoL. 1990, 144, 4604-4612
and Kavanaugh, A.; et al., Arthritis Rheum. 1994, 37, 992-1004) and
antibodies directed against LFA-1 have demonstrated
immunosuppressive effects in bone marrow transplantation and in the
prevention of early rejection of renal allografts (Fischer, A.; et
al., Lancet, 1989, 2, 1058-1060 and Le Mauff, B.; et al.,
Transplantation, 1991, 52, 291-295).
[0004] As described above, the use of anti-LFA-1 or anti-ICAM-1
antibodies to antagonize this interaction has been investigated.
Additionally, the use of LFA-1 or ICAM-1 peptides, fragments or
peptide antagonists (see, for example, U.S. Pat. Nos. 5,149,780,
5,288,854, 5,340,800, 5,424,399, 5,470,953, Published PCT
applications WO 90/03400, WO90/13316, WO90/10652, WO91/19511,
WO92/03473, WO94/11400, WO95/28170, JP4193895, EP314862, EP362526,
EP362531), and small molecule antagonists have been investigated.
For example, several small molecules have been described in the
literature which affect the interaction of CAMs and leukointegrins.
A natural product isolated from the root of Trichilia rubra was
found to be inhibitory in an in vitro cell binding assay (Musza, L.
L.; et al., Tetrahedron, 1994, 50, 11369-11378). One series of
molecules (Boschelli, D. H.; et al., J. Med. Chem. 1994, 37, 717
and Boschelli, D. H.; et al., J. Med. Chem. 1995, 38, 5497-4614)
was found to be orally active in a reverse passive Arthus reaction,
an induced model of inflammation that is characterized by
neutrophil accumulations (Chang, Y. H.; et al., Eur. J. PharmacoL.
1992, 69, 155-164). Another series of molecules was also found to
be orally active in a delayed type hypersensitivity reaction in
rats (Sanfilippo, P. J.; et al., J. Med. Chem. 1995, 38,
1057-1059). All of these molecules appear to act nonspecifically,
either by inhibiting the transcription of ICAM-1 along with other
proteins or act intracellularly to inhibit the activation of the
leukointegrins by an unknown mechanism, and none appear to directly
antagonize the interaction of the CAMs with the leukointegrins.
[0005] Clearly, although several classes of compounds have been
investigated for therapeutic use, there remains a need for the
development of novel therapeutics that are capable of modulating
interactions between CAMs and leukointegrins. In particular, it
would be desirable to develop therapeutics capable of selectively
targeting (preferably inhibiting) the interaction between LFA-1 and
ICAM-1 that would be useful as a therapeutic agent for immune
and/or inflammatory disorders.
SUMMARY OF THE INVENTION
[0006] As discussed above, there remains a need for the development
of novel therapeutics that are capable of modulating interactions
between CAMs and leukointegrins. The present invention provides
novel compounds of general formula (I).
##STR00002##
[0007] and pharmaceutical compositions thereof, as described
generally and in subclasses herein, which compounds are useful as
modulators of the CD11/CD18 family of cellular adhesion molecules.
Thus these compounds are useful, for example, for the treatment of
various LFA-1-related disorders including immune and/or
inflammatory disorders.
[0008] In yet another aspect, the present invention provides
methods for treating any disorder mediated through the CD11/CD18
family of cellular adhesion molecules comprising administering to a
subject in need thereof a therapeutically effective amount of a
compound of the invention.
DEFINITIONS
[0009] The term "aliphatic", as used herein, includes both
saturated and unsaturated, straight chain (i.e., unbranched) or
branched aliphatic hydrocarbons, which are optionally substituted
with one or more functional groups. As will be appreciated by one
of ordinary skill in the art, "aliphatic" is intended herein to
include, but is not limited to, alkyl, alkenyl, alkynyl moieties.
Thus, as used herein, the term "alkyl" includes straight and
branched alkyl groups. An analogous convention applies to other
generic terms such as "alkenyl", "alkynyl" and the like.
Furthermore, as used herein, the terms "alkyl", "alkenyl",
"alkynyl" and the like encompass both substituted and unsubstituted
groups. In certain embodiments, as used herein, "lower alkyl" is
used to indicate those alkyl groups (substituted, unsubstituted,
branch or unbranched) having about 1-6 carbon atoms.
[0010] In certain embodiments, the alkyl, alkenyl and alkynyl
groups employed in the invention contain about 1-20 aliphatic
carbon atoms. In certain other embodiments, the alkyl, alkenyl, and
alkynyl groups employed in the invention contain about 1-10
aliphatic carbon atoms. In yet other embodiments, the alkyl,
alkenyl, and alkynyl groups employed in the invention contain about
1-8 aliphatic carbon atoms. In still other embodiments, the alkyl,
alkenyl, and alkynyl groups employed in the invention contain about
1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl,
alkenyl, and alkynyl groups employed in the invention contain about
1-4 carbon atoms. Illustrative aliphatic groups thus include, but
are not limited to, for example, methyl, ethyl, n-propyl,
isopropyl, allyl, n-butyl, sec-butyl, iso-butyl, tert-butyl,
n-pentyl, sec-pentyl, isopentyl, tert-pentyl, n-hexyl, sec-hexyl,
moieties and the like, which again, may bear one or more
substituents. Alkenyl groups include, but are not limited to, for
example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the
like. Representative alkynyl groups include, but are not limited
to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like.
[0011] The term "alicyclic", as used herein, refers to compounds
which combine the properties of aliphatic and cyclic compounds and
include but are not limited to monocyclic, or polycyclic aliphatic
hydrocarbons and bridged cycloalkyl compounds, which are optionally
substituted with one or more functional groups. As will be
appreciated by one or ordinary skill in the art, "alicyclic" is
intended herein to include, but is not limited to, cycloalkyl,
cycloalkenyl, and cycloalkynyl moieties, which are optionally
substituted with one or more functional groups. Illustrative
alicyclic groups thus include, but are not limited to, for example,
cyclopropyl, --CH.sub.2-cyclopropyl, cyclobutyl,
--CH.sub.2-cyclobutyl, cyclopentyl, --CH.sub.2-cyclopentyl,
cyclohexyl, --CH.sub.2-cyclohexyl, cyclohexenylethyl,
cyclohexanylethyl, norborbyl moieties and the like, which again,
may bear one or more substituents.
[0012] The term "alkoxy" or "alkyloxy", as used herein refers to a
saturated (i.e., O-alkyl) or unsaturated (i.e., O-alkenyl and
O-alkynyl) group attached to the parent molecular moiety through an
oxygen atom. In certain embodiments, the alkyl group contains about
1-20 aliphatic carbon atoms. In certain other embodiments, the
alkyl group contains about 1-10 aliphatic carbon atoms. In yet
other embodiments, the alkyl group employed in the invention
contains about 1-8 aliphatic carbon atoms. In still other
embodiments, the alkyl group contains about 1-6 aliphatic carbon
atoms. In yet other embodiments, the alkyl group contains about 1-4
aliphatic carbon atoms. Examples of alkoxy, include but are not
limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy,
i-butoxy, sec-butoxy, tert-butoxy, neopentoxy, n-hexoxy and the
like.
[0013] The term "thioalkyl" as used herein refers to a saturated
(i.e., S-alkyl) or unsaturated (i.e., S-alkenyl and S-alkynyl)
group attached to the parent molecular moiety through a sulfur
atom. In certain embodiments, the alkyl group contains about 1-20
aliphatic carbon atoms. In certain other embodiments, the alkyl
group contains about 1-10 aliphatic carbon atoms. In yet other
embodiments, the alkyl group employed in the invention contains
about 1-8 aliphatic carbon atoms. In still other embodiments, the
alkyl group contains about 1-6 aliphatic carbon atoms. In yet other
embodiments, the alkyl group contains about 1-4 aliphatic carbon
atoms. Examples of thioalkyl include, but are not limited to,
methylthio, ethylthio, propylthio, isopropylthio, n-butylthio, and
the like.
[0014] The term "alkylamino" refers to a group having the structure
--NHR' wherein R' is alkyl, as defined herein. The term
"aminoalkyl" refers to a group having the structure NH.sub.2R'--,
wherein R' is alkyl, as defined herein. In certain embodiments, the
alkyl group contains about 1-20 aliphatic carbon atoms. In certain
other embodiments, the alkyl group contains about 1-10 aliphatic
carbon atoms. In yet other embodiments, the alkyl group employed in
the invention contains about 1-8 aliphatic carbon atoms. In still
other embodiments, the alkyl group contains about 1-6 aliphatic
carbon atoms. In yet other embodiments, the alkyl group contains
about 1-4 aliphatic carbon atoms. Examples of alkylamino include,
but are not limited to, methylamino, ethylamino, iso-propylamine
and the like.
[0015] Some examples of substituents of the above-described
aliphatic (and other) moieties of compounds of the invention
include, but are not limited to aliphatic; alicyclic;
heteroaliphatic; heterocyclic; aromatic; heteroaromatic; aryl;
heteroaryl; alkylaryl; heteroalkylaryl; alkylheteroaryl;
heteroalkylheteroaryl; alkoxy; aryloxy; heteroalkoxy:
heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --OH; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; --C(O)R.sub.x; --CO.sub.2(R.sub.x);
--CON(R.sub.x).sub.2; --OC(O)R.sub.x; --OCO.sub.2R.sub.x;
--OCON(R.sub.x).sub.2; --N(R.sub.x).sub.2; --S(O).sub.2R.sub.x;
--NR.sub.x(CO)R.sub.x wherein each occurrence of R.sub.x
independently includes, but is not limited to, aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl,
alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl, wherein any of the aliphatic, alicyclic,
heteroaliphatic, heterocyclic, alkylaryl, or alkylheteroaryl
substituents described above and herein may be substituted or
unsubstituted, branched or unbranched, saturated or unsaturated,
and wherein any of the aryl or heteroaryl substituents described
above and herein may be substituted or unsubstituted. Additional
examples of generally applicable substituents are illustrated by
the specific embodiments shown in the Examples that are described
herein.
[0016] In general, the term "aromatic moiety", as used herein,
refers to a stable mono- or polycyclic, unsaturated moiety having
preferably 3-14 carbon atoms, each of which may be substituted or
unsubstituted. In certain embodiments, the term "aromatic moiety"
refers to a planar ring having p-orbitals perpendicular to the
plane of the ring at each ring atom and satisfying the Huckel rule
where the number of pi electrons in the ring is (4n+2) wherein n is
an integer. A mono- or polycyclic, saturated moiety that does not
satisfy one or all of these criteria for aromaticity is defined
herein as "non-aromatic", and is encompassed by the term
"alicyclic".
[0017] In general, the term "heteroaromatic moiety", as used
herein, refers to a stable mono- or polycyclic, unsaturated moiety
having preferably 3-14 carbon atoms, each of which may be
substituted or unsubstituted; and comprising at least one
heteroatom selected from O, S and N within the ring (i.e., in place
of a ring carbon atom). In certain embodiments, the term
"heteroaromatic moiety" refers to a planar ring comprising at least
on heteroatom, having p-orbitals perpendicular to the plane of the
ring at each ring atom, and satisfying the Huckel rule where the
number of pi electrons in the ring is (4n+2) wherein n is an
integer.
[0018] It will also be appreciated that aromatic and heteroaromatic
moieties, as defined herein may be attached via an alkyl or
heteroalkyl moiety and thus also include -(alkyl)aromatic,
-(heteroalkyl)aromatic, -(heteroalkyl)heteroaromatic, and
-(heteroalkyl)heteroaromatic moieties. Thus, as used herein, the
phrases "aromatic or heteroaromatic moieties" and "aromatic,
heteroaromatic, -(alkyl)aromatic, -(heteroalkyl)aromatic,
-(heteroalkyl)heteroaromatic, and -(heteroalkyl)heteroaromatic" are
interchangeable. Substituents include, but are not limited to, any
of the previously mentioned substituents, i.e., the substituents
recited for aliphatic moieties, or for other moieties as disclosed
herein, resulting in the formation of a stable compound.
[0019] The term "aryl", as used herein, does not differ
significantly from the common meaning of the term in the art, and
refers to an unsaturated cyclic moiety comprising at least one
aromatic ring. In certain embodiments, "aryl" refers to a mono- or
bicyclic carbocyclic ring system having one or two aromatic rings
including, but not limited to, phenyl, naphthyl,
tetrahydronaphthyl, indanyl, indenyl and the like.
[0020] The term "heteroaryl", as used herein, does not differ
significantly from the common meaning of the term in the art, and
refers to a cyclic aromatic radical having from five to ten ring
atoms of which one ring atom is selected from S, O and N; zero, one
or two ring atoms are additional heteroatoms independently selected
from S, O and N; and the remaining ring atoms are carbon, the
radical being joined to the rest of the molecule via any of the
ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl,
pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl,
thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl,
isoquinolinyl, and the like.
[0021] It will be appreciated that aryl and heteroaryl groups
(including bicyclic aryl groups) can be unsubstituted or
substituted, wherein substitution includes replacement of one or
more of the hydrogen atoms thereon independently with any one or
more of the following moieties including, but not limited to:
aliphatic; alicyclic; heteroaliphatic; heterocyclic; aromatic;
heteroaromatic; aryl; heteroaryl; alkylaryl; heteroalkylaryl;
alkylheteroaryl; heteroalkylheteroaryl; alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --OH; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; --C(O)R.sub.x; --CO.sub.2(R.sub.x);
--CON(R.sub.x).sub.2; --OC(O)R.sub.x; --OCO.sub.2R.sub.x;
--OCON(R.sub.x).sub.2; --N(R.sub.x).sub.2; --S(O)R.sub.x;
S(O).sub.2R.sub.x; --NR.sub.x(CO)R.sub.x wherein, each occurrence
of R.sub.x independently includes, but is not limited to,
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic,
heteroaromatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl or heteroalkylheteroaryl, wherein any of the
aliphatic, alicyclic, heteroaliphatic, heterocyclic, alkylaryl, or
alkylheteroaryl substituents described above and herein may be
substituted or unsubstituted, branched or unbranched, saturated or
unsaturated, and wherein any of the aromatic, heteroaromatic, aryl,
heteroaryl, -(alkyl)aryl or -(alkyl)heteroaryl substituents
described above and herein may be substituted or unsubstituted.
Additionally, it will be appreciated, that any two adjacent groups
taken together may represent a 4, 5, 6, or 7-membered substituted
or unsubstituted alicyclic or heterocyclic moiety. Additional
examples of generally applicable substituents are illustrated by
the specific embodiments shown in the Examples that are described
herein.
[0022] The term "cycloalkyl", as used herein, refers specifically
to groups having three to seven, preferably three to ten carbon
atoms. Suitable cycloalkyls include, but are not limited to
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and
the like, which, as in the case of aliphatic, alicyclic,
heteroaliphatic or herterocyclic moieties, may optionally be
substituted with substituents including, but not limited to
aliphatic; alicyclic; heteroaliphatic; heterocyclic; aromatic;
heteroaromatic; aryl; heteroaryl; alkylaryl; heteroalkylaryl;
alkylheteroaryl; heteroalkylheteroaryl; alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --OH; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; --C(O)R.sub.x; --CO.sub.2(R.sub.x);
--CON(R.sub.x).sub.2; --OC(O)R.sub.x; --OCO.sub.2R.sub.x;
--OCON(R.sub.x).sub.2; --N(R.sub.x).sub.2; --S(O).sub.2R.sub.x;
NR.sub.x(CO)R.sub.x wherein each occurrence of R.sub.x
independently includes, but is not limited to, aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic,
aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl, wherein any of the aliphatic, alicyclic,
heteroaliphatic, heterocyclic, alkylaryl, or alkylheteroaryl
substituents described above and herein may be substituted or
unsubstituted, branched or unbranched, saturated or usaturated, and
wherein any of the aromatic, heteroaromatic, aryl or heteroaryl
substituents described above and herein may be substituted or
unsubstituted. Additional examples of generally applicable
substituents are illustrated by the specific embodiments shown in
the Examples that are described herein.
[0023] The term "heteroaliphatic", as used herein, refers to
aliphatic moieties in which one or more carbon atoms in the main
chain have been substituted with a heteroatom. Thus, a
heteroaliphatic group refers to an aliphatic chain which contains
one or more oxygen, sulfur, nitrogen, phosphorus or silicon atoms,
e.g., in place of carbon atoms. Heteroaliphatic moieties may be
linear or branched, and saturated or unsaturated. In certain
embodiments, heteroaliphatic moieties are substituted by
independent replacement of one or more of the hydrogen atoms
thereon with one or more moieties including, but not limited to
aliphatic; alicyclic; heteroaliphatic; heterocyclic; aromatic;
heteroaromatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl;
alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio;
heteroalkylthio; heteroarylthio; F; Cl; Br; I; --OH; --NO.sub.2;
--CN; --CF.sub.3; --CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; --C(O)R.sub.x; --CO.sub.2(R.sub.x);
--CON(R.sub.x).sub.2; --OC(O)R.sub.x; --OCO.sub.2R.sub.x;
--OCON(R.sub.x).sub.2; --N(R.sub.x).sub.2; --S(O).sub.2R.sub.x;
--NR.sub.x(CO)R.sub.x wherein each occurrence of R.sub.x
independently includes, but is not limited to, aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic,
aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl, wherein any of the aliphatic, alicyclic,
heteroaliphatic, heterocyclic, alkylaryl, or alkylheteroaryl
substituents described above and herein may be substituted or
unsubstituted, branched or unbranched, saturated or unsaturated,
and wherein any of the aromatic, heteroaromatic, aryl or heteroaryl
substituents described above and herein may be substituted or
unsubstituted. Additional examples of generally applicable
substituents are illustrated by the specific embodiments shown in
the Examples that are described herein.
[0024] The term "heterocycloalkyl", "heterocycle" or
"heterocyclic", as used herein, refers to compounds which combine
the properties of heteroaliphatic and cyclic compounds and include,
but are not limited to, saturated and unsaturated mono- or
polycyclic cyclic ring systems having 5-16 atoms wherein at least
one ring atom is a heteroatom selected from O, S and N (wherein the
nitrogen and sulfur heteroatoms may be optionally be oxidized),
wherein the ring systems are optionally substituted with one or
more functional groups, as defined herein. In certain embodiments,
the term "heterocycloalkyl", "heterocycle" or "heterocyclic" refers
to a non-aromatic 5-, 6- or 7-membered ring or a polycyclic group
wherein at least one ring atom is a heteroatom selected from O, S
and N (wherein the nitrogen and sulfur heteroatoms may be
optionally be oxidized), including, but not limited to, a bi- or
tri-cyclic group, comprising fused six-membered rings having
between one and three heteroatoms independently selected from
oxygen, sulfur and nitrogen, wherein (i) each 5-membered ring has 0
to 2 double bonds, each 6-membered ring has 0 to 2 double bonds and
each 7-membered ring has 0 to 3 double bonds, (ii) the nitrogen and
sulfur heteroatoms may be optionally be oxidized, (iii) the
nitrogen heteroatom may optionally be quaternized, and (iv) any of
the above heterocyclic rings may be fused to an aryl or heteroaryl
ring. Representative heterocycles include, but are not limited to,
heterocycles such as furanyl, thiofuranyl, pyranyl, pyrrolyl,
thienyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl,
imidazolidinyl, piperidinyl, piperazinyl, oxazolyl, oxazolidinyl,
isooxazolyl, isoxazolidinyl, dioxazolyl, thiadiazolyl, oxadiazolyl,
tetrazolyl, triazolyl, thiatriazolyl, oxatriazolyl, thiadiazolyl,
oxadiazolyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl,
isothiazolidinyl, dithiazolyl, dithiazolidinyl, tetrahydrofuryl,
and benzofused derivatives thereof. In certain embodiments, a
"substituted heterocycle, or heterocycloalkyl or heterocyclic"
group is utilized and as used herein, refers to a heterocyclic or
heterocycloalkyl or heterocyclic group, as defined above,
substituted by the independent replacement of one, two or three of
the hydrogen atoms thereon with but are not limited to aliphatic;
alicyclic; heteroaliphatic; heterocyclic; aromatic; heteroaromatic;
aryl; heteroaryl; alkylaryl; heteroalkylaryl; alkylheteroaryl;
heteroalkylheteroaryl; alkoxy; aryloxy; heteroalkoxy;
heteroaryloxy; alkylthio; arylthio; heteroalkylthio;
heteroarylthio; F; Cl; Br; I; --OH; --NO.sub.2; --CN; --CF.sub.3;
--CH.sub.2CF.sub.3; --CHCl.sub.2; --CH.sub.2OH;
--CH.sub.2CH.sub.2OH; --CH.sub.2NH.sub.2;
--CH.sub.2SO.sub.2CH.sub.3; --C(O)R.sub.x; --CO.sub.2(R.sub.x);
--CON(R.sub.x).sub.2; --OC(O)R.sub.x; --OCO.sub.2R.sub.x;
--OCON(R.sub.x).sub.2; --N(R.sub.x).sub.2; --S(O).sub.2R.sub.x;
--NR.sub.x(CO)R.sub.x wherein each occurrence of R.sub.x
independently includes, but is not limited to, aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic, heteroaromatic,
aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl, wherein any of the aliphatic, alicyclic,
heteroaliphatic, heterocyclic, alkylaryl, or alkylheteroaryl
substituents described above and herein may be substituted or
unsubstituted, branched or unbranched, saturated or unsaturated,
and wherein any of the aromatic, heteroaromatic, aryl or heteroaryl
substituents described above and herein may be substituted or
unsubstituted. Additional examples or generally applicable
substituents are illustrated by the specific embodiments shown in
the Examples, which are described herein.
[0025] Additionally, it will be appreciated that any of the
alicyclic or heterocyclic moieties described above and herein may
comprise an aryl or heteroaryl moiety fused thereto. Additional
examples of generally applicable substituents are illustrated by
the specific embodiments shown in the Examples that are described
herein.
[0026] The terms "halo" and "halogen" as used herein refer to an
atom selected from fluorine, chlorine, bromine and iodine.
[0027] The term "haloalkyl" denotes an alkyl group, as defined
above, having one, two, or three halogen atoms attached thereto and
is exemplified by such groups as chloromethyl, bromoethyl,
trifluoromethyl, and the like.
[0028] The term "amino", as used herein, refers to a primary
(--NH.sub.2), secondary (--NHR.sub.x), tertiary (--NR.sub.xR.sub.y)
or quaternary (--N.sup.+R.sub.xR.sub.yR.sub.z) amine, where
R.sub.x, R.sub.y and R.sub.z are independently an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic or
heteroaromatic moiety, as defined herein. Examples of amino groups
include, but are not limited to, methylamino, dimethylamino,
ethylamino, diethylamino, diethylaminocarbonyl, methylethylamino,
iso-propylamino, piperidino, trimethylamino, and propylamino.
[0029] The term "acyl", as used herein, refers to a group having
the general formula --C(.dbd.O)R, where R is an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic or
heteroaromatic moiety, as defined herein.
[0030] The term "sulfonamido", as used herein, refers to a group
having the general formula --SO.sub.2NR.sub.xR.sub.y, where R.sub.x
and R.sub.y are independently hydrogen, or an aliphatic, alicyclic,
heteroaliphatic, heterocyclic, aromatic, heteroaromatic or acyl
moiety, as defined herein.
[0031] The term "benzamido", as used herein, refers to a group of
the general formula PhNR.sub.x--, where R.sub.x is hydrogen, or an
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic,
heteroaromatic or acyl moiety, as defined herein.
[0032] The "term C.sub.1-6alkylidene", as used herein, refers to a
substituted or unsubstituted, linear or branched saturated divalent
radical consisting solely of carbon and hydrogen atoms, having from
one to six carbon atoms, having a free valence "--"at both ends of
the radical.
[0033] The term "C.sub.2-6alkenylidene", as used herein, refers to
a substituted or unsubstituted, linear or branched unsaturated
divalent radical consisting solely of carbon and hydrogen atoms,
having from two to six carbon atoms, having a free valence "--" at
both ends of the radical, and wherein the unsaturation is present
only as double bonds and wherein a double bond can exist between
the first carbon of the chain and the rest of the molecule.
[0034] As used herein, the terms "aliphatic", "heteroaliphatic",
"alkyl", "alkenyl", "alkynyl", "heteroalkyl", "heteroalkenyl",
"heteroalkynyl", and the like encompass substituted and
unsubstituted, saturated and unsaturated, and linear and branched
groups. Similarly, the terms "alicyclic", "heterocyclic",
"heterocycloalkyl", "heterocycle" and the like encompass
substituted and unsubstituted, and saturated and unsaturated
groups. Additionally, the terms "cycloalkyl", "cycloalkenyl",
"cycloalkynyl", "heterocycloalkyl", "heterocycloalkenyl",
"heterocycloalkynyl", "aromatic", "heteroaromatic", "aryl",
"heteroaryl" and the like encompass both substituted and
unsubstituted groups.
[0035] By the term "protecting group", has used herein, it is meant
that a particular functional moiety, e.g., O, S, or N, is
temporarily blocked so that a reaction can be carried out
selectively at another reactive site in a multifunctional compound.
In preferred embodiments, a protecting group reacts selectively in
good yield to give a protected substrate that is stable to the
projected reactions; the protecting group must be selectively
removed in good yield by readily available, preferably nontoxic
reagents that do not attack the other functional groups; the
protecting group forms an easily separable derivative (more
preferably without the generation of new stereogenic centers); and
the protecting group has a minimum of additional functionality to
avoid further sites of reaction. As detailed herein, oxygen,
sulfur, nitrogen and carbon protecting groups may be utilized. For
example, in certain embodiments, as detailed herein, certain
exemplary oxygen protecting groups are utilized. These oxygen
protecting groups include, but are not limited to methyl ethers,
substituted methyl ethers (e.g., MOM (methoxymethyl ether), MTM
(methylthiomethyl ether), BOM (benzyloxymethyl ether), PMBM or MPM
(p-methoxybenzyloxymethyl ether), to name a few), substituted ethyl
ethers, substituted benzyl ethers, silyl ethers (e.g., TMS
(trimethylsilyl ether), TES (triethylsilylether), TIPS
(triisopropylsilyl ether), TBDMS (T-butyldimethylsilyl ether),
tribenzyl silyl ether, TBDPS (T-butylidiphenyl silyl ether), to
name a few) esters (e.g., formate, acetate, benzoate (Bz),
trifluoroacetate, dichloroacetate, to name a few), carbonates,
cyclic acetals and ketals. In certain other exemplary embodiments,
nitrogen protecting groups are utilized. These nitrogen protecting
groups include, but are not limited to, carbamates (including
methyl, ethyl, and substituted ethyl carbamates (e.g., Troc), to
name a few) amides, cyclic imide derivatives, N-Alkyl and N-Aryl
amines, imine derivatives, and enamine derivatives, to name a few.
Certain other exemplary protecting groups are detailed herein,
however, it will be appreciated that the present invention is not
intended to be limited to these protecting groups; rather, a
variety of additional equivalent protecting groups can be readily
identified using the above criteria and utilized in the present
invention. Additionally, a variety of protecting groups are
described in "Protective Groups in Organic Synthesis" Third Ed.
Greene, T. W. and Wuts, P. G., Eds., John Wiley & Sons, New
York: 1999, the entire contents of which are hereby incorporated by
reference.
[0036] The term "natural amino acid" as used herein refers to any
one of the common, naturally occurring L-amino acids found in
naturally occurring proteins: glycine (Gly), alanine (Ala), valine
(Val), leucine (Leu), isoleucine (Ile), lysine (Lys), arginine
(Arg), histidine (His), proline (Pro), serine (Ser), threonine
(Thr), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp),
aspartic acid (Asp), glutamic acid (Glue), asparagine (Asn),
glutamine (Glu), cysteine (Cys) and methionine (Met).
[0037] The term "unnatural amino acid" as used herein refers to all
amino acids which are not natural amino acids. This includes, for
example, .alpha.-, .beta.-, D-, L-amino acid residues, and
compounds of the general formula
##STR00003##
wherein the side chain R is other than the amino acid side chains
occurring in nature.
[0038] More generally, the term "amino acid", as used herein,
encompasses natural amino acids and unnatural amino acids.
[0039] The term "bioisosteres", as used herein, generally refers to
two or more compounds or moieties that possess similar molecular
shapes and/or volumes. In certain embodiments, bioisoesteres have
approximately the same distribution of electrons. In certain
embodiments, bioisoesteres exhibit similar biological properties.
In preferred embodiments, bioisosteres possess similar molecular
shapes and volumes; have approximately the same distribution of
electrons; and exhibit similar biological properties.
[0040] As used herein, the term "isolated", when applied to the
compounds of the present invention, refers to such compounds that
are (i) separated from at least some components with which they are
associated in nature or when they are made and/or (ii) produced,
prepared or manufactured by the hand of man.
[0041] The term, "pharmaceutically acceptable derivative", as used
herein, denotes any pharmaceutically acceptable salt, ester, or
salt of such ester, of such compound, or any other adduct or
derivative which, upon administration to a patient, is capable of
providing (directly or indirectly) a compound as otherwise
described herein, or a metabolite or residue thereof.
Pharmaceutically acceptable derivatives that include among others
pro-drugs. A pro-drug is a derivative of a compound, usually with
significantly reduced pharmacological activity, which contains an
additional moiety, which is susceptible to removal in vivo yielding
the parent molecule as the pharmacologically active species. An
example of a pro-drug is an ester, which is cleaved in vivo to
yield a compound of interest. Pro-drugs of a variety of compounds,
and materials and methods for derivatizing the parent compounds to
create the pro-drugs, are known and may be adapted to the present
invention. Certain exemplary pharmaceutical compositions and
pharmaceutically acceptable derivatives will be discussed in more
detail herein below.
[0042] As used herein, the term "pharmaceutically acceptable salt"
refers to those slats which are, within the scope of sound medical
judgment, suitable for use in contact with the tissues of humans
and lower animals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. Pharmaceutically acceptable salts of amines,
carboxylic acids, and other types of compounds, are well known in
the art. For example, S. M. Berge, et aL. describe pharmaceutically
acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19
(1977), incorporated herein by reference. The salts can be prepared
in situ during the final isolation and purification of the
compounds of the invention, or separately by reacting a free base
or free acid function with a suitable reagent, as described
generally below. For example, a free base function can be reacted
with a suitable acid. Furthermore, where the compounds of the
invention carry an acidic moiety, suitable pharmaceutically
acceptable salts thereof may, include metal salts such as alkali
metal salts, e.g. sodium or potassium salts; and alkaline earth
metal salts, e.g. calcium or magnesium salts. Examples of
pharmaceutically acceptable, nontoxic acid addition salts are salts
of an amino group formed with inorganic acids such as hydrochloric
acid, hydrobromic acid, phosphoric acid, sulfuric acid and
perchloric acid or with organic acids such as acetic acid, oxalic
acid, maleic acid, tartaric acid, citric acid, succinic acid or
malonic acid or by using other methods used in the art such as ion
exchange. Other pharmaceutically acceptable salts include adipate,
alginate, ascorbate, aspartate, benzenesulfonate, benzoate,
bisulfate, borate, butyrate, camphoraic, camphosulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, gluconate, hernisulfate; heptanoate, hexanoate,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, malcate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
p-toluenesulfonate, undecanoate, valerate salts, and the like.
Representative alkali or alkaline earth metal salts include sodium,
lithium, potassium, calcium, magnesium, and the like. Further
pharmaceutically acceptable salts include, when appropriate,
nontoxic ammonium, quaternary ammonium, and amine cations formed
using counterions such as halide, hydroxide, carboxylate, sulfate,
phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[0043] As used herein, the term "pharmaceutically acceptable ester"
refers to esters that hydrolyze in vivo and include those that
break down readily in the human body to leave the parent compound
or a salt thereof. Suitable ester groups include, for example,
those derived from pharmaceutically acceptable aliphatic carboxylic
acids, particularly alkanoic, alkenoic, cycloalkanoic and
alkanedioic acids, in which each alkyl or alkenyl moiety
advantageously has not more than 6 carbon atoms. Examples of
particular esters include formates, acetates, propionates,
butyrates, acrylates and ethylsuccinates.
[0044] As used herein, the term "pharmaceutically acceptable
prodrugs" refers to those prodrugs of the compounds of the present
invention which are, within the scope of sound medical judgement,
suitable for use in contact with the issues of humans and lower
animals with undue toxicity, irritation, allergic response, and the
like, commensurate with a reasonable benefit/risk ratio, and
effective for their intended use, as well as the zwitterionic
forms, where possible, of the compounds of the invention. The term
"prodrug" refers to compounds that are rapidly transformed in vivo
to yield the parent compound of the above formula, for example by
hydrolysis in blood. A thorough discussion is provided in T.
Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, VoL. 14
of the A.C.S. Symposium Series, and in Edward B. Roche, ed.,
Bioreversible Carriers in Drug Design, American Pharmaceutical
Association and Pergamon Press, 1987, both of which are
incorporated herein by reference.
[0045] The term "LFA-1 mediated disorders", as used herein refers
generally to pathological states caused by cell adherence
interactions involving the LFA-1 receptor on lymphocytes. Examples
of such disorders include, but are not limited to T-cell
inflammatory responses such as inflammatory skin diseases including
psoriasis; responses associated with inflammatory bowel disease
(such as Crohn's disease and ulcerative colitis); adult respiratory
distress syndrome, dermatitis, meningitis, encephalitis, uveitic,
allergic conditions such as eczema and asthma and other conditions
involving infiltration of T-cells and chronic inflammatory
responses, skin hypersensitivity reactions (including poison ivy
and poison oak), atherosclerosis, leukocyte adhesion deficiency,
autoimmune diseases such as rheumatoid arthritis, systemic lupus
erythermatosus (SLE), diabetes mellitus, multiple sclerosis,
Reynaud's syndrome, autoimmune thyroiditis, experimental autoimmune
encephalomyclitis, Sjorgen's syndrome, type 1 diabetes, juvenile
onset diabetes, and immune responses associated with delayed
hypersensitivity mediated by cytokines and T-lymphocytes typically
found in tuberculosis, sarcoidosis, polymyositis, granulomatosis,
and vasculitis, pernicious anemia, diseases involving leukocyte
diapedesis, CNS inflammatory disorder, multiple organ injury
syndrome secondary to septicaemia or trauma, autoimmune haemolytic
anemia, myethamia gravis, antigen-antibody complex mediated
diseases, and all types of transplantations, including graft vs.
host or host vs. graft disease.
[0046] The term "LFA-1 antagonist", as used herein, generally
refers to inventive compounds, as described herein, that act as a
competitive inhibitors of the CD11a and/or CD18 interaction with
ICAM-1, ICAM-2 or ICAM-3.
[0047] The term "treating", as used herein generally means that the
compounds of the invention can be used in humans or animals with at
least a tentative diagnosis of disease. The compounds of the
invention will delay or slow the progression of the disease thereby
extending the individual's life span.
[0048] The term "preventing" as used herein generally means that
the compounds of the present invention are useful when administered
to a patient who has not been diagnosed as possibly having the
disease at the time of administration, but who would normally be
expected to develop the disease or be at increased risk for the
disease. In certain embodiments, compounds of the invention slow
the development of disease symptoms, delay the onset of disease, or
prevent the individual from developing the disease at all.
[0049] As used herein the term "biological sample" includes,
without limitation, cell cultures or extracts thereof; biopsied
material obtained from an animal (e.g., mammal) or extracts
thereof, and blood, saliva, urine, feces, semen, tears, or other
body fluids or extracts thereof. For example, the term "biological
sample" refers to any solid or fluid sample obtained from, excreted
by or secreted by any living organism, including single-celled
micro-organisms (such as bacteria and yeasts) and multicellular
organisms (such as plants and animals, for instance a vertebrate or
a mammal, and in particular a healthy or apparently healthy human
subject or a human patient affected by a condition or disease to be
diagnosed or investigated). The biological sample can be in any
form, including a solid material such as a tissue, cells, a cell
pellet, a cell extract, cell homogenates, or cell fractions; or a
biopsy, or a biological fluid. The biological fluid may be obtained
from any site (e.g. blood, saliva (or a mouth wash containing
buccal cells), tears, plasma, serum, urine, bile, cerebrospinal
fluid, amniotic fluid, peritoneal fluid, and pleural fluid, or
cells therefrom, aqueous or vitreous humor, or any bodily
secretion), a transudate, an exudate (e.g. fluid obtained from an
abcess or any other site of infection or inflammation), or fluid
obtained from a joint (e.g. a normal joint or a joint affected by
disease such as rheumatoid arthritis, osteoarthritis, gout or
septic arthritis). The biological sample can be obtained from any
organ or tissue (including a biopsy or autopsy specimen) or may
comprise cells (whether primary cells or cultured cells) or medium
conditioned by any cell, tissue or organ. Biological samples may
also include sections of tissues such as frozen sections taken for
histological purposes. Biological samples also include mixtures of
biological molecules including proteins, lipids, carbohydrates and
nucleic acids generated by partial or complete fractionation of
cell or tissue homogenates. Although the sample is preferably taken
from a human subject, biological samples may be from any animal,
plant, bacteria, virus, yeast, etc. The term animal, as used
herein, refers to humans as well as non-human animals, at any stage
of development, including, for example, mammals, birds, reptiles,
amphibians, fish, worms and single cells. Cell cultures and live
tissue samples are considered to be pluralities of animals. In
certain exemplary embodiments, the non-human animal is a mammal
(e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat,
a sheep, cattle, a primate, or a pig). An animal may be a
transgenic animal or a human clone. If desired, the biological
ample may be subjected to preliminary processing, including
preliminary separation techniques.
DETAILED DESCRIPTION
[0050] The present invention provides compounds that modulate
interactions between intracellular adhesion molecules (e.g.,
ICAM-1, -2 and -3) and the leukocyte integrin family of receptors.
In certain embodiments, the inventive compounds are antagonists and
are useful for the treatment of CD11/CD18 mediated disorders. In
certain embodiments of special interest, the inventive compounds
are useful for the treatment of Mac-1 and LFA-1 mediated disorders.
In still other embodiments, the compounds are useful for the
treatment of LFA-1 mediated disorders, for example, inflammatory
disorders and autoimmune disorders to name a few.
[0051] 1) General Description of Compounds of the Invention
[0052] The compounds of the invention include compounds of the
general formula (I) as further defined below:
##STR00004##
[0053] and pharmaceutically acceptable derivatives thereof;
[0054] wherein R.sup.1 and R.sup.2 are each independently hydrogen,
an amino acid side chain, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic or heteroaromatic moiety, or wherein R.sup.1
and R.sup.2 taken together are an alicyclic or heterocyclic moiety,
or together are
##STR00005##
wherein R.sup.1A is hydrogen, an aliphatic, alicyclic,
heteroaliphatic, heterocyclic, aromatic or heteroaromatic
moiety;
[0055] R.sup.3 is --C(.dbd.O)OR.sup.3A, --C(.dbd.O)H,
--CH.sub.2OR.sup.3A, --CH.sub.2O--C(.dbd.O)-alkyl,
--C(.dbd.O)NH(R.sup.3A) or --CH.sub.2X.sup.0; wherein each
occurrence of R.sup.3A is independently hydrogen, a protecting
group, an aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic or heteroaromatic moiety, or R.sup.3A, taken together with
R.sup.1 or R.sup.2, forms a heterocyclic moiety; wherein X.sup.0 is
a halogen selected from F, Cl, Br or I;
[0056] R.sup.4, for each occurrence, is independently hydrogen,
halogen, --CN, --NO.sub.2, an aliphatic, alicyclic,
heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety,
or is -GR.sup.G1 wherein G is --O-, --S--, --NR.sup.G2--, --CO--,
--SO--, --SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--,
--OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic or
heteroaromatic moiety;
[0057] n is an integer from 0-3;
[0058] AR.sup.1 is an aromatic heteroaromatic, alicyclic, or
heterocyclic moiety;
[0059] A, B, D and E are connected by either a single or double
bond, as a valency permits; wherein each occurrence of A, B, D and
E is independently C.dbd.O, CR.sup.iR.sup.ii, NR.sup.i, CR.sup.i,
N, O, S, S(.dbd.O) or SO.sub.2; wherein each occurrence of R.sup.i
is independently hydrogen; halogen, --CN, --NO.sub.2, an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aromatic or
heteroaromatic moiety, or is -GR.sup.G1 wherein G is --O--, --S--,
--NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic or heteroaromatic moiety, or any two adjacent occurrences
of R.sup.i, taken together, represent an alicyclic, heterocyclic,
aromatic or heteroaromatic moiety;
[0060] p is an integer from 0-4; and
[0061] L is absent or is V-W-X-Y-Z, wherein each occurrence of V,
W, X, Y and Z is independently absent, C.dbd.O, NR.sup.L1, --O--,
--C(R.sup.L1)--, --C(R.sup.L1)--, --C(R.sup.L1)(R.sup.L2),
C(.dbd.N--O--R.sup.L1), C(.dbd.N--R.sup.L1), --N.dbd.,
S(O).sub.0-2; as substituted or unsubstituted C.sub.1-6alkylidene
or C.sub.2-6alkenylidene chain wherein up to two non-adjacent
methylene units are indecently optionally replaced by
--C(.dbd.O)--, --CO.sub.2--, --C(.dbd.O)C(.dbd.O)--,
--C(.dbd.O)NR.sup.L3--, --OC(.dbd.O)--, --OC(.dbd.O)NR.sup.L3--,
--NR.sup.L3NR.sup.L4--, --NR.sup.L3NR.sup.L4C(.dbd.O)--,
--NR.sup.L3C(.dbd.O)--, --NR.sup.L3CO.sub.2--,
--NR.sup.L3C(.dbd.O)NR.sup.L4--, --S(.dbd.O)--, --SO.sub.2--,
--NR.sup.L3SO.sub.2--, --SO.sub.2NR.sup.L3--,
--NR.sup.L3SO.sub.2NR.sup.L4--, --O--, --S--, or --NR.sup.L3--;
wherein each occurrence of R.sup.L3 and R.sup.L4 is independently
hydrogen, alkyl, heteroalkyl, aromatic, heteroaromatic or acyl; or
an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or
heteroaromatic moiety, and each occurrence of R.sup.L1 and R.sup.L2
is independently hydrogen, hydroxyl, protected hydroxyl, amino,
protected amino, thio, protected thio, halogen, cyano, isocyanate,
carboxy, carboxyalkyl, formyl, formyloxy, azido, nitro, ureido,
thioureido, thiocyanato, alkoxy, aryloxy, mercapto, sulfonamido,
benzamido, tosyl, or an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aromatic or heteroaromatic moiety, or wherein one or
more occurrences of R.sup.L1 and R.sup.L3, taken together, or taken
together with one of V, W, X, Y or Z form an alicyclic or
heterocyclic moiety or from an aromatic or heteroaromatic
moiety.
[0062] In another aspect, the invention provides compounds of
formula (II):
##STR00006##
[0063] wherein AR has one of the following structures:
##STR00007##
[0064] and pharmaceutically acceptable derivatives thereof;
[0065] wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, A, B, D, E, n, p
are as defined generally above and in classes and subclasses
herein; and
[0066] Y.sup.1, Y.sup.2 and Y.sup.4 are each independently CR.sup.4
or N;
[0067] with the proviso that, when AR has the structure:
##STR00008##
wherein Y.sup.1 is CH or N and p is 0-2,
[0068] then R.sup.4 is not carbocycle, aryl, heteroaryl or
heterocyle, and A, B, D and E do not comprise a carbocyclic, aryl,
heteroaryl or heterocyclic moiety.
[0069] In certain embodiments, for compounds of formula (II), AR
represents a moiety having one of the following structures:
##STR00009## ##STR00010##
[0070] wherein each occurrence of n is an integer from 0-6; each
occurrence of R.sup.4 is independently hydrogen, halogen, CN,
isocyanate, NO.sub.2, -P(.dbd.O)(YR.sup.P5).sub.2, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic moiety, or is -GR.sup.G1
wherein G is --O--, --S--, --NR.sup.G2--, --CO--, --SO--,
--SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--,
--OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic moiety; each occurrence of Y
is independently a bond or O; each occurrence of R.sup.P5 is
independently alkyl, heteroalkyl, aryl or heteroaryl, or when Y is
O R.sup.P5 may also be hydrogen; and each occurrence of R.sup.4A is
independently hydrogen, an alkyl, cycloalkyl, heteroalkyl,
heterocyclic moiety or a nitrogen protecting group; wherein any two
adjacent occurrences of R.sup.4 and R.sup.4A, taken together, may
form a cycloalkyl, heterocyclic, aryl or heteroaryl moiety. In
certain exemplary embodiments, AR has the structure;
##STR00011##
In yet other exemplary embodiments, AR has the structure:
##STR00012##
wherein each occurrence of X.sub.0 is independently a halogen
selected from F, Cl, Br and I. In certain embodiments, each
occurrence of X.sup.0 is Cl.
[0071] i) R.sup.1 and R.sup.2 are each independently hydrogen, an
amino acid side chain, --(CH.sub.2).sub.mOH,
--(CH.sub.2).sub.maryl, --(CH.sub.2).sub.mheteroaryl, wherein m is
0-6, --CH(R.sup.1A)(OR.sup.1B), --CH(R.sup.1A)(NHR.sup.1B), U-T-Q,
or an alkyl, cycloalkyl, heteroalkyl or heterocyclic moiety
optionally substituted with U-T-Q, wherein U is absent, --O--,
--S(O).sub.0-2--, --SO.sub.2N(R.sup.1A), --N(R.sup.1A)--,
--N(R.sup.1A)C(.dbd.O)--, --N(R.sup.1A)C(.dbd.O)--O--,
--N(R.sup.1A)C(.dbd.O)--N(R.sup.1B)--, --N(R.sup.1A)--SO.sub.2--,
--C(.dbd.O)--, --C(.dbd.O)--O--, --O--C(.dbd.O)--, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, --C(.dbd.O)--N(R.sup.1A)--,
--O--C(.dbd.O)--N(R.sup.1A)--, --C(.dbd.N--R.sup.1E)--,
--C(.dbd.N--R.sup.1E)--O--, --C(.dbd.N--R.sup.1E)--N(R.sup.1A)--,
--O--C(.dbd.N--R.sup.1E)--N(R.sup.1A)--,
--N(R.sup.1A)C(.dbd.N--R.sup.1E)--,
--N(R.sup.1A)C(.dbd.N--R.sup.1E)--O--,
N(R.sup.1A)C(.dbd.N--R.sup.1E)--N(R.sup.1B)--,
-P(.dbd.O)(OR.sup.1A)--O--, or -P(.dbd.O)(R.sup.1A)--O--; wherein T
is absent, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl moiety, and wherein Q is hydrogen, halogen,
cyano, isocyanate, --OR.sup.1B, --SR.sup.1B; --N(R.sup.1B).sub.2,
--NHC(.dbd.O)OR.sup.1B, --NHC(.dbd.O)N(R.sup.1B).sub.2,
--NHC(.dbd.O)R.sup.1B, --NHSO.sub.2R.sup.1B,
--NHSO.sub.2N(R.sup.1B).sub.2, --NHSO.sub.2NHC(.dbd.O)OR.sup.1B,
--NHC(.dbd.O)NHSO.sub.2R.sup.1B, --C(.dbd.O)NHC(.dbd.O)OR.sup.1B,
--C(.dbd.O)NHC(.dbd.O)R.sup.1B,
--C(.dbd.O)NHC(.dbd.O)N(R.sup.1B).sub.2,
--C(.dbd.O)NHSO.sub.2R.sup.1B,
--C(.dbd.O)NHSO.sub.2N(R.sup.1B).sub.2,
--C(.dbd.S)N(R.sup.1B).sub.2, --SO.sub.2--R.sup.1B,
--SO.sub.2--O--R.sup.1B, --SO.sub.2--N(R.sup.1B).sub.2,
--SO.sub.2--NHC(.dbd.O)OR.sup.1B,
--SO.sub.2--NHC(.dbd.O)--N(R.sup.1B).sub.2,
--SO.sub.2--NHC(.dbd.O)R.sup.1B, --O--C(.dbd.O)N(R.sup.1B).sub.2,
--O--C(.dbd.O)R.sup.1B, --O--C(.dbd.O)NHC(.dbd.O)R.sup.1B,
--O--C(.dbd.O)NH--SO.sub.2R.sup.1B, --O--SO.sub.2R.sup.1B, or an
alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl or heteroaryl
moiety, or wherein R.sup.1 and R.sup.2 taken together are a
cycloalkyl or heterocyclic moiety, or together are
##STR00013##
wherein each occurrence of R.sup.1A and R.sup.1B is independently
hydrogen, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl or
heteroaryl moiety, --COR.sup.1C, or --CONR.sup.1CR.sup.1D; wherein
each occurrence of R.sup.1C and R.sup.1D is independently hydrogen,
hydroxyl, or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl
or heteroaryl moiety; and R.sup.1B is hydrogen, an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl,
alkylaryl or alkylheteroaryl moiety, --CN, --OR.sup.1C,
--NR.sup.1CR.sup.1D or --SO.sub.2R.sup.1C;
[0072] ii) R.sup.3 is carboxyl, protected carboxyl or a prodrug
thereof, wherein R.sup.3 is C(.dbd.O)R.sup.3A, wherein R.sup.3A is
hydroxy, alkoxy, cycloalkoxy, aralkoxy, arcycloalkoxy, aryloxy,
alkylcarbonyloxyalkyloxy, alkoxycarbonyloxyalkyloxy,
alkoxycarbonylalkyloxy, cycloalkylcarbonyloxyalkyloxy,
cycloalkoxycarbonyloxyalkyloxy, cycloalkoxycarbonylalkyloxy,
arylcarbonyloxyalkyloxy, aryloxycarbonyloxyalkyloxy,
arylcarbonyloxyalkyloxy, alkoxyalkylcarabonyloxyalkyloxy, or one or
the structures:
##STR00014##
[0073] ii) R.sup.3 is --C(.dbd.O)OR.sup.3A, --C(.dbd.O)H,
--CH.sub.2OR.sup.3A, --CH.sub.2O--C(.dbd.O)-alkyl,
--C(.dbd.O)NH(R.sup.3A), or --CH.sub.2X.sup.0; wherein each
occurrence of R.sup.3A is independently hydrogen, a protecting
group, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety, or R.sup.3A, taken
together with R.sup.1 or R.sup.2, forms a heterocyclic moiety;
wherein X.sup.0 is a halogen selected from F, Cl, Br or I;
[0074] iv) R.sup.3 is --C(.dbd.O)OR.sup.3A; wherein R.sup.3A is
hydrogen, a protecting group, an alkyl, cycloalkyl, heteroalkyl,
heterocyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl
moiety, or R.sup.3A, taken together with R.sup.1 or R.sup.2, forms
a heterocyclic moiety;
[0075] v) R.sup.3 is --C(.dbd.O)OR.sup.3A; wherein R.sup.3A is
C.sub.1-5alkyl
[0076] vi) R.sup.3 is --C(.dbd.O)OR.sup.3A; wherein R.sup.3A is
C.sub.1-3alkyl;
[0077] vii) R.sup.3 is --C(.dbd.O)OR.sup.3A; wherein R.sup.3A is
ethyl;
[0078] viii) R.sup.3 is --C(.dbd.O)OR.sup.3A; wherein R.sup.3A is
benzyl;
[0079] ix) R.sup.3 is CO.sub.2H;
[0080] x) R.sup.3 is --C(.dbd.O)OR.sup.3A, wherein R.sup.3A is as
defined in any one of subsets ii)-ix) above, and
--C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having the
following structure:
##STR00015##
[0081] wherein Ar.sub.2 is a cycloalkyl, heterocyclic, aryl or
heteroaryl moiety; and R.sup.S is hydrogen, alkyl, heteroalkyl,
aryl, heteroaryl, or is -G.sup.0R.sup.G1 wherein G.sup.0 is --O--,
--S-- or NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aromatic or heteroaromatic moiety;
[0082] xi) Compounds of subset x) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH(R.sup.S))Ar.sub.2 has the
following stereochemistry:
##STR00016##
[0083] xii) R.sup.3 is --C(.dbd.O)OR.sup.3A, wherein R.sup.3A is as
defined in any one of subsets ii)-ix) above, and
--C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having the
following structure:
##STR00017##
[0084] wherein R.sup.1A is Ar.sub.2, --OR.sup.1B, --SR.sup.1B or
--NR.sup.1BR.sup.1C; or an alkyl or heteroalkyl moiety; and
Ar.sub.2 is a cycloalkyl, heterocyclic, aryl or heteroaryl moiety;
wherein R.sup.1B and R.sup.1C are independently hydrogen, alkyl,
heteroalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or
R.sup.1B and R.sup.1C, taken together with the nitrogen atom to
which they are attached, form a heterocyclic or heteroaryl
moiety;
[0085] xiii) Compounds of subset xii) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2NHC(.dbd.O)R.sup.1A has
the following stereochemistry:
##STR00018##
[0086] xiv) R.sup.3 is --C(.dbd.O)OR.sup.3A, wherein R.sup.3A is as
defined in any one of subsets ii)-ix) above, and
--C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having the
following structure:
##STR00019##
[0087] wherein Ar.sub.2 is cycloalkyl, heterocyclic, aryl or
heteroaryl moiety; and R.sup.2A is hydrogen, C.sub.1-6alkyl,
C.sub.2-6alkenyl, --C(.dbd.O)R.sup.2B or --SO.sub.2R.sup.2B,
wherein R.sup.2B is alkyl, cycloalkyl, heteroalkyl, heterocyclyl,
aryl or heteroaryl; or R.sup.2A, taken together with a substituent
on Ar.sub.2, forms a substituted or unsubstituted heterocyclic
heteroaryl moiety;
[0088] xv) Compounds of subset xiv) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)Ar.sub.2 has
the following stereochemistry:
##STR00020##
[0089] xvi) R.sup.3 is --C(.dbd.O)OR.sup.3A, wherein R.sup.3A is as
defined in any one of subsets ii)-ix) above, and
--C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having the
following structure:
##STR00021##
[0090] wherein R.sup.2A is hydrogen, C.sub.1-6alkyl,
C.sub.2-6alkenyl, aryl, heteroaryl, --C(.dbd.O)R.sup.2B or
--SO.sub.2R.sup.2B, wherein R.sup.2B is alkyl, cycloalkyl,
heteroalkyl, heterocyclyl, aryl or heteroaryl; or R.sup.2A, taken
together with R.sup.2C or R.sup.2D, forms a substituted or
unsubstituted heterocyclic or heteroaryl moiety; R.sup.2C is
hydrogen, CN, --C.dbd.NMe, --NO.sub.2, .dbd.NC(.dbd.O)NH.sub.2,
.dbd.NS(O).sub.2R, .dbd.NS(O).sub.2NRR', --SO.sub.2R.sup.2G, or an
aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl,
heteroaryl, alkylaryl, or alkylheteroaryl moiety; wherein R and R'
are each independently hydrogen or methyl, and R.sup.2G is lower
alkyl; and R.sup.2D is Ar.sub.2, hydrogen, halogen, CN, NO.sub.2,
an aliphatic, heteroaliphatic, alkylaryl or alkylheteroaryl moiety,
or is -GR.sup.G1 wherein G is --O--, --S--, --NR.sup.G2--, --CO--,
--SO--, --SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--,
--OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic,
alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl,
alkylaryl or alkylheteroaryl moiety;
[0091] xvii) Compounds of subset xvi) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)C(.dbd.NR.sup.2C)R.su-
p.2D has the following stereochemistry:
##STR00022##
[0092] xviii) Compounds of subset xvii) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)C(.dbd.NR.sup.2D
has the following structure:
##STR00023##
[0093] wherein R.sup.2E and R.sup.2F are each independently
hydrogen, or an aliphatic, alicyclic, heteroaliphatic,
heteroalicyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl
moiety, or R.sup.2E and R.sup.2F, taken together, form a
substituted or unsubstituted heterocyclic or heteroaryl moiety;
[0094] xix) Compounds of subset xvii) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)C(.dbd.NR.sup.2C)R.su-
p.2D has the following structure:
##STR00024##
[0095] wherein R.sup.2C is hydrogen, CN, --C.dbd.NMe,
.dbd.NO.sub.2, .dbd.NC(.dbd.O)NH.sub.2, .dbd.NS(O).sub.2R, or
.dbd.NSO(O).sub.2NRR'; wherein R and R' are each independently
hydrogen or methyl;
[0096] xx) Compounds of subset xvii) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)C(.dbd.NR.sup.2C)R.su-
p.2D has the following structure:
##STR00025##
[0097] wherein R.sup.2C is hydrogen, CN, --C.dbd.NMe,
.dbd.NO.sub.2, .dbd.NC(.dbd.O)NH.sub.2, .dbd.NS(O).sub.2R, or
.dbd.NS(O).sub.2NRR'; wherein R and R' are each independently
hydrogen or methyl;
[0098] xxi) Compounds of subset xvii) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)C(.dbd.NR.sup.2C)R.su-
p.2D has the following structure:
##STR00026##
[0099] xxii) Compounds of subset xvii) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)C(.dbd.NR.sup.2C)R.su-
p.2D has the following structure:
##STR00027##
[0100] xxiii) Compounds of subsets xvii) and xviii) above wherein
--C(.dbd.O)NHCH(CO.sub.2R.sup.3A)CH.sub.2N(R.sup.2A)C(.dbd.NR.sup.2C)R.su-
p.2D has the following structure:
##STR00028##
[0101] or bioisosteres thereof;
[0102] wherein R.sup.2A, R.sup.2D, R.sup.2E and R.sup.2F are as
defined in xvi) and xviii) above;
[0103] xxiv) Compounds of subset xxiii) above wherein the
bioiosteres have one of the following structures:
##STR00029## ##STR00030##
wherein R.sup.2C is lower alkyl;
[0104] xxv) Compounds of subset xxiii) above wherein R.sup.2D is,
or R.sup.2E and R.sup.2F together with the nitrogen atom to which
they are attached form, a moiety having one of the structures:
##STR00031##
[0105] wherein s is an integer between 0 and 6; each occurrence of
R.sup.P1 is independently hydrogen, halogen, CN, isocyanate,
NO.sub.2, -P(.dbd.O)(YR.sup.P5).sub.2; an alkyl, cycloalkyl,
heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl or
alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--, --S--,
--NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety; each occurrence of
Y is independently a bond or O; each occurrence of R.sup.P5 is
independently alkyl, heteroalkyl, aryl or heteroaryl, or when Y is
O R.sup.P5 may also be hydrogen; and each occurrence of R.sup.P2 is
independently hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl moiety or a nitrogen
protecting group; wherein any two adjacent occurrences of R.sup.P1
and R.sup.P2, taken together, may form a cycloalkyl, heterocyclic,
aryl or heteroaryl moiety;
[0106] xxvi) Compounds of subset xxv) above wherein R.sup.2D is, or
R.sup.2E and R.sup.2F together with the nitrogen atom to which they
are attached form, a moiety having one of the structures:
##STR00032##
[0107] wherein each occurrence of R.sup.P1 is independently
hydrogen, halogen, methyl, --OCH.sub.3, --OH, --NH.sub.2,
--NHCH.sub.3, or --N(CH.sub.3).sub.2;
[0108] xxvii) Compounds of subset xxvi) above wherein R.sup.2D is,
or R.sup.2E and R.sup.2F together with the nitrogen atom to which
they are attached form, a moiety having one of the structures:
##STR00033##
[0109] xxviii) R.sup.3 is --C(.dbd.O)OR.sup.3A, wherein R.sup.3A is
as defined in any one of subsets ii)-ix) above, and
--C(.dbd.O)NHC(R.sup.1)R.sup.2)R.sup.3 is a moiety having the
following structure:
##STR00034##
[0110] wherein Ar.sub.2 is a cycloalkyl, heterocyclic, aryl or
heteroaryl moiety;
[0111] xxix) Compounds of subsets x)-xii), xiv)-xv) and xxviii);
and compounds of subset xvi) wherein R.sup.2D is Ar.sub.2; wherein
Ar.sub.2 is one of the following structures:
##STR00035## ##STR00036## ##STR00037## ##STR00038##
[0112] wherein each occurrence of s is an integer from 0-6; w is an
integer from 1-6; X.sub.1 is CHR.sup.P1 or NR.sup.P2; X.sub.2 and
X.sub.3 are independently CHR.sup.P1, NR.sup.P2, CHSO.sub.2R.sup.P3
or NSO.sub.2R.sup.P3; each occurrence of R.sup.P1 is independently
hydrogen, halogen, CN, isocyanate, NO.sub.2,
-P(.dbd.O)(YR.sup.P5).sub.2, an aliphatic, alicyclic,
heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl
or -(aliphatic)heteroaryl moiety, or is -GR.sup.G1 wherein G is
--O--, --S--, --NR.sup.G2--, --CO--, --SO--, --SO.sub.2--,
--C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--,
--NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--, and R.sup.G1 and
R.sup.G2 are independently hydrogen, an aliphatic, alicyclic,
heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl
or (aliphatic)heteroaryl moiety; each occurrence of Y is
independently a bond or O; each occurrence of R.sup.P5 is
independently alkyl, heteroalkyl, aryl, or heteroaryl, or when Y is
O R.sup.P5 may also be hydrogen; and each occurrence of R.sup.P2 is
independently hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl moiety or a nitrogen
protecting group; wherein any two adjacent occurrences of R.sup.P1
and R.sup.P2, taken together, may form a cycloalkyl, heterocyclic,
aryl or heteroaryl moiety; and each occurrence of R.sup.P3
independently alkyl, aryl, heteroaryl or --N(R.sup.P2).sub.2;
[0113] xxx) Compounds of subset xxix) above wherein Ar.sub.2 is one
of the following structures:
##STR00039##
[0114] wherein s, X.sup.1, X.sup.2 and X.sup.3 are as defined in
xx) above; X.sup.2 is O, S or NR.sup.P2; each occurrence of
R.sup.P1 is independently hydrogen, halogen, CN, isocyanate,
NO.sub.2, -P(.dbd.0)(YR.sup.P5).sub.2, an alkyl, cycloalkyl,
heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl or
alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--, --S--,
--NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety; each occurrence of
Y is independently a bond or O; each occurrence of R.sup.P5 is
independently alkyl, heteroalkyl, aryl or heteroaryl, or when Y is
O R.sup.P5 may also be hydrogen; each occurrence of R.sup.P2 is
independently hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl moiety or a nitrogen
protecting group; wherein any two adjacent occurrences of R.sup.P1
and R.sup.2, taken together, may form a cycloalkyl, heterocyclic,
aryl or heteroaryl moiety; and each occurrence of R.sup.P3 is
independently alkyl, aryl, heteroaryl or --N(R.sup.P2).sub.2;
[0115] xxxi) Compounds of subset xxx) above wherein each occurrence
of R.sup.P1 is independently hydrogen, halogen,
-P(.dbd.O)(YR.sup.P5).sub.2, lower alkyl or heteroalkyl moiety, or
is -GR.sup.G1 wherein G is --O--, --S--, --NR.sup.G2--, or
--SO.sub.2--, and R.sup.G1 and R.sup.G2 are independently hydrogen,
lower alkyl or aryl; each occurrence of Y is independently a bond
or O; each occurrence of R.sup.P5 is independently lower alkyl, or
when Y is O R.sup.P5 may also be hydrogen; and each occurrence of
R.sup.P2 is independently hydrogen, lower alkyl or a nitrogen
protecting group; wherein any two adjacent occurrences of R.sup.P1
and R.sup.P2, taken together, may form a cycloalkyl, heterocyclic,
aryl or heteroaryl moiety;
[0116] xxxii) Compounds of subset xxx) above wherein Ar.sub.2 has
one of the following structures:
##STR00040##
[0117] wherein X.sub.1 is N or CR.sup.P1; s is an integer from 0-6;
each occurrence of R.sup.P1 is independently hydrogen, halogen, CN,
NO.sub.2, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety, or is -GR.sup.G1
wherein G is --O--, --S--, --NR.sup.G2--, --CO--, --SO--,
--SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--,
--OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety; and R.sup.P3 is independently lower
alkyl or aryl;
[0118] xxxiii) Compounds of subsets xxix), xxx) and xxxii) wherein
s is 0;
[0119] xxxiv) Compounds of subsets xxix), xxx) and xxxii) wherein s
is 1;
[0120] xxxv) Compounds of subsets xxix), xxx) and xxxii) wherein s
is 2;
[0121] xxxvi) Compounds of subsets x) and xi) above wherein
Ar.sub.2 is one of the following structures:
##STR00041##
[0122] wherein s is an integer from 0-2; each occurrence of
R.sup.P1 independently hydrogen, halogen, CN, isocyanate, NO.sub.2,
--OR.sup.G1, --SR.sup.G1, --NR.sup.G1R.sup.G2--, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety; each occurrence of Y is independently a
bond or O; each occurrence of R.sup.P5 is independently lower
alkyl, or when Y is OR.sup.P5 may also be hydrogen; each occurrence
of R.sup.P2 is independently hydrogen, alkyl, cycloalkyl,
heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl,
alkylheteroaryl, heteroalkylaryl, or heteroalkylheteroaryl moiety
or a nitrogen protecting group; R.sup.P3 is lower alkyl or
--N(R.sup.P2).sub.2; and R.sup.G1 and R.sup.G2 are independently
hydrogen, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety;
[0123] xxxvii) Compounds of subsets x) and xi) above wherein
Ar.sub.2 is one of the following structures:
##STR00042##
[0124] xxxviii) Compounds of subsets x) and xi) above wherein one
of the following structures:
##STR00043##
[0125] wherein R.sup.P3 is lower alkyl; and R.sup.P2 and R.sup.G1
are independently hydrogen or lower alkyl;
[0126] xxxix) Compounds of subsets x) and xi) above wherein
Ar.sub.2 is one of the following structures:
##STR00044##
[0127] wherein R.sup.P3 is lower alkyl and R.sup.G1 is hydrogen or
lower alkyl;
[0128] xl) Compounds of subsets x) and xi) above wherein R.sup.S is
hydrogen, hydroxyl or lower alkoxy and Ar.sub.2 is one of the
following structures:
##STR00045##
[0129] wherein R.sup.P3 is lower alkyl; and R.sup.G1 is hydrogen or
lower alkyl;
[0130] xli) Compounds of subsets xii) and xiii) wherein R.sup.1A is
alkyl or --NR.sup.1BR.sup.1C; wherein R.sup.1B and R.sup.1C are
independently hydrogen or lower alkyl;
[0131] xlii) Compounds of subsets xii) and xiii) wherein R.sup.1A
is --NH.sub.2 or a moiety having the structure:
##STR00046##
[0132] wherein R.sup.P1 is independently hydrogen, hydroxyl, lower
alkyl or lower heteroalkyl; and each occurrence of R.sup.P2 is
independently hydrogen or lower alkyl;
[0133] xliii) Compounds of subsets xii) and xiii) wherein R.sup.1A
is --NH.sub.2 or a moiety having the structure:
##STR00047##
[0134] wherein R.sup.P1 is hydrogen or lower alkyl;
[0135] xliv) Compounds of subsets xii) and xiii) wherein R.sup.1A
is cycloalkyl, aryl, or a moiety having one of the structures:
##STR00048##
[0136] wherein s is an integer between 0 and 6; each occurrence of
R.sup.P1 is independently hydrogen, halogen, CN, isocyanate,
NO.sub.2; -P(.dbd.O)(YR.sup.P5).sub.2, an alkyl, cycloalkyl,
heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl or
alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--, --S--,
--NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety; each occurrence of
Y is independently a bond or O; each occurrence of R.sup.P5 is
independently alkyl, heteroalkyl, aryl or heteroaryl, or when Y is
O R.sup.P5 may also be hydrogen; and each occurrence of R.sup.P2 is
independently hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl moiety or a nitrogen
protecting group; wherein any two adjacent occurrences of R.sup.P1
and R.sup.P2, taken together, may form a cycloalkyl, heterocyclic,
aryl, or heteroaryl moiety;
[0137] xlv) Compounds of subset xliv) wherein s is an integer
between 0 and 2; each occurrence of R.sup.P1 is independently lower
alkyl or is -GR.sup.G1 wherein G is --O-- or --NR.sup.G2, and
R.sup.G1 and R.sup.G2 are independently hydrogen, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety; and each occurrence of R.sup.P2 is
independently hydrogen, lower alkyl, aryl or heteroaryl.
[0138] xlvi) Compounds of subsets xxi) and xxi) wherein R.sup.1A in
a moiety having one of the structures:
##STR00049##
[0139] wherein s is an integer between 0 and 2; X.sup.0 is halogen;
each occurrence of R.sup.P1 is independently hydrogen, hydroxyl,
lower alkyl or lower heteroalkyl; G is --O-- or --NR.sup.G2--, and
R.sup.G1 and R.sup.G2 are independently hydrogen or lower alkyl;
and R.sup.P2 is independently hydrogen or lower alkyl;
[0140] xlvii) Compounds of subsets xlvi) wherein R.sup.1A is a
moiety having one of the structures:
##STR00050##
[0141] wherein G is --O-- or --NR.sup.G2--, and R.sup.G1 and
R.sup.G2 are independently hydrogen or lower alkyl;
[0142] xlix) compounds of subsets xiv)-xv) above wherein
--NH(R.sup.2A)Ar.sub.2 has one of the following structures:
##STR00051##
[0143] wherein X.sub.1 is N or CR.sup.P1; s is an integer from 0-5;
and each occurrence of R.sup.P1 is independently hydrogen, halogen,
CN, NO.sub.2, an alkyl, cycloalkyl, heteroalkyl, heterocyclic,
aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, or is
-GR.sup.G1 wherein G is --O--, --S--, --NR.sup.G2--, --CO--,
--SO--, --SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--,
--OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety; and R.sup.P3 is alkyl, heteroalkyl, aryl
or heteroaryl;
[0144] l) compounds of subset xlix) above wherein s is 0;
[0145] li) compounds of subset xlix) above wherein R.sup.P1 is
hydrogen, halogen or lower alkyl;
[0146] lii) compounds of subset li) above wherein R.sup.P1 is
hydrogen, chloro or methyl;
[0147] liii) compounds of subset xlix) above wherein R.sup.P3 is
lower alkyl;
[0148] liv) compounds of subset liii) above wherein R.sup.P3 is
methyl;
[0149] lv) compounds of subset xlix) above wherein
--NH(R.sup.2A)Ar.sub.2 has the following structure:
##STR00052##
[0150] wherein R.sup.P1 is hydrogen, halogen or lower alkyl;
[0151] lvi) compounds of subset xlix) above wherein
--NH(R.sup.2A)Ar.sub.2 has the following structure:
##STR00053##
[0152] lvii) Compounds of subsets xvii) having the following
structure:
##STR00054##
[0153] or bioisosteres thereof;
[0154] wherein each occurrence of R.sup.P1 is independently
hydrogen, halogen, methyl, --OCH.sub.3, --OH, --NH.sub.2,
--NHCH.sub.3 or --B(CH.sub.3).sub.2; R.sup.2A is hydrogen,
C.sub.1-6alkyl, C.sub.2-6alkenyl, aryl, heteroaryl,
--C(.dbd.O)R.sup.2B or --SO.sub.2R.sup.2B, wherein R.sup.2B is
alkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl or heteroaryl;
and q is 1 or 2;
[0155] lviii) Compounds of subset lvii) above wherein the
bioisosteres have one of the following structures:
##STR00055##
[0156] wherein q is 1 or 2; and R.sup.2C is lower alkyl;
[0157] lix) Compounds of subset xxviii) wherein
--C(.dbd.O)NHC(.dbd.CHAr.sub.2)CO.sub.2R.sup.3A has one of the
following structures:
##STR00056##
[0158] wherein R.sup.P3 is lower alkyl or aryl; X.sub.1 and X.sub.2
are independently N or CR.sup.P1; X.sub.3 is O, S or NR.sup.P2;
wherein R.sup.P1 is hydrogen, halogen, CN, NO.sub.2, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--,
--S--, --NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety; and R.sup.P2 is
hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, or
heteroalkylheteroaryl moiety;
[0159] lx) Compounds of subset xxviii) wherein
--C(.dbd.O)NHC(.dbd.CHAr.sub.2)CO.sub.2R.sup.3A has the following
structure:
##STR00057##
[0160] wherein X.sub.1 is N or CH;
[0161] lxi) R.sup.3 is --C(.dbd.O)OR.sup.3A, wherein R.sup.3A is as
defined in any one of subsets ii)-ix) above, and
--C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 has the structure
--C(.dbd.O)NHC(.dbd.C(R.sup.S)Ar.sub.2)CO.sub.2R.sup.3A wherein
R.sup.3A and R.sup.S, taken together, form a substituted or
unsubstituted heterocyclic moiety;
[0162] lxii) Compounds of subset lxi) wherein
--C(.dbd.O)NHC(.dbd.C(R.sup.S)Ar.sub.2)CO.sub.2R.sup.3A has one of
the following structures:
##STR00058##
[0163] wherein Ar.sub.2 is as defined in classes and subclasses
herein; and X.sub.1 is O, S or NH;
[0164] lxiii) Compounds of subset lxi) wherein
--C(.dbd.O)NHC(.dbd.C(R.sup.S)Ar.sub.2)CO.sub.2R.sup.3A has one of
the following structures:
##STR00059##
[0165] wherein X.sub.1 is O, S or NH; and X.sub.2 is N or CH;
[0166] lxiv) L is absent, --C(.dbd.O), --CH.sub.2C(.dbd.O)NH--,
--CH.sub.2NH--C(.dbd.O)--, --O--CH.sub.2--C(.dbd.O)--,
--CH.sub.2--CH.sub.2--C(.dbd.O)--,
--CH.dbd.CH--C(.dbd.O)NH--CH.sub.2--, --CH(OH)--CH.sub.2--O--,
--CH(OH)--CH.sub.2--N(CH.sub.3)--, --CH(OH)--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH(OH)--, --O--CH.sub.2--CH(OH)--,
--O--CH.sub.2--CH(OH)--CH.sub.2--,
--O--CH.sub.2--CH.sub.2--CH(OH)--, O--CH.sub.2--CH.sub.2--O--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--CH.sub.2--CH(OH)--CH.sub.2--O, --CH.sub.2--CH.sub.2--O--,
--CH--(CH.sub.3)--NH--C(.dbd.O)--, --CH.sub.2--NH--SO.sub.2--,
--NH--SO.sub.2--CH.sub.2--, --CH.sub.2--SO.sub.2--NH--,
--SO.sub.2NH--CH.sub.2--, --C(.dbd.O)--NH--C(.dbd.O)--,
--NH--C(.dbd.O)--NH--, --NH--C(.dbd.O)--NH--CH.sub.2--,
--CH.sub.2--NH--C(.dbd.O)--NH--,
--C(.dbd.O)--NH--CH.sub.2--C(.dbd.O)--NH, --NH--C(.dbd.O)--O--,
--O--C(.dbd.O)--NH--; or a substituted or unsubstituted
C.sub.1-6alkylidene or C.sub.2-6alkenylidene chain wherein up to
two non-adjacent methylene units are independently optionally
replaced by --C(.dbd.O)--, --CO.sub.2--, --C(.dbd.O)C(.dbd.O)--,
--C(.dbd.O)NR.sup.L3--, --OC(.dbd.O)--, --OC(.dbd.O)NR.sup.L3--,
--NR.sup.L3NR.sup.L4--, --NR.sup.L3NR.sup.L4C(.dbd.O)--,
--NR.sup.L3C(.dbd.O)--, --NR.sup.L3CO.sub.2--,
--NR.sup.L3C(.dbd.O)NR.sup.L4--, --S(.dbd.O)--, --SO.sub.2--,
--NR.sup.L3SO.sub.2--, --SO.sub.2NR.sup.L3--,
--NR.sup.L3SO.sub.2NR.sup.L4--, --O--, --S--, or --NR.sup.L3--;
wherein each occurrence or R.sup.L3 and R.sup.L4 is independently
hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl;
[0167] lxv) L is absent, --C(.dbd.O), or a substituted or
unsubstituted C.sub.1-6alkylidene or C.sub.2-6alkenylidene chain
wherein up to two non-adjacent methylene units are independently
optionally replaced by --C(.dbd.O)--, --CO.sub.2--,
--C(.dbd.O)C(.dbd.O)--, --C(.dbd.O)NR.sup.L3--, --OC(.dbd.O)--,
--OC(.dbd.O)NR.sup.L3--, --NR.sup.L3NR.sup.L4--,
--NR.sup.L3NR.sup.L4C(.dbd.O)--, --NR.sup.L3C(.dbd.O)--,
--NR.sup.L3CO.sub.2--, --NR.sup.L3C(.dbd.O)NR.sup.L4--,
--S(.dbd.O)--, --SO.sub.2--, --NR.sup.L3SO.sub.2--,
--SO.sub.2NR.sup.L3--, --NR.sup.L3SO.sub.2NR.sup.L4--, --O--,
--S--, or --NR.sup.L3--; wherein each occurrence of R.sup.L3 and
R.sup.L4 is independently hydrogen, alkyl, heteroalkyl, aryl,
heteroaryl or acyl;
[0168] lxvi) L is absent;
[0169] lxvii) L is --C(.dbd.O);
[0170] lxviii) L is absent, --C(.dbd.O), --CH.sub.2C(.dbd.O)NH--,
--CH.sub.2NH--C(.dbd.O)--, --O--CH.sub.2--C(.dbd.O)--,
--CH.sub.2--CH.sub.2--C(.dbd.O)--,
--CH.dbd.CH--C(.dbd.O)NH--CH.sub.2--, --CH(OH)--CH.sub.2--O--,
--CH(OH)--CH.sub.2--N(CH.sub.3)--, --CH(OH)--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH(OH)--, --O--CH.sub.2--CH(OH)--,
--O--CH.sub.2--CH(OH)--CH.sub.2--,
--O--CH.sub.2--CH.sub.2--CH(OH)--, O--CH.sub.2--CH.sub.2--O--,
--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--CH.sub.2--CH(OH)--CH.sub.2--O, --CH.sub.2--CH.sub.2--O--,
--CH--(CH.sub.3)--NH--C(.dbd.O)--, --CH.sub.2--NH--SO.sub.2--,
--NH--SO.sub.2--CH.sub.2--, --CH.sub.2--SO.sub.2--NH--,
--SO.sub.2NH--CH.sub.2--, --C(.dbd.O)--NH--C(.dbd.O)--,
--NH--C(.dbd.O)--NH--, --NH--C(.dbd.O)--NH--CH.sub.2--,
--CH.sub.2--NH--C(.dbd.O)--NH--,
--C(.dbd.O)--NH--CH.sub.2--C(.dbd.O)--NH, --NH--C(.dbd.O)--O--, or
--O--C(.dbd.O)--NH--;
[0171] lxix) L is --(CH.sub.2).sub.q-- wherein q is 1-5;
[0172] lxx) L is --CH.sub.2--;
[0173] lxxi) L is --(CH.sub.2).sub.3--;
[0174] lxxii) L is a moiety having the structure:
##STR00060##
[0175] lxxii) AR.sup.1 is one of the following structures:
##STR00061## ##STR00062## ##STR00063##
[0176] wherein each occurrence of r is an integer from 0-6;
X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently N or
CR.sup.Q1; AR.sub.3 is a heterocyclic, aryl or heteroaryl moiety;
each occurrence of R.sup.Q1 is independently hydrogen, OR.sup.Q3,
OCF.sub.3, SR.sup.Q3, halogen, CN, isocyanate, NO.sub.2, CF.sub.3,
NR.sup.Q3QR.sup.Q4, --SO.sub.2R.sup.Q3, alkyl-NR.sup.Q3R.sup.Q4,
alkyl-C(.dbd.O)--NR.sup.Q3R.sup.Q4, alkyl-C(.dbd.O)R.sup.Q3, or an
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, or
heteroalkylheteroaryl moiety, wherein each occurrence of R.sup.Q3
and R.sup.Q4 is independently hydrogen, a protecting group, or an
aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and R.sup.Q2
is hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl moiety or a nitrogen
promoting group;
[0177] lxxiv) AR.sup.1 is one of the following structures:
##STR00064## ##STR00065##
[0178] wherein each occurrence of r is an integer from 0-6;
X.sub.1, X.sub.2, X.sub.3 and X.sub.4 is independently N or
CR.sup.Q1; X.sub.5 is O, S or NR.sup.Q2; AR.sup.3 is a
heterocyclic, aryl or heteroaryl moiety; each occurrence of
R.sup.Q1 is independently hydrogen, OR.sup.Q3, OCF.sub.3,
SR.sup.Q3, halogen, CN, isocyanate, NO.sub.2, CF.sub.3,
NR.sup.Q3QR.sup.Q4, --SO.sub.2R.sup.Q3, alkyl-NR.sup.Q3R.sup.Q4,
alkyl-C(.dbd.O)--NR.sup.Q3R.sup.Q4, alkyl-C(.dbd.O)R.sup.Q3, or an
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, or
heteroalkylheteroaryl moiety, wherein each occurrence of R.sup.Q3
and R.sup.Q4 is independently hydrogen, a protecting group, or an
aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and R.sup.Q2
is hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl moiety or a nitrogen
protecting group;
[0179] lxxv) AR.sup.1 is one of the following structures:
##STR00066##
[0180] wherein r is as defined above; X.sub.1, X.sub.2, X.sub.3 and
X.sub.4 is independently N or CH; X.sub.5 is CHR.sup.Q1 or NH; each
occurrence of R.sup.Q1 is independently hydrogen, OR.sup.Q3,
OCF.sub.3, SR.sup.Q3, halogen, CN, isocyanate, NO.sub.2, CF.sub.3,
NR.sup.Q3QR.sup.Q4, --SO.sub.2R.sup.Q3, alkyl-NR.sup.Q3R.sup.Q4,
alkyl-C(.dbd.O)--NR.sup.Q3R.sup.Q4, alkyl-C(.dbd.O)R.sup.Q3, or an
aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, or
heteroalkylheteroaryl moiety, wherein each occurrence of R.sup.Q3
and R.sup.Q4 is independently hydrogen, a protecting group, or an
aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and R.sup.Q2
is hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl moiety or a nitrogen
protecting group;
[0181] lxxvi) AR.sup.1 is one of the following structures:
##STR00067##
[0182] wherein X.sup.0 is F or Cl; X.sub.2 is N or CR.sup.Q1;
X.sub.5 is CH, O, S or NH; R.sup.Q1 is hydrogen, methyl,
--CF.sub.3, --OCH.sub.3, --OCF.sub.3 or halogen;
[0183] lxxvii) AR.sup.1 is one of the following structures:
##STR00068##
[0184] lxxviii) AR.sup.1 is one of the following structures:
##STR00069##
[0185] lxxix) AR.sup.1-L- is one of the following structures:
##STR00070##
[0186] lxxx) AR.sup.1-L- is one of the following structures:
##STR00071##
[0187] lxxxi) R.sup.4, for each occurrence is independently
hydrogen, halogen, --CN, --NO.sub.2, an alkyl, alkylenyl; alkynyl;
cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--,
--S--, --NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sub.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an alkyl, alkylenyl; alkynyl; cycloalkyl, heteroalkyl,
heterocyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl
moiety;
[0188] lxxxii) R.sup.4, for each occurrence, is independently
hydrogen, halogen, or lower alkyl;
[0189] lxxxiii) R.sup.4, for each occurrence, is independently
hydrogen or chloro;
[0190] lxxxiv) n is 0;
[0191] lxxxv) n is 2;
[0192] lxxxvi) n is 2 and each occurrence of R.sup.4 is a
halogen;
[0193] lxxxvii) n is 2 and each occurrence of R.sup.4 is Cl;
[0194] lxxxviii) p is 1;
[0195] lxxxix) p is 2; and/or
[0196] xc) Compounds of formula (II) wherein when
--C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 has the structure:
##STR00072##
[0197] then AR.sup.1 is not one of:
##STR00073##
[0198] wherein Y.sup.1 is N or CR.sup.Q1; X.sup.1, X.sup.2, X.sup.3
and X.sup.4 are independently CR.sup.Q1; X5 is NR.sup.Q1, O or S; r
is 0-3; and each occurrence of R.sup.Q1 is independently CN,
NO.sub.2, halogen, CF.sub.3, an alkyl, cycloalkyl, heteroalkyl,
heterocyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety
or is GR.sup.G1 wherein G is --O--, --S--, --NR.sup.G2--, --CO--,
--SO--, --C.sub.0-6alkylSO.sub.2--,
--C.sub.0-6alkylSO.sub.2NR.sup.G2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)-- or --NR.sup.G2C(.dbd.O)--,
and R.sup.G1 and R.sup.G2 are independently hydrogen, an alkyl,
cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety.
[0199] It will be appreciated that for each of the classes and
subclasses described above and herein, any one or more occurrences
of aliphatic or heteroaliphatic may independently be substituted or
unsubstituted, cyclic or acyclic, linear or branched and any one or
more occurrences of aryl, heteroaryl, cycloaliphatic,
cycloheteroaliphatic may be substituted or unsubstituted.
[0200] The reader will also appreciate that all possible
combinations of the variables described in i)- through xc) above
(e.g., R1, R.sup.2, R.sup.3, R.sup.4, L, and AR.sup.1, among
others) are considered part of the invention. Thus, the invention
encompasses any and all compounds of formula I or II generated by
taking any possible permutation of variables R.sup.1, R.sup.2,
R.sup.3, R.sup.4, L, AR.sup.1, etc. and other
variables/substituents (e.g., X.sup.1, X.sup.2, X.sup.3, X.sup.4,
R.sup.1A, R.sup.2A, R.sup.2C, R.sup.2D, etc.) as further defined
for R.sup.1, R.sup.2, R.sup.3, R.sup.4, L, AR.sup.1, etc. described
in i)- through xc) above.
[0201] For example, an exemplary combination of variables described
in i)- through xc) above includes those compounds of Formula I
wherein:
[0202] R.sup.1 and R.sup.2 are each independently hydrogen, an
amino acid side chain, --(CH.sub.2).sub.mOH--,
--(CH.sub.2).sub.maryl, --(CH.sub.2).sub.mheteroaryl, wherein m is
0-6, --CH(R.sup.1A)(OR.sup.1B), --CH(R.sup.1A)(NHR.sup.1B), U-T-Q,
or an aliphatic, alicyclic, heteroaliphatic or heteroalicyclic
moiety optionally substituted with U-T-Q, wherein U is absent,
--O--, --S(O).sub.0-2--, --SO.sub.2N(R.sup.1A), --N(R.sup.1A)--,
--N(R.sup.1A)C(.dbd.O)--, --N(R.sup.1A)C(.dbd.O)--O--,
--N(R.sup.1A)C(.dbd.O)--N(R.sup.1B)--, --N(R.sup.1A)--SO.sub.2--,
--C(.dbd.O)--, --C(.dbd.O)--O--, --O--C(.dbd.O)--, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, --C(.dbd.O)--N(R.sup.1A)--,
--O--C(.dbd.O)--N(R.sup.1A)--, --C(.dbd.N--R.sup.1E)--,
--C(.dbd.N--R.sup.1E)--O--, --C(.dbd.N--R.sup.1E)--N(R.sup.1A)--,
--O--C(.dbd.N--R.sup.1E)--N(R.sup.1A)--,
--N(R.sup.1A)C(.dbd.N--R.sup.1E)--,
--N(R.sup.1A)C(.dbd.N--R.sup.1E)--O--,
N(R.sup.1A)C(.dbd.N--R.sup.1E)--N(R.sup.1B)--,
-P(.dbd.O)(OR.sup.1A)--O--, or -P(.dbd.O)(R.sup.1A)--O--; T is
absent, an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl
or alkylheteroaryl moiety; and Q is hydrogen, halogen, cyano,
isocyanate, --OR.sup.1B, --SR.sup.1B; --N(R.sup.1B).sub.2,
--NHC(.dbd.O)OR.sup.1B, --NHC(.dbd.O)N(R.sup.1B).sub.2,
--NHC(.dbd.O)R.sup.1B, --NHSO.sub.2R.sup.1B,
--NHSO.sub.2N(R.sup.1B).sub.2, --NHSO.sub.2NHC(.dbd.O)OR.sup.1B,
--NHC(.dbd.O)NHSO.sub.2R.sup.1B, --C(.dbd.O)NHC(.dbd.O)OR.sup.1B,
--C(.dbd.O)NHC(.dbd.O)R.sup.1B,
--C(.dbd.O)NHC(.dbd.O)N(R.sup.1B).sub.2,
--C(.dbd.O)NHSO.sub.2R.sup.1B,
--C(.dbd.O)NHSO.sub.2N(R.sup.1B).sub.2,
--C(.dbd.S)N(R.sup.1B).sub.2, --SO.sub.2R.sup.1B,
--SO.sub.2--O--R.sup.1B, --SO.sub.2--N(R.sup.1B).sub.2,
--SO.sub.2--NHC(.dbd.O)OR.sup.1B,
--SO.sub.2NHC(.dbd.O)--N(R.sup.1B).sub.2,
--SO.sub.2--NHC(.dbd.O)R.sup.1B, --O--C(.dbd.O)N(R.sup.1B).sub.2,
--O--C(.dbd.O)R.sup.1B, --O--C(.dbd.O)NHC(.dbd.O)R.sup.1B,
--O--C(.dbd.O)NH--SO.sub.2R.sup.1B, --O--SO.sub.2R.sup.1B, or an
aliphatic heteroaliphatic, aryl or heteroaryl moiety, or wherein
R.sup.1 and R.sup.2 taken together are an alicyclic or heterocyclic
moiety, or together are
##STR00074##
wherein each occurrence of R.sup.1A and R.sup.1B is independently
hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic,
aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety,
--COR.sup.1C, or --CONR.sup.1CR.sup.1D; wherein each occurrence of
R.sup.1C and R.sup.1D is independently hydrogen, hydroxyl, or an
aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or
alkylheteroaryl moiety; and R.sup.1E is hydrogen, an aliphatic,
alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl,
alkylaryl or alkylheteroaryl moiety, --CN, --OR.sup.1C,
--NR.sup.1CR.sup.1D or --SO.sub.2R.sup.1C;
[0203] R.sup.3 is --C(.dbd.O)OR.sup.3A, --C(.dbd.O)H,
--CH.sub.2OR.sup.3A, --CH.sub.2O--C(.dbd.O)-alkyl,
--C(.dbd.O)NH(R.sup.3A), --CH.sub.2X.sup.0; wherein each occurrence
of R.sup.3A is independently hydrogen, a protecting group, an
aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl,
heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or
heteroalkylheteroaryl moiety, or R.sup.3A, taken together with
R.sup.1 or R.sup.2, forms a heterocyclic moiety; wherein X.sup.0 is
a halogen selected from F, Cl, Br or I;
[0204] R.sup.4, for each occurrence, is independently hydrogen,
halogen, --CN, --NO.sub.3, an aliphatic, alicyclic,
heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl or
alkylheteroaryl moiety, or is a -GR.sup.G1 wherein G is --O--,
--S--, --NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heteroalicyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl
moiety;
[0205] AR.sup.1 is a monocyclic or polycyclic aryl, heteroaryl,
alkylaryl, alkylheteroaryl, alicyclic or heterocyclic moiety;
[0206] A, B, D and E are connected by either a single or double
bond, as valency permits; wherein each occurrence of A, B, D and E
is independently C.dbd.0, CR.sup.iR.sup.ii, NR.sup.i, CR.sup.i, N,
S, S(.dbd.O) or SO.sub.2; wherein each occurrence of R.sup.1 is
independently hydrogen, halogen, --CN, --NO.sub.2, an aliphatic,
alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl,
alkylaryl or alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is
--O--, --S--, --NR.sup.G2--, --CO--, --SO--, --SO.sub.2--,
--C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--,
--NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--, and R.sup.G1 and
R.sup.G2 are independently hydrogen, an aliphatic, alicyclic,
heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl or
alkylheteroaryl moiety, or any two adjacent occurrences of R.sup.i,
taken together, represent an alicyclic, heteroalicyclic, aryl, or
heteroaryl moiety; and
[0207] L is absent or is V-W-X-Y-Z, wherein each occurrence of V,
W, X, Y and Z is independently absent, C.dbd.O, NR.sup.L1, --O--,
--C(R.sup.L1).dbd., .dbd.C(R.sup.L1)--, --C(R.sup.L1)(R.sup.L2),
C(.dbd.N--O--R.sup.L1), C(.dbd.N--R.sup.L1), --N.dbd.,
S(O).sub.0-2; a substituted or unsubstituted C.sub.1-6alkylidene or
C.sub.2-6alkenylidene chain wherein up to two non-adjacent
methylene units are independently optionally replaced by
--C(.dbd.O)--, --CO.sub.2--, --C(.dbd.O)C(.dbd.O)--,
--C(.dbd.O)NR.sup.L3--, --OC(.dbd.O)--, --OC(.dbd.O)NR.sup.L3--,
--NR.sup.L3NR.sup.L4--, --NR.sup.L3NR.sup.L4C(.dbd.O)--,
--NR.sup.L3C(.dbd.O)--, --NR.sup.L3CO.sub.2--,
--NR.sup.L3C(.dbd.O)NR.sup.L4--, --S(.dbd.O)--, --SO.sub.2--,
--NR.sup.L3SO.sub.2--, --SO.sub.2NR.sup.L3--,
--NR.sup.L3SO.sub.2NR.sup.L4--, --O--, --S--, or --NR.sup.L3--;
wherein each occurrence of R.sup.L3 and R.sup.L4 is independently
hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl; or an
aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety; and each
occurrence of R.sup.L1 and R.sup.L3 is independently hydrogen,
hydroxyl, protected hydroxyl, amino, protected amino, thio,
protected thio, halogen, cyano, isocyanate, carboxy, carboxyalkyl,
formyl, formyloxy, azido, nitro, ureido, thioureido, thiocyanato,
alkoxy, aryloxy, mercapto, sulfonamido, benzamido, tosyl, or an
aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety, or wherein one or
more occurrences of R.sup.L1 and R.sup.L3, taken together, or taken
together with one of V, W, X, Y or Z form an alicyclic or
heterocyclic moiety or form an aryl or heteroaryl moiety.
[0208] Other exemplary combinations are illustrated by compounds of
the following subgroups I through XIV:
[0209] I) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00075##
[0210] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.B1, R.sup.B2 and R.sup.E
are independently hydrogen or substituted or unsubstituted lower
alkyL. In certain embodiments, R.sup.4A and R.sup.4B are each CL.
In yet other embodiments, one of R.sup.B1 and R.sup.B2 is hydrogen,
the other is substituted or unsubstituted lower alkyL. In certain
exemplary embodiments, R.sup.B1 and R.sup.B2 are each hydrogen. In
certain other exemplary embodiments, R.sup.B1 and R.sup.B2 are each
lower alkyL. In certain exemplary embodiments, R.sup.B1 and
R.sup.B2 are each methyL. In other embodiments, R.sup.E is
hydrogen. In yet other embodiments, R.sup.E is substituted or
unsubstituted lower alkyL. In yet other embodiments, R.sup.E is
substituted or unsubstituted methyl, ethyl, propyl, i-propyl,
n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, tert-pentyl
or n-hexyl. In certain embodiments, R.sup.4A and R.sup.4B are each
Cl; and R.sup.B1 and R.sup.B2 are each hydrogen.
[0211] II) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00076##
[0212] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.E is hydrogen or
substituted or unsubstituted lower alkyL. In certain embodiments,
R.sup.4A and R.sup.4B are each CL. In other embodiments, R.sup.E is
hydrogen. In yet other embodiments, R.sup.E is substituted or
unsubstituted lower alkyL. In yet other embodiments, R.sup.E is
substituted or unsubstituted methyl, ethyl, propyl, i-propyl,
n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, tert-pentyl
or n-hexyl.
[0213] III) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00077##
[0214] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.E is hydrogen or
substituted or unsubstituted lower alkyL. In certain embodiments,
R.sup.4A and R.sup.4B are each CL. In other embodiments, R.sup.E is
hydrogen. In yet other embodiments, R.sup.E is substituted or
unsubstituted lower alkyL. In yet other embodiments, R.sup.E is
substituted or unsubstituted methyl, ethyl, propyl, i-propyl,
n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, tert-pentyl
or n-hexyl.
[0215] IV) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00078##
[0216] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.E is hydrogen or
substituted or unsubstituted lower alkyL. In certain embodiments,
R.sup.4A and R.sup.4B are each CL. In other embodiments, R.sup.E is
hydrogen. In yet other embodiments, R.sup.E is substituted or
unsubstituted lower alkyL. In yet other embodiments, R.sup.E is
substituted or unsubstituted methyl, ethyl, propyl, i-propyl,
n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, tert-pentyl
or n-hexyl.
[0217] V) Compounds Have the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00079##
[0218] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; R.sup.A is hydrogen, lower alkyl or
acyl; and R.sup.E is hydrogen or substituted or unsubstituted lower
alkyL. In certain embodiments, R.sup.4A and R.sup.4B are each CL.
In other embodiments, R.sup.E is hydrogen. In yet other
embodiments, R.sup.E is substituted or unsubstituted lower alkyL.
In yet other embodiments, R.sup.E is substituted or unsubstituted
methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl, tert-butyl,
n-pentyl, sec-pentyl, tert-pentyl or n-hexyl.
[0219] VI) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00080##
[0220] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; R.sup.A1, R.sup.A2, R.sup.B1 and
R.sup.B2 are independently hydrogen or substituted or unsubstituted
lower alkyL. In certain embodiments, R.sup.4A and R.sup.4B are each
CL. In certain embodiments, R.sup.A1, R.sup.A2, R.sup.B1 And
R.sup.B2 are each hydrogen.
[0221] VII) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00081##
[0222] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.A and R.sup.B are
independently hydrogen or substituted or unsubstituted lower alkyL.
In certain embodiments, R.sup.4A and R.sup.4B are each CL. In
certain embodiments, R.sup.A and R.sup.B are each hydrogen.
[0223] VIII) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00082##
[0224] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.A is hydrogen or
substituted or unsubstituted lower alkyL. In certain embodiments,
R.sup.4A and R.sup.4B are each CL. In certain embodiments, R.sup.A
is hydrogen.
[0225] IX) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00083##
[0226] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.B is hydrogen or
substituted or unsubstituted lower alkyL. In certain embodiments,
R.sup.4A and R.sup.4B are each CL. In certain embodiments, R.sup.B
is hydrogen.
[0227] X) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00084##
[0228] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and R.sup.A is hydrogen or
substituted or unsubstituted lower alkyL. In certain embodiments,
R.sup.4A and R.sup.4B are each CL. In certain embodiments, R.sup.4A
is hydrogen.
[0229] XI) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00085##
[0230] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; R.sup.A, R.sup.B and R.sup.E are
independently hydrogen or substituted or unsubstituted lower alkyL.
In certain embodiments, R.sup.4A and R.sup.4B are each CL. In
certain embodiments, R.sup.A and R.sup.B are each hydrogen. In
certain other embodiments, R.sup.E is hydrogen. In yet other
embodiments, R.sup.A, R.sup.B and R.sup.E are each hydrogen.
[0231] XII) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00086##
[0232] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; R.sup.A, R.sup.B and R.sup.E are
independently hydrogen or substituted or unsubstituted lower alkyL.
In certain embodiments, R.sup.4A and R.sup.4B are each CL. In
certain embodiments, R.sup.A and R.sup.B are each hydrogen. In
certain other embodiments, R.sup.E is hydrogen. In yet other
embodiments, R.sup.A, R.sup.B and R.sup.E are each hydrogen.
[0233] XIII) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00087##
[0234] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and A and B are independently N or
CH. In certain embodiments, R.sup.4A and R.sup.4B are each CL. In
certain embodiments, A is N. In certain embodiments, A is CH. In
certain embodiments, B is N. In certain embodiments, A is CH. In
certain embodiments, A and B are each N. In certain embodiments, A
is CH. In certain embodiments, A and B are each CH.
[0235] XIV) Compounds Having the Structure (and Pharmaceutically
Acceptable Derivatives Thereof):
##STR00088##
[0236] wherein R.sup.4A and R.sup.4B are independently a halogen
selected from F, Cl, Br or I; and A and B are independently N or
CH. In certain embodiments, R.sup.4A and R.sup.4B are each CL. In
certain embodiments, A is N. In certain embodiments, A is CH. In
certain embodiments, B is N. In certain embodiments, A is CH. In
certain embodiments, A and B are each N. In certain embodiments, A
is CH. In certain embodiments, A and B are each CH.
[0237] In certain embodiments, for compounds of classes I-XIV
above, AR.sup.1-L- is a moiety having one of the following
structures:
##STR00089##
and --C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having one
of the following structures:
##STR00090##
[0238] or bioisosteres thereof;
[0239] wherein R.sup.2A and R.sup.3A are as defined in classes and
subclasses herein; and R.sup.2D is a moiety having one of the
following structures:
##STR00091##
[0240] wherein s is an integer between 0 and 6; each occurrence of
R.sup.P1 is independently hydrogen, halogen, CN, isocyanate,
NO.sub.2, -P(.dbd.O)(YR.sup.5).sub.2, an alkyl, cycloalkyl,
heteroalkyl, heterocyclic, aryl, heteroaryl, alkylaryl or
alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--, --S--,
--NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--,
--C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or
--SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently
hydrogen, an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl,
heteroaryl, alkylaryl or alkylheteroaryl moiety; each occurrence of
Y is independently a bond or O; each occurrence of R.sup.P5 is
independently alkyl, heteroalkyl, aryl or heteroaryl, or when Y is
O R.sup.P5 may also be hydrogen; and each occurrence of R.sup.P2 is
independently hydrogen, an aliphatic, alicyclic, heteroaliphatic,
heterocyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl,
heteroalkylaryl, or heteroalkylheteroaryl, moiety or a nitrogen
protecting group; wherein any two adjacent occurrences of R.sup.P1
1and R.sup.P2, taken together, may form a cycloalkyl, heterocyclic,
aryl or heteroaryl moiety.
[0241] In certain embodiments, R.sup.2A and R.sup.3A are each
hydrogen.
[0242] In certain embodiments, R.sup.2D is a moiety having one of
the structures:
##STR00092##
[0243] wherein each occurrence of R.sup.P1 is independently
hydrogen, halogen, methyl, --OCH.sub.3, --OH, --NH.sub.3,
--NHCH.sub.3, or N(CH.sub.3).sub.2.
[0244] In certain embodiments, R.sup.2d is a moiety having one of
the structures:
##STR00093##
[0245] It will also be appreciated that for each of the subgroups
I-XIV described above, a variety of other subclasses are of special
interest, including, but not limited to those classes described
above i)-xc) and classes, subclasses and species of compounds
described above and in the examples herein.
[0246] Some of the foregoing compounds can comprise one or more
asymmetric centers, and thus can exist in various isomeric forms,
e.g., stereoisomers and/or diastereomers. Thus, inventive compounds
and pharmaceutical compositions thereof may be in the form of an
individual enantiomer, diastereomer or geometric isomer, or may be
in the form of a mixture of stereoisomers. In certain embodiments,
the compounds of the invention are enantiopure compounds. In
certain other embodiments, mixtures of stereoisomers or
diastereomers are provided.
[0247] Furthermore, certain compounds, as described herein may have
one or more double bonds that can exist as either the Z or E
isomer, unless otherwise indicated. The invention additionally
encompasses the compounds as individual isomers substantially free
of other isomers and alternatively, as mixtures of various isomers,
e.g., racemic mixtures of stereoisomers. In addition to the
above-mentioned compounds per se, this invention also encompasses
pharmaceutically acceptable derivatives of these compounds and
compositions comprising one or more compounds of the invention and
one or more pharmaceutically acceptable excipients or
additives.
[0248] Compounds of the invention may be prepared by
crystallization of compound of formula (I) or (II) under different
conditions and may exist as one or a combination of polymorphs of
compound of general formula (I) or (II) forming part of this
invention. For example, different polymorphs may be identified
and/or prepared using different solvents, or different mixtures of
solvents for recrystallization; by performing crystallizations at
different temperatures; or by using various modes of cooling,
ranging from very fast to very slow cooling during
crystallizations. Polymorphs may also be obtained by heating or
melting the compound followed by gradual or fast cooling. The
presence of polymorphs may be determined by solid probe NMR
spectroscopy, IR spectroscopy, differential scanning calorimetry,
powder X-ray diffractogram and/or other techniques. Thus, the
present invention encompasses inventive compounds, their
derivatives, their tautomeric forms, their stereoisomers, their
polymorphs, their pharmaceutically acceptable salts their
pharmaceutically acceptable solvates and pharmaceutically
acceptable compositions containing them.
[0249] 2) Pharmaceutical Compositions
[0250] As discussed above this invention provides novel compounds
that have biological properties useful for the treatment of Mac-1
and LFA-1 mediated disorders.
[0251] Accordingly, in another aspect of the present invention,
pharmaceutical compositions are provided, which comprise any one of
the compounds described herein (or a prodrug, pharmaceutically
acceptable salt or other pharmaceutically acceptable derivative
thereof), and optionally comprise a pharmaceutically acceptable
carrier. In certain embodiments, these compositions optionally
further comprise one or more additional therapeutic agents.
Alternatively, a compound of this invention may be administered to
a patient in need thereof in combination with the administration of
one or more other therapeutic agents. For example, additional
therapeutic agents for conjoint administration or inclusion in a
pharmaceutical composition with a compound of this invention may be
an approved anti-inflammatory agent, or it may be any one of a
number of agents undergoing approval in the Food and Drug
Administration that ultimately obtain approval for the treatment of
any disorder mediated by Mac-1 or LFA-1. It will also be
appreciated that certain of the compounds of present invention can
exist in free form for treatment, or where appropriate, as a
pharmaceutically acceptable derivative thereof.
[0252] As described above, the pharmaceutical compositions of the
present invention additionally comprise a pharmaceutically
acceptable carrier, which, as used herein, includes any and all
solvents, diluents, or other liquid vehicle, dispersion or
suspension aids, surface active agents, isotonic agents, thickening
or emulsifying agents, preservatives, solid binders, lubricants and
the like, as suited to the particular dosage form desired.
Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W.
Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various
carriers used in formulating pharmaceutical compositions and known
techniques for the preparation thereof. Except insofar as any
conventional carrier medium is incompatible with the compounds of
the invention, such as by producing any undesirable biological
effect or otherwise interacting in a deleterious manner with any
other component(s) of the pharmaceutical composition, its use is
contemplated to be within the scope of this invention. Some
examples of materials which can serve as pharmaceutically
acceptable carriers include, but are not limited to, sugars such as
lactose, glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatine; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil; safflower oil, sesame oil; olive oil; corn oil and soybean
oil; glycols; such as propylene glycol; esters such as ethyl oleate
and ethyl laurate; agar; buffering agents such as magnesium
hydroxide and aluminum hydroxide; alginic acid; pyrogen free water;
isotonic saline; Ringer's solution; ethyl alcohol, and phosphate
buffer solutions, as well as other non-toxic compatible lubricants
such as sodium lauryl sulfate and magnesium stearate, as well as
coloring agents, releasing agents, coating agents, sweetening,
flavoring and perfuming agents, preservatives and antioxidants can
also be present in the composition, according to the judgment of
the formulator.
[0253] Liquid dosage forms for oral administration include, but are
not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0254] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispensing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanedioL. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0255] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0256] In order to prolong the effect of a drug, it is often
desirable to slow the absorption of the drug from subcutaneous or
intramuscular injection. This may be accomplished by the use of a
liquid suspension or crystalline or amorphous material with poor
water solubility. The rate of absorption of the drug then depends
upon its rate of dissolution that, in turn, may depend upon crystal
size and crystalline form. Alternatively, delayed absorption of a
parenterally administered drug form is accomplished by dissolving
or suspending the drug in an oil vehicle. Injectable depot forms
are made by forming microencapsule matrices of the drug in
biodegradable polymers such as polylactide-polyglycolide. Depending
upon the ratio of drug to polymer and the nature of the particular
polymer employed, the rate of drug release can be controlled.
Examples of other biodegradable polymers include (poly(orthoesters)
and poly(anhydrides). Depot injectable formulations are also
prepared by entrapping the drug in liposomes or microemulsions
which are compatible with body tissues.
[0257] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0258] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof, In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0259] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes. Solid
compositions of a similar type may also be employed as fillers in
soft and hard-filled gelatin capsules using such excipients as
lactose or milk sugar as well as high molecular weight polethylene
glycols and the like.
[0260] The active compounds can also be in micro-encapsulated form
with one or more excipients noted above. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose and starch. Such dosage forms may also
comprise, as in normal practice, additional substances other than
inert diluents, e.g., tableting lubricants and other tableting aids
such as magnesium stearate and microcrystalline cellulose. In the
case of capsules, tablets and pills, the dosage forms may also
comprise buffering agents. They may optionally contain opacifying
agents and can also be of a composition that they release the
active ingredient(s) only, or preferentially, in a certain part of
the intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions which can be used include polymeric
substances and waxes.
[0261] the present invention encompasses pharmaceutically
acceptable topical formulations of inventive compounds. The term
"pharmaceutically acceptable topical formulation", as used herein,
means any formulation which is pharmaceutically acceptable for
intradermal administration of a compound of the invention by
application of the formulation to the epidermis. In certain
embodiments of the invention, the topical formulation comprises a
carrier system. Pharmaceutically effective carriers include, but
are not limited to, solvents (e.g., alcohols, poly alcohols,
water), creams, lotions, ointments, oils, plasters, liposomes,
powders, emulsions, microemulsions, and buffered solutions (e.g.,
hypotonic or buffered saline) or any other carrier known in the art
for topically administering pharmaceuticals. A more complete
listing of arT-known carriers is provided by references texts that
are standard in the art, for example, Remington's Pharmaceutical
Sciences, 16th Edition, 1980 and 17th Edition, 1985, both published
by Mack Publishing Company, Easton, Pa., the disclosures of which
are incorporated herein by reference in their entireties. In
certain other embodiments, the topical formulations of the
invention may comprise excipients. Any pharmaceutically acceptable
excipient known in the art may be used to prepare the inventive
pharmaceutically acceptable topical formulations. Examples of
excipients that can be included in the topical formulations of the
invention include, but are not limited to, preservatives,
antioxidants, moisturizers, emollients, buffering agents,
solubilizing agents, other penetration agents, skin protectants,
surfactants, and propellants, and/or additional therapeutic agents
used in combination to the inventive compound. Suitable
preservatives include, but are not limited to, alcohols, quaternary
amines, organic acids, parabens, and phenols. Suitable antioxidants
include, but are not limited to, ascorbic acid and its esters,
sodium bisulfite, butylated hydroxytoluene, butylated
hydroxyanisole, tocopherols, and chelating agents like EDTA and
citric acid. Suitable moisturizers include, but are not limited to,
glycerine, sorbitol, polyethylene glycols, urea, and propylene
glycoL. Suitable buffering agents for use with the invention
include, but are not limited to, citric, hydrochloric, and lactic
acid buffers. Suitable solubilizing agents include, but are not
limited to, quaternary ammonium chlorides, cyclodextrins, benzyl
benzoate, lecithin, and polysorbates. Suitable skin protectants
that can be used in the topical formulations of the invention
include, but are not limited to, vitamin E oil, allatoin,
dimethicone, glycerin, petrolatum, and zinc oxide.
[0262] In certain embodiments, the pharmaceutically acceptable
topical formulations of the invention comprise at least a compound
of the invention and a penetration enhancing agent. The choice of
topical formulation will depend or several factors, including the
condition to be treated, the physiochemical characteristics of the
inventive compound and other excipients present, their stability in
the formulation, available manufacturing equipment, and costs
constraints. As used herein the term "penetration enhancing agent"
means an agent capable of transporting a pharmacologically active
compound through the stratum corncum and into the epidermis or
dermis, preferably, with little or no systemic absorption. A wide
variety of compounds have been evaluated as to their effectiveness
in enhancing the rate of penetration of drugs through the skin.
See, for example, Percutaneous Penetration Enhancers, Maibach H. I.
and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, Fla. (1995),
which surveys the use and testing of various skin penetration
enhancers, and Buyuktimkin et al., Chemical Means of Transdermal
Drug Permeation Enhancement in Transdermal and Topical Drug
Delivery Systems, Gosh T. K., Pfister W. R., Yum S. I. (Eds.),
Interpharm Press Inc., Buffalo Grove, Ill. (1997). In certain
exemplary embodiments, penetration agents for use with the
invention include, but are not limited to, triglycerides (e.g.,
soybean oil), aloe compositions (e.g., aloe-vera gel), ethyl
alcohol, isopropyl alcohol, oetolyphenylpolyethylene glycol, oleic
acid, polyethylene glycol 400, propylene glycol,
N-decylmethylsulfoxide, fatty acid esters (e.g., isopropyl
myristate, methyl laurate, glycerol monooleate, and propylene
glycol moneoleate) and N-methyl pyrrolidone.
[0263] In certain embodiments, the compositions may be in the form
of ointments, pastes, creams, lotions, gels, powders, solutions,
sprays, inhalants or patches. In certain exemplary embodiments,
formulations of the compositions according to the invention are
creams, which may further contain saturated or unsaturated fatty
acids such as stearic acid, palmitic acid, oleic acid,
palmito-oleic acid, cetyl or oleyl alcohols, stearic acid being
particularly preferred. Creams of the invention may also contain a
non-ionic surfactant, for example, polyoxy-40-stearate. In certain
embodiments, the active component is admixed under sterile
conditions with a pharmaceutically acceptable carrier and any
needed preservatives or buffers as may be required. Ophthalmic
formulation, eardrops, and eye drops are also contemplated as being
within the scope of this invention. Additionally, the present
invention contemplates the use of transdermal patches, which have
the added advantage of providing controlled delivery of a compound
to the body. Such dosage forms are made by dissolving or dispensing
the compound in the proper medium. As discussed above, penetration
enhancing agents can also be used to increase the flux of the
compound across the skin. The rate can be controlled by either
providing a rate controlling membrane or by dispersing the compound
in a polymer matrix or gel.
[0264] It will also be appreciated that the compounds and
pharmaceutical compositions of the present invention can be
formulated and employed in combination therapies, that is, the
compounds and pharmaceutical compositions can be formulated with or
administered concurrently with, prior to, or subsequent to, one or
more other desired therapeutics or medical procedures. The
particular combination of therapies (therapeutics or procedures) to
employ in a combination regimen will take into account
compatibility of the desired therapeutics and/or procedures and the
desired therapeutic effect to be achieved. It will also be
appreciated that the therapies employed may achieve a desired
effect for the same disorder (for example, an inventive compound
may be administered concurrently with another anti-inflammatory
agent), or they may achieve different effects (e.g., control of any
adverse effects).
[0265] In certain embodiments, the pharmaceutical compositions of
the present invention further comprise one or more additional
therapeutically active ingredients (e.g., anti-inflammatory and/or
palliative). For purposes of the invention, the term "Palliative"
refers to treatment that is focused on the relief of symptoms of a
disease and/or side effects of a therapeutic regimen, but is not
curative. For example, palliative treatment encompasses
painkillers, antinausea medications and anti-sickness drugs.
[0266] 3) Research Uses, Pharmaceutical Uses and Methods of
Treatment
[0267] Research Uses
[0268] According to the present invention, the inventive compounds
may be assayed in any of the available assays known in the art for
identifying compounds having the ability to modulate adhesion
between intracellular adhesion molecules and the leukocyte integrin
family of receptors; to antagonize CD11/CD18 receptors associated
with leukocytes and/or to antagonize Mac-1 and/or LFA-1. For
example, the assay may be cellular or non-cellular, in vivo or in
vitro, high- or low-throughput format, etc.
[0269] Thus, in one aspect, compounds of this invention which are
of particular interest include those which: [0270] modulate
adhesion between intracellular adhesion molecules (e.g., ICAM-1, -2
and -3) and the leukocyte integrin family of receptors; [0271]
exhibit the ability to antagonize CD11/CD18 receptors associated
with leukocytes; [0272] exhibit the ability to antagonize Mac-1
and/or LFA-1; and [0273] are useful for the treatment of LFA-1
mediated disorders.
[0274] As detailed in the exemplification herein, in assays to
determine the ability of compounds to modulate T-cell adhesion to
5dICAM-IG (e.g., cell attachment assay), certain inventive
compounds exhibited IC.sub.50 values .ltoreq.50 .mu.M. In certain
other embodiments, inventive compounds exhibit IC.sub.50 values
.ltoreq.40 .mu.M. In certain other embodiments, inventive compounds
exhibit IC.sub.50 values .ltoreq.30 l.mu.M. In certain other
embodiments, inventive compounds exhibit IC.sub.50 values
.ltoreq.20 .mu.M. In certain other embodiments, inventive compounds
exhibit IC.sub.50 values .ltoreq.10 .mu.M. In certain other
embodiments, inventive compounds exhibit IC.sub.50 values
.ltoreq.7.5 .mu.M. In certain embodiments, inventive compounds
exhibit IC.sub.50 values .ltoreq.5 .mu.M. In certain other
embodiments, inventive compounds exhibit IC.sub.50 values
.ltoreq.2.5 .mu.M. In certain embodiments, inventive compounds
exhibit IC.sub.50 values .ltoreq.1 .mu.M. In certain other
embodiments, inventive compounds exhibit IC.sub.50 values
.ltoreq.750 nM. In certain other embodiments, inventive compounds
exhibit IC.sub.50 values .ltoreq.500 nM. In certain other
embodiments, inventive compounds exhibit IC.sub.50 values
.ltoreq.250 nM. In certain other embodiments, inventive compounds
exhibit IC.sub.50 values .ltoreq.100 nM. In other embodiments,
exemplary compounds exhibited IC.sub.50 values .ltoreq.75 nM. In
other embodiments, exemplary compounds exhibited IC.sub.50 values
.ltoreq.50 nM. In other embodiments, exemplary compounds exhibited
IC.sub.50 values .ltoreq.40 nM. In other embodiments, exemplary
compounds exhibited IC.sub.50 values .ltoreq.30 nM. In other
embodiments, exemplary compounds exhibited IC.sub.50 values
.ltoreq.20 nM. In other embodiments, exemplary compounds exhibited
IC.sub.50 values .ltoreq.10 nM. In other embodiments, exemplary
compounds exhibited IC.sub.50 values .ltoreq.5 nM.
[0275] Pharmaceutical Uses and Methods of Treatment
[0276] As discussed above, certain of the compounds as described
herein exhibit activity generally as modulators of adhesion between
intracellular adhesion molecules. More specifically, compounds of
the invention demonstrate the ability to antagonize CD11/CD18
receptors associated with leukocytes and in certain embodiments
exhibit the ability to antagonize LFA-1 interactions. Thus, in
certain embodiments, compounds of the invention are useful for the
treatment of LFA-1 mediated disorders.
[0277] Accordingly, in another aspect of the invention, methods for
treating (or preventing) of LFA-1 mediated disorders are provided
comprising administering a therapeutically effective amount of a
compound of formula (I) or (II) as described herein, to a subject
in need thereof. In certain embodiments, a method for the treatment
of LFA-1 mediated disorders is provided comprising administering a
therapeutically effective amount of an inventive compound, or a
pharmaceutical composition comprising an inventive compound to a
subject in need thereof, in such amounts and for such time as is
necessary to achieve the desired result.
[0278] In certain embodiments, the method involves the
administration of a therapeutically effective amount of the
compound or a pharmaceutically acceptable derivative thereof to a
subject (including, but not limited to a human or animal) in need
of it.
[0279] As discussed above this invention provides novel compounds
that have biological properties useful for the treatment of Mac-1
and/or LFA-1 mediated disorders. In certain embodiments, the
inventive compounds as useful for the treatment of psoriasis,
responses associated with inflammatory bowel disease (such as
Crohn's disease and ulcerative colitis), dermatitis, meningitis,
encephalitis, uveitis, allergic conditions such as eczema and
asthma, conditions involving infiltration of T-cells and chronic
inflammatory responses, skin hypersensitivity reactions (including
poison ivy and poison oak), artherosclerosis, autoimmune diseases
such as rheumatoid arthritis, systemic lupus erythematosus (SLE),
diabetes mellitus, multiple sclerosis, Reynaud's syndrome,
autoimmune thyroiditis, experimental autoimmune encephalomyelitis,
Sjorgen's syndrome, juvenile onset diabetes and immune responses
associated with delayed hypersensitivity mediated by cytokines and
T-lymphocytes typically found in tuberculosis, sarcoidosis,
polymyositis, granulomatosis and vasculitis, pernicious anemia,
diseases involving leukocyte diapedeses, CNS inflammatory disorder,
multiple organ injury syndrome secondary to septicaemia or trauma,
autoimune hemolytic anemia, myasthermia gravis, antigen-antibody
complex mediated diseases, all types of transplantations, including
graft versus host or host versus graft disease, HIV and rhinovirus
infection, and pulmonary fibrosis to name a few.
[0280] As described in more detail herein, in general, compounds of
the invention are useful as antagonists of the interaction between
intracellular adhesion molecules (e.g., ICAM-1, 2 or 3) and the
leukocyte integrin family of receptors. Thus, in certain
embodiments, the present invention provides compounds useful for
the treatment of disorders mediated by the CD11/CD18 family of
cellular adhesion molecules. In certain embodiments of special
interest, the present invention provides compounds useful for the
treatment of disorders mediated by Mac-1 and/or LFA-1. For example,
compounds of the invention are particularly useful for the
treatment inflammatory disorders, organ graft rejection and
autoimmune disorders, to name a few.
[0281] Thus, as described above, in another aspect of the
invention, a method for the treatment of disorders mediated by the
CD11/CD18 family of cellular adhesion molecules is provided
comprising administering a therapeutically effective amount of a
compound of formula (I) or (II) as described herein, to a subject
in need thereof. In certain embodiments of special interest the
inventive method is used for the treatment of disorders mediated by
Mac-1 or LFA-1. It will be appreciated that the compounds and
compositions, according to the method of the present invention, may
be administered using any amount and any route of administration
effective for the treatment of disorders mediated by the CD11/CD18
family of cellular adhesion molecules. For example, in certain
exemplary embodiments, compounds of the invention are useful as
antagonists of the interaction between Mac-1 or LFA-1 and
intracellular adhesion molecules (e.g., ICAM-1) and thus the
compounds are useful for the treatment of LFA-1 mediated disorders
including, but not limited to, psoriasis, responses associated with
inflammatory bowel disease (such as Crohn's disease and ulcerative
colitis), dermatitis, meningitis, encephalitis, uveitis, allergic
conditions such as eczema and asthma, conditions involving
infiltration of T-cells and chronic inflammatory responses, skin
hypersensitivity reaction (including poison ivy and poison oak),
altherosclerosis, autoimmune diseases such as rheumatoid arthritis,
systemic lupus erythematosus (SLE), diabetes mellitus, multiple
sclerosis, Reynaud's syndrome, autoimmune thyroiditis, experimental
autoimmune encephalamyelitis, Sjorgen's syndrome, juvenile onset
diabetes, and immune responses associated with delayed
hypersensitivity mediated by cytokines and T-lymphocytes typically
found in tuberculosis, sarcoidosis, polymyositis, granulomatosis
and vasculitis, pernicious anemia, diseases involving leukocyte
diapedesis, CNS inflammatory disorder, multiple organ injury
syndrome secondary to septicaemia or trauma, autoimmune hemolytic
anemia, myasthemia gravis, antigen-antibody complex mediated
diseases, all types of transplantations, including graft versus
host or host versus graft disease, HIV and rhinovirus infection,
pulmonary fibrosis and the like, to name a few. Thus, the
expression "effective amount" as used herein, refers to a
sufficient amount of agent to antagonize the interaction between
intracellular adhesion molecules (e.g., ICAM) and the leukocyte
integrin family of receptors, and to exhibit a therapeutic effect.
The exact amount required will vary from subject to subject,
depending on the species, age, and general condition of the
subject, the severity of the infection, the particular therapeutic
agent, its mode of administration, and the like. The compounds of
the invention are preferably formulated in dosage unit form for
ease of administration and uniformity of dosage. The expression
"dosage unit form" as used herein refers to a physically discrete
unit of therapeutic agent appropriate for the patient to be
treated. It will be understood, however, that the total daily usage
of the compounds and compositions of the present invention will be
decided by the attending physician within the scope of sound
medical judgement. The specific therapeutically effective dose
level for any particular patient or organism will depend upon a
variety of factors including the disorder being treated and the
severity of the disorder; the activity of the specific compound
employed; the specific composition employed; the age, body weight,
general health, sex and diet of the patient; the time of
administration, route of administration, and rate of excretion of
the specific compound employed; the duration of the treatment;
drugs used in combination or coincidental with the specific
compound employed; and like factors well known in the medical arts
(see, for example, Goodman and Gilman's, "The Pharmacological Basis
of Therapeutics", Tenth Edition, A. Gilman, J. Hardman and L.
Limbird, eds., McGraw-Hill Press, 155-173, 2001, which is
incorporated herein by reference in its entirety).
[0282] Another aspect of the invention relates to a method for
inhibiting the interaction between LFA-1 and ICAM-1 in a biological
sample or a patient, which method comprises administering to the
patient, or contacting said biological sample with a compound of
formula I or II or a composition comprising said compound.
[0283] Another aspect of the invention relates to a method for
inhibiting the CD11a and/or CD18 interaction with ICAM-1, ICAM-2 or
ICAM-3 in a biological sample or a patient, which method comprises
administering to the patient, or contacting said biological sample
with a compound of formula I or II or a composition comprising said
compound.
[0284] Furthermore, after formulation with an appropriate
pharmaceutically acceptable carrier in a desired dosage, the
pharmaceutical compositions of this invention can be administered
to humans and other animals orally, rectally, parenterally,
intracisternally, intravaginally, intraperitoneally, topically (as
by powders, ointments, or drops), bucally, as an oral or nasal
spray, or the like, depending on the severity of the infection
being treated. In certain embodiments, the compounds of the
invention may be administered at dosage levels of about 0.001 mg/kg
to about 50 mg/kg, from about 0.01 mg/kg to about 25 mg/kg, or from
about 0.1 mg/kg to about 10 mg/kg of subject body weight per day,
one or more times a day, to obtain the desired therapeutic effect.
It will also be appreciated that dosages smaller than 0.001 mg/kg
or greater than 50 mg/kg (for example 50-100 mg/kg) can be
administered to a subject. In certain embodiments, compounds are
administered orally or parenterally.
Treatment Kit
[0285] In other embodiments, the present invention relates to a kit
for conveniently and effectively carrying out the methods in
accordance with the present invention. In general, the
pharmaceutical peak or kit comprises one or more containers filled
with one or more of the ingredients of the pharmaceutical
compositions of the invention. Such kits are especially suited for
the delivery of solid oral forms such as tablets or capsules. Such
a kit preferably includes a number of unit dosages, and may also
include a card having the dosages oriented in the order of their
intended use. If desired, a memory aid can be provided, for example
in the form of numbers, letters, or other markings or with a
calendar insert, designating the days in the treatment schedule in
which the dosages can be administered. Alternatively, placebo
dosages, or calcium dietary supplements, either in a form similar
to or distinct from the dosages of the pharmaceutical compositions,
can be included to provide a kit in which a dosage is taken every
day. Optionally associated with such container(s) can be a notice
in the form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceutical products, which notice
reflects approval by the agency of manufacture, use or sale for
human administration.
Equivalents
[0286] The representative examples that follow are intended to help
illustrate the invention, and are not intended to, nor should they
be construed to, limit the scope of the invention. Indeed, various
modifications of the invention and many further embodiments
thereof, in addition to those shown and described herein, will
become apparent to those skilled in the art from the full contents
of this document, including the examples which follow and the
references to the scientific and patent literature cited herein. It
should further be appreciated that the contents of those cited
references are incorporated herein by reference to help illustrate
the state of the art.
[0287] The following examples contain important additional
information, exemplification and guidance that can be adapted to
the practice of this invention in its various embodiments and the
equivalents thereof.
Exemplification
[0288] The compounds of this invention and their preparation can be
understood further by the examples that illustrate some of the
processes by which these compounds are prepared or used. It will be
appreciated, however, that these examples do not limit the
invention. Variations of the invention, now known or further
developed, are considered to fall within the scope of the present
invention as described herein and as hereinafter claimed.
[0289] 1) General Description of Synthetic Methods:
[0290] The practitioner has a well-established literature of
macrolide chemistry to draw upon, in combination with the
information contained herein, for guidance on synthetic strategies,
protecting groups, and other materials and methods useful for the
synthesis of the compounds of this invention.
[0291] The various references cited herein provide helpful
background information on preparing compounds similar to the
inventive compounds described herein or relevant intermediates, as
well as information on formulation, uses, and administration of
such compounds which may be of interest.
[0292] Moreover, the practitioner is directed to the specific
guidance and examples provided in this document relating to various
exemplary compounds and intermediates thereof.
[0293] The compounds of this invention and their preparation can be
understood further by the examples that illustrate some of the
processes by which these compounds are prepared or used. It will be
appreciated, however, that these examples do not limit the
invention. Variations of the invention, now know or further
developed, are considered to fall within the scope of the present
invention as described herein and as hereinafter claimed.
[0294] According to the present invention, any available techniques
can be used to make or prepare the inventive compounds or
compositions including them. For example, a variety of solution
phase synthetic methods such as those discussed in detail below may
be used. Alternatively or additionally, the inventive compounds may
be prepared using any of a variety combinatorial techniques,
parallel synthesis and/or solid phase synthetic methods known in
the art.
[0295] It will be appreciated as described below, that a variety of
inventive compounds can be synthesized according to the methods
described herein. The starting materials and reagents used in
preparing these compounds are either available from commercial
suppliers such as Aldrich Chemical Company (Milwaukee, Wis.),
Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or are prepared
by methods well known to a person of ordinary skill in the art
following procedures described in such references as Fieser and
Fieser 1991, "Reagents for Organic Synthesis", vols 1-17, John
Wiley and Sons, New York, N.Y., 1991; Rodd 1989 "Chemistry of
Carbon Compounds", vols. 1-5 and supps. Elsevier Science
Publishers, 1989; "Organic Reactions", vols 1-40, John Wiley and
Sons, New York, N.Y., 1991; March 2001, "Advanced Organic
Chemistry", 5th ed. John Wiley and Sons, New York, N.Y.; and Larock
1990, "Comprehensive Organic Transformations: A Guide to Functional
Group Preparations", 2nd ed. VCH Publishers. These schemes are
merely illustrative of some methods by which the compounds of this
invention can be synthesized, and various modifications to these
schemes can be made and will be suggested to a person or ordinary
skill in the art having regard to this disclosure.
[0296] The starting materials, intermediates, and compounds of this
invention may be isolated and purified using conventional
techniques, including filtration, distillation, crystallization,
chromatography, and the like. They may be characterized using
conventional methods, including physical constants and spectral
data.
[0297] General Reaction Procedure:
[0298] Unless mentioned specifically, reaction mixtures were
stirred using a magnetically driven stirrer bar. An inert
atmosphere refers to either dry argon or dry nitrogen. Reactions
were monitored either by thin layer chromatography, by proton
nuclear magnetic resonance (NMR) or by high-pressure liquid
chromatography (HPLC), of a suitably worked up sample of the
reaction mixture.
[0299] General Work Up Procedures:
[0300] Unless mentioned specifically, reaction mixtures were cooled
to room temperature or below then quenched, when necessary, with
either water or a saturated aqueous solution of ammonium chloride.
Desired products were extracted by partitioning between water and a
suitable water-immiscible solvent (e.g. ethyl acetate,
dichloromethane, diethyl ether). The desired product containing
extracts were washed appropriately with water followed by a
saturated solution of brine. On occasions where the product
containing extract was deemed to contain residual oxidants, the
extract was washed with a 10% solution of sodium sulphite in
saturated aqueous sodium bicarbonate solution, prior to the
aforementioned washing procedure. On occasions where the product
containing extract was deemed to contain residual acids, the
extract was washed with saturated aqueous sodium biocarbonate
solution, prior to the aforementioned washing procedure (except in
those cases where the desired product itself has acidic character).
On occasions where the product containing extract was deemed to
contain residual bases, the extract was washed with 10% aqueous
citric acid solution, prior to the aforementioned washing procedure
(except in those cases where the desired product itself had basic
character). Post washing, the desired product containing extracts
were dried over anhydrous magnesium sulphate, and then filtered.
The crude products were then isolated by removal of solvent(s) by
rotary evaporation under reduced pressure, at an appropriate
temperature (generally less than 45.degree. C.).
[0301] General Purification Procedures:
[0302] Unless mentioned specifically, chromatographic purification
refers to flash column chromatography on silica, using a single
solvent or mixed solvent as eluent. Suitably purified desired
product containing elutes were combined and concentrated under
reduced pressure at an appropriate temperature (generally less than
45.degree. C.) to constant mass. Final compounds were dissolved in
50% aqueous acetonitrile, filtered and transferred to vials, then
freeze-dried under high vacuum before submission for biological
testing.
[0303] 1) Synthesis of Exemplary Compounds:
[0304] Unless otherwise indicated, starting materials are either
commercially available or readily accessibly through laboratory
synthesis by anyone reasonably familiar with the art. Described
generally below, are procedures and general guidance for the
synthesis of compounds as described generally and in subclasses and
species herein. In addition, synthetic guidance can be found in
published PCT application WO99/49856 and WO 02/059114, the entire
contents of which are hereby incorporated by reference.
EXAMPLE 1
[0305] This example describes the synthesis of
##STR00094##
which was prepared according to Scheme 1A and the procedure
below.
##STR00095## ##STR00096##
[0306] a) A solution of 3-methoxyphenylethylamine (0.2 mol) and
formaldehyde (0.22 mol) in aqueous HCl (20%, 500 mL) was heated at
80.degree. C. for 4 hours. The reaction was then concentrated to
dryness, and the residue was dissolved in hydrobromic acid (40%
aqueous, 500 ML), and refluxed for 24 hours. The reaction was
concentrated to give a brownish solid, which was used without
purification. To the residue was added water (200 mL) and
tetrahydrofuran ("THF") (300 mL), and to the resulting mixture was
very carefully added with sodium carbonate (solid, 0.5 moil),
followed by di-tert-butyl dicarbonate (0.3 mol). After 15 hours at
room temperature, the reaction was extracted with ethyl acetate (1
L), and the organic extract was washed with saturated potassium
dihydrophosphate and brine, dried over anhydrous magnesium sulfate
and filtered.
[0307] The residue after concentration of the filtrate was
dissolved in dichloromethane ("DCM"; 100 mL), and to it was slowly
added acetic acid (500 mL) and surfuryl chloride (0.6 mol). After
the reaction mixture was stirred at room temperature for 24 hours,
the reaction was concentrated to dryness, and further dried under
high vacuum for 2 hours. The crude product was used without further
purification for next step. The crude product was dissolved in
water/THF (200 mL/400 mL), and to it was added carefully and slowly
sodium carbonate (0.5 mol) with good stirring, followed by
di-tert-butyl dicarbonate (0.3 mol). After the reaction mixture was
stirred for 12 hours, the reaction was carefully neutralized with
phosphoric acid (2 M) to pH about 7. The resulting mixture was
extracted with ethyl acetate (500 mL.times.2), and the combined
extracts were washed with water and brine, dried over anhydrous
magnesium sulfate, filtered and concentrated. The crude solid was
recrystallized from ethyl acetate and hexane (about 1:2 ratio) to
yield a white solid. The mother liquid was concentrated and
purified by column, eluting with 0-10% ethyl acetate in 4:1
hexane:methylene chloride. The combined yield is 14.5 g (23% from
commercial 3-methoxyphenethylamine), MS (API-ES.sup.+) m/z: 262,
264, 266 (M+H-tert-butyl.sup.+).
[0308] The product obtained above was dissolved in DCM (100 mL) and
pyridine (50 mL). The resulting solution was cooled to -40.degree.
C., and to it was added triflic anhydride (51 mmol) slowly. After
the reaction mixture was gradually warmed to room temperature over
4 hours, the reaction mixture was partitioned between ethyl acetate
(500 mL) and water (100 mL), and the organic layer was washed with
water (100 mL, twice) and brine (50 mL), dried over anhydrous
magnesium sulfate, filtered and concentrated. The residue was
purified by column, eluting with 0-5% ethyl acetate in 5:1
hexane:DCM to give the corresponding triflate (9.73 g, 48%
yield),
[0309] A mixture of 10 mmol of the triflate, 1.0 mmol of
1,3--diphenylphosinepropane ("dppp") and 40 mmol of
di-isopropylethylamine ("DIEA") in 100 mL of dry dimethylformamide
("DMF") and 50 mL of anhydrous CH3OH was flushed with CO for 15
min, and then 1.0 mmol of Pd(OAc)2 was added under the atmosphere
of CO. Subsequently, the resulting mixture was stirred at
70.degree. C. overnight under as atmosphere of CO. The solvent was
removed and the residue was purified by column chromatography using
EtOAc/hexane=1/4 (v/v) as the eluent to give compound 1.1 with a
yield. ESI-MS (m/z): (M.sup.+)+Na 382.1; .sup.1H NMR (CD3OD, 400
MHz); .delta. 7.32 (s, 1H), 4.60 (s, 2H), 3.95 (s, 3H), 3.69 (m,
2H), 2.84 (m, 2H), 1.50 (s, 9H) ppm.
[0310] b) A mixture of 1.1 (5 mmol) and 30 mmol of LiI in 20 mL of
pyridine was reflux overnight. The solvent was removed and the
residue was dissolved in EtOAc. The resulting solution was then
washed with saturated aqueous NH4Cl and dried with anhydrous
Na2SO4. The solvent was removed and the residue was dried in vacuo
to give a quantitative yield of compound 1.3. The crude product was
carried on the next step without further purification. ESI-MS
(m/z): (M-tBu+1), 290.
[0311] c) A solution of Boc-Dap-OH (10 mmol) in methanol (30 mL)
was treated with trimethylsilyldiazomethane until the color
remained light yellow for 10 seconds. The mixture was concentrated,
and the residue was dissolved in DCM (30 mL). To the solution was
added triethylamine (20 mmol) and followed by 3-thienylcarboxyl
chloride (11 mmol). After 0.5 hour at room temperature, the
reaction was filtered through silica gel, and concentrated. The
residue was purified by column with 10-50% ethyl acetate in hexane.
The product obtained this way was dissolved in DCM (10 mL) and
treated with HCl (4 M in dioxane, 10 mL). After 5 hours, the
reaction was concentrated to give the title compound (60-80%
overall yield).
[0312] d) A mixture of 1.2 (4 mmol), 1.3 (4.4 mmol), 5.0 mmol of
o-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
fluorophosphate ("HATU") and 20 mmol of Et3N in 20 mL of DMF was
stirred at room temperature overnight. The solvent was removed and
the residue-was purified by column chromatography using
CH.sub.2Cl.sub.2/EtOAc=6/4 (v/v) as eluent to give compound 1.4
with a 60% yield. ESI-MS (m/z): (M+1) 556.1.
[0313] e) A solution of 2 mmol of 1.4 in 9 mL of TFA and 3 mL of
CH.sub.2Cl.sub.2 was stirred at room temperature for 6 hours. The
solvent was then removed and the residue was diluted with saturated
aqueous NaHCO.sub.3. The mixture was extracted with EtOAc for 3
times. The extracts were then dried with anhydrous
Na.sub.2SO.sub.4. The solvent was removed and the residue was dried
in vacuo to give compound 1.5 which was used without further
purification. ESI-MS (m/z): (M+1) 456.1.
[0314] f) Intermediate compound 1.11 was prepared according to
Scheme 1B and the procedure below.
##STR00097##
[0315] To a solution of 100 mmol of commercially available
6-hydroxy-[2H]-benzofuran-3-one (compound 1.8) and 150 mmol of
imidazole in 300 mL of dry DMF was added 110 mmol of
tert-butyldimethylsilylchloride ("TBDMSCl") at room temperature,
the resulting mixture was stirred at room temperature overnight.
The solvent was removed, and the residue was diluted with 100 mL of
EtOAc, washed with saturated aqueous NH.sub.4Cl, and dried with
anhydrous Na.sub.2SO.sub.4. The solvent was removed, and the
residue was purified to give corresponding intermediate in 70%
yield. ESI-MS (m/z): (M+H.sup.+) 265.1.
[0316] The intermediate is dissolved in 100 mL of CH.sub.3OH was
added 20 mmol of NaBH.sub.4 at room temperature. After stirring at
room temperature for 12 hours, the reaction mixture was treated
with 10 mL of acetone. Subsequently, 60 mL of 4.0 N HCl were added
to the mixture, and the mixture was stirred at room temperature
overnight. The organic solvent was removed, and the residue was
extracted with EtOAc for several times. The extract was then washed
with brine and dried with anhydrous Na.sub.2So.sub.4. The solvent
was removed and the residue was dissolved in 100 mmol of Et.sub.3N
and 180 mL of dry CH.sub.2Cl.sub.2 was added 66 mmol of PhNTf.sub.3
at 0.degree. C., the resulting mixture was stirred at room
temperature overnight. The solvent was removed, and the residue was
purified to give compound 1.9 in 90% yield. .sup.1H NMR (400 MHz,
CD.sub.3Cl): .delta. 7.75 (d, J=1.9 Hz, 1H), 7.66 (d, J=8.5 Hz,
1H), 7.50 (s, 1H), 7.21 (d, J=8.5 Hz, 1H), 6.85 (d, J=1.9 Hz, 1H)
ppm.
[0317] A mixture of 50 mmol of compound 1.9, 2.5 mmol of dppp
(diphenylphosphine)1,3-propane) and 2.5 mmol of Pd(OAc).sub.2 in
100 mmol of DIEA, 125 mL of dry DMF, and 125 mL of anhydrous MeOH
was stirred at 65.degree. C. under an atmosphere of CO overnight.
The solvent was removed and the residue was purified by column
chromatography to give compound 1.10 in 65% yield. .sup.1H NMR (400
MHz, CDCl.sub.3)L .delta. 8.23 (s, 1H), 7.99 (d, J=8.3 Hz, 1H),
7.78 (s, 1H), 7.65 (d, J=8.3 Hz, 1H), 6.85 (s, 1H), 3.97 (s, 3H)
ppm; ESI-MS (m/z): (M+1) 177.10.
[0318] A mixture of 20 mmol of compound 1.10 and 80 mmol of
LiOH.H.sub.2O in 60 mL of THF and 15 mL of H.sub.2O was stirred at
room temperature for 1 hour, followed by adding 80 mL of 1.0N aq.
HCl. The organic solvent was removed and the residue was diluted
with 50 mL of brine. The mixture was then extracted with EtOAc, and
the extract was dried with anyhdrous Na.sub.2SO4. The solvent was
removed and the residue was dried in vacuo to give a quantitative
yield of compound 1.11. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta.
8.14 (s, 1H), 7.92 (m, 2H), 7.67 (d, J=8.5 Hz, 1H), 6.92 (s, 1H)
ppm; ESI-MS (m/z): (M+H.sup.+) 163.1.
[0319] g) A mixture of 0.25 mmol of compound 1.11 and 0.26 mmol of
HATU in 1 mmol of DIEA and 2 mL of DMF was stirred at room
temperature for 30 min, followed by adding a solution of 0.22 mmol
of compound 1.5 in 1 mL of DMF. The resulting mixture was stirred
45.degree. C. for 12 hours. The solvent was removed, and the
residue was purified to give compound 1.6 in 50-65% yield.
Subsequently, compound 1.6 was hydrolyzed with LiOH (1.0 M aqueous,
0.5 mL) in THF (3 mL) for 2 hours. The reaction mixture was then
acidified with HCl (aqueous), extracted with ethyl acetate (50 mL),
dried over anhydrous magnesium sulfate and concentrated to give
compound 1 in quantitative yield. .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 7.91 (s, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.67 (s,
3H), 7.36 (d, J=8.0 Hz, 1H), 7.13 (s, 1H), 6.96 (s, 1H), 5.01 (t,
J=6.8 Hz, 1H), 4.68 and 4.89 (m, 2H), 3.85 (d, J=6.8 Hz, 2H), 3.70
and 4.02 (m, 2H), 2.93 (m, 2H) ppm; ESI-MS (m/z): (M+1) 586.10.
EXAMPLE 2
[0320] This example describes the synthesis of
##STR00098##
which was prepared according to the procedure of Example 1g except
that 4-chlorobenzoic acid was used instead of compound 1.11.
.sup.1H NMR (400 MHz, CD3OD): .delta. 7.64 (m, 2H). 7.35-7.49 (m,
5H), 7.11 (s, 1H), 4.98 (t, J=8.0 Hz, 1H), 4.63 and 4.88 (m, 2H),
3.83 (d, J=8.0 Hz, 2H), 3.68 and 3.98 (m, 2H), 2.89 (m, 2H) ppm;
ESI-MS (m/z): (M+1) 579.90.
EXAMPLE 3
[0321] This example describes the synthesis of
##STR00099##
which was prepared according to Scheme 2 and the procedure
below.
##STR00100## ##STR00101##
[0322] a) To a solution of 10 mmol of commercially available 3.1 in
20 mL of MeOH and 20 mL of CH.sub.2Cl.sub.2 was slowly added 20
mmol of 2.0M TMSCHN.sub.2 in hexanes at 0.degree. C., and the
resulting mixture was stirred at room temperature for 30 minutes.
The solvent was removed and the residue was dried in vacuo to give
crude 3.2.
[0323] b) Compound 3.2 was then stirred with 15 mmol of
isopropylazide in the presence of 0.2 mmol of CuI, 0.2 mmolf of
Et.sub.3N in 50 mL of CH.sub.3CN at room temperature overnight. The
solvent was removed and the residue was purified by column
chromatography to give compound 3.3 in 55% yield. ESI-MS (m/z):
(M+1) 313.20.
[0324] c) A mixture of 2 mmol of compound 3.3 in 10 mL of 4.0 N HCl
in dioxane was stirred at room for 12 hours. The solvent was
removed and the residue was dried in vacuo to give compound 3.4 in
quantitative yield. ESI-MS (m/z): (M+1) 213.10.
[0325] d) A solution of 1.1 (3.60 g, 10 mmol) in DCM (20 mL) was
treated with HCl in 1,4-dioxane (4.0 M, 10 mL) at room temperature.
After 2 hours, the reaction was concentrated to give compound 3.5
in quantitative yield.
[0326] e) Example 3.5 (10 mmol) was mixed with EDC (2.11 g, 11
mmol), N,N-dimethylaminopyridine ("DMAF", 0.1 g), triethylamine
(2.02 g) and Example 1.11 (1.62 g, 10 mmol) in anhydrous DMF (50
mL). After 15 hours at room temperature, the reaction mixture was
diluted with ethyl acetate (200 mL), washed with water (30 mL, 3
times), dried with anhydrous magnesium sulfate and filtered. The
residue after concentration of the filtrate was purified by column
eluting with 10-30% ethyl acetate in hexane to give the title
compound (3.7 g, 92%): ESI-MS (m/z): (M+1) 213.1.
[0327] f) Compound 3.7 was made according to Example 1b except that
compound 3.6 was used instead of compound 1.1.
[0328] g) A mixture of 0.25 mmol of compound 3.7 and 0.26 mmol of
HATU in 1 mmol of DIEA and 2 mL of DMF was stirred at room
temperature for 30 minutes, following by adding a solution of 0.22
mmol of compound 3.4 in 1 mL of DMF. The resulting mixture was
stirred 45.degree. C. for 4 hours. The solvent was removed, and the
residue was purified to give intermediate ester, which was
subsequently treated with LiOH in THF and water to give the desired
compound 3 in quantitative yield. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 7.90 (s, 2H), 7.74 (m, 1H), 7.64 (s, 1H), 7.34 (m, 1H),
6.93 (s, 1H), 5.03 (m, 1H), 4.82 (m, 1H), 4.65 and 4.88 (m, 2H),
3.72 and 3.97 (m, 2H), 3.40 (m, 1H), 3.18 (m, 1H), 2.90 (m, 2H),
1.55 (m, 6H), ppm; ESI-MS (m/z): (M+1) 570.1.
EXAMPLE 4
[0329] This example describes the synthesis of
##STR00102##
which was prepared according to Scheme 3 and the procedure
below.
##STR00103##
[0330] a) Boc-DAP-OH (0.2 g, 1.0 mmol), 2,4-dichloropyrimidine
(0.29 g, 2.0 mmol), and diisopropylethylamine (0.51 mL, 2.9 mmol)
in ethanol (5 mL) were heated to 75.degree. C. for 14 hours. The
reaction mixture was cooled to room temperature and the solvent
removed under reduced pressure. The resulting crude product 4.1 was
pure enough to carry forward to the next chemical
transformation.
[0331] b) Crude residue 4.1 (0.31 g, 1.0 mmol) was dissolved in 9:1
benzene: methanol (5 mL). Trimethylsilyldiazomethane (1.0 mL, 2.0M
in hexanes) was added slowly to the stirring reaction mixture and
stirred for an additional 1 hour. The solvents were removed under
reduced pressure to obtain oily crude residue. Purification by
silica gel column chromatography using 50% ethyl acetate in hexanes
was performed to afford pure 4.2 (0.21 g, 65%).
[0332] c) Compound 4.2 (0.21 g, 0.6 mmol) was dissolved in
dichloromethane (5 mL). Trifluroracetic acid (2.5 mL) was added and
the reaction was stirred for 1 hour. The resulting reaction mixture
was concentrated to remove any excess trifluoroacetic acid to
afford amine 4.3 in quantitative yield.
[0333] d) Compound 4.4 was made according to Example 3d-f except
that 4-chlorobenzoic acid was used instead of compound 1.11.
[0334] c) Compound 4 was made according to Example 3g except that
compound 4.4 was used instead of compound 3.7 and compound 4.3 was
used instead of Compound 3.4.
EXAMPLE 5
[0335] This example describes the synthesis of
##STR00104##
which was prepared according to Scheme 4 and the procedure
below.
##STR00105##
[0336] a) To a solution of methane sulfonamide (1.01 g, 10.7 mmol)
in 15 mL DMF was added 20 M aqueouos NaOH (0.68 mL, 13.6 mmol),
resulting in a white precipitate. The solution was cooled to
0.degree. C., carbon disulfide (0.4 mL, 6.63 mmol) slowly added,
and stirred at 0.degree. C. for 15 minutes. Additional 20M aqueous
NaOH (0.32 mL, 6.4 mmol) and carbon disulfide (0.2 mL, 3.31 mmol)
were added and the reaction stirred at 0.degree. C. for 20 minutes,
then raised to room temperature. At 30 minutes all precipitate had
returned to solution, and the reaction mixture was cooled to
0.degree. C. Methyl iodide (1.33 mL, 21.364 mmol) was added and the
reaction stirred at 0.degree. C. for 20 minutes and at room
temperature for 1.5 hours. 20 mL water was added to the reaction
and extracted five times with ethyl acetate. The combined organic
extracts were dried over MgSO.sub.4 and concentrated to dryness.
Recrystallization from hot ethyl acetate and hexanes afforded 1.44
g compound 5.1. ESI-MS (m/z): (M+H.sup.+) 200.0.
[0337] b) To a solution of Boc-Dap-OH (109 mg, 0.53 mmol) and
compound 5.1 (125.7 mg, 0.632 mmol) in 5 mL ethanol was added 1.0M
aqueous NaOH (0.8 mL, 0.8 mmol). The reaction was stirred until
conversion was complete, and then concentrated to dryness. The
residue was dissolved in water and washed three times with ether.
The aqueous layer was acidified to pH 1 with 2.0M phosphoric acid,
and extracted four times with ethyl acetate. The combined ethyl
acetate extracts were dried over MgSO.sub.4 and concentrated to
dryness to afford 160.4 mg of compound 5.2. ESI-MS (m/z):
(M+Na.sup.+) 378.0.
[0338] c) To a solution of compound 5.2 (150.4 mg, 0.452 mmol) in
1:1 dichloromethane:methanol was added trimethylsilyldiazomethane
as a 2.0 M solution in ether (0.4 mL, 0.8 mmol). The reaction was
stirred at room temperature until conversion to the methyl ester
was complete, and then concentrated to dryness. The product was
purified via flash chromatography to afford 146.6 mg of compound
5.3. ESI-MS (m/z): (M+Na.sup.+) 270.0 .sup.1H NMR (400 MHz,
chloroform-d) .delta. 1.46 (s, 9H), 2.42 (s, 3H), 3.02 (s, 3H),
3.63 (m, 1H), 3.75 (m, 1H), 3.82 (s, 3H), 4.51 (m, 1H).
[0339] d) To a solution of compound 5.3 (146.6 mg, 0.40 mmol) in 2
mL methanol was added ammonia, 7N in methanol (0.6 mL, 4.2 mmol).
This mixture was cooled to 0.degree. C., and a solution of silver
nitrate (75.5 mg, 0.444 mmol) in 0.4 mL acetonitrile was dropwise
added. The reaction was stirred and allowed to reach room
temperature. At three hours solvent was removed, the residue
suspended in ethyl acetate, and filtered through celite. The
filtrate was concentrated to dryness and redissolved in
dichloromethane, to which was added HCl, 4.0 M in dioxane (0.5 mL,
2.0 mmol). This solution was stirred at room temperature for 8
hours and concentrated to dryness to afford compound 5.4 as an HCl
salt. ESI-MS (m/z): (m+H.sup.+) 239.
[0340] e) Compound 5 was made according to Example 3g except that
compound 4.1 was used instead of 3.7 and compound 5.4 was used
instead of compound 3.4. ESI-MS (m/z): (M+H.sup.+) 590.0.
EXAMPLE 6
[0341] This example describes the synthesis of
##STR00106##
which was prepared according to Scheme 5 and the procedure
below.
##STR00107##
[0342] a) A solution of (L)-Boc-Dap-OH (10 mmol), dimethyl
N-cyanodithioimniocarbonate (10 mmol) and DIEA (30 mmol) in ethanol
was stirred at room temperature for 1 hour. Then, pyrrolidine (20
mmol) was added, and the reaction was heated at 65.degree. C. for
10 hours. the reaction mixture was then diluted with ethyl acetate
(150 mL), and was extracted with saturated NaH.sub.2PO.sub.4 (50
mL, the aqueous layer pH is between 4-6), water (50 ml) and brine.
The organic layer was dried with anhydrous magnesium sulfate,
filtered and concentrated. The crude product was dissolved in 4:1
DCM:MeOH, cooled at 0.degree. C. and to it was added
trimethylsilyldiazomethane until it stays yellow for 30 seconds.
The solution is concentrated and the residue was purified by column
with 30-100% ethyl acetate in hexane to give the title compound in
20-30% yield. MS (m/z): 240 (M-99).
[0343] b) Compound 6.1 (72 mg, 0.20 mmol) in DCM (1 mL) was treated
with HCl (4 M in dioxane) for 2 hours. The reaction mixture was
concentrated to give compound 6.2.
[0344] c) Compound 6 was made according to Example 3g except that
compound 6.2 was used instead of compound 3.4. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 7.77 (s, 1H), 7.63 (m, 3H), 7.37 (d, 1H),
6.85 (s, 1H), 6.32 (d, 1H), 4.68 (s, 2H), 4.31 (m, 1H), 3.85 (m,
2H), 3.60 (m, 4H), 2.88 (m, 2H), 1.89 (m, 4H), ppm; ESI-MS (m/z):
(M+1) 597.1.
EXAMPLE 7
[0345] This example describes the synthesis of
##STR00108##
which was prepared according to Scheme 6 and the procedure
below.
##STR00109##
[0346] a) To a solution of H-2-Mercapto-His-OH (598.8 mg, 3.2 mmol)
in 5 mL methanol was added 0.26 mL sulfuric acid. This mixture was
stirred at room temperature for 18 hours. Additional sulfuric acid
(0.1 mL, 0.6 mmol) was added and the reaction stirred at 50.degree.
C. for 4.5 hours. Sodium carbonate (850.3 mg, 8.02 mmol) was slowly
added, and the reaction concentrated via rotary evaporation to
remove most of the methanol. 6 mL THF and 3 mL water were added
with sodium carbonate (0.851 g, 8.03 mmol) and Boc.sub.2O (696.5
mg, 3.19 mmol). The reaction was stirred at room temperature for 1
hour, diluted with ethyl acetate, and washed with water and brine.
The organic layer was dried over MgSO.sub.4 and concentrated to
dryness. Purification via flash chromatography afforded 283.5 mg of
compound 7.1. ESI-MS (m/z): (M+H.sup.+) 316.1.
[0347] b) Compound 7.1 (283.5 mg, 0.90 mmol) and
3-chloroperoxybenzoic acid (568.4 mg, 2.53 mmol) were dissolved in
6 mL dichloromethane and stirred at room temperature for 1.5 hours.
The reaction was diluted with dichloromethane and poured into 1.0 M
potassium carbonate. The aqueous layer was adjusted to neutral pH
with 2.0 M phosphoric acid and extracted three times with
dichloromethane. The combined organic extracts were dried over
MgSO.sub.4 and concentrated to dryness. Purification via flash
chromatography afforded 240.8 mg of compound 7.2. ESI-MS (m/z):
370.1 (M+Na.sup.+), 248.1 (M-Boc+H.sup.+); .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 1.43 (s, 9H), 3.14 (m, 2H), 3.26 (s, 3H), 3.74
(s, 3H), 4.61 (m, 1H), 7.02 (s, 1H).
[0348] c) To a solution of compound 7.2 (240.8 mg, 0.6931 mmol) in
dichloromethane was added HCl, 4.0 M in dioxane (1.0 mL, 4.0 mmol).
The reaction was stirred at room temperature for 1.5 hours and then
concentrated to dryness to afford compound 7.3 as an HCl salt.
ESI-MS (m/z): M+H.sup.+) 248.
[0349] Compound 7 was made according to Example 3g except that
compound 4.1 was used instead of compound 3.7 and compound 7.3 was
used instead of compound 3.4. ESI-MS (m/z): (M+H.sup.+) 599.0;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 2.88 (s, 2H), 3.10 (m,
1H), 3.21 (s, 3H), 3.34 (m, 1H), 3.67 (1H), 3.97 (1H), 4.63 (1H),
4.85 (1H), 5.04 (dd, 1H), 7.19 (s, 1H), 7.49 (m, 5H).
EXAMPLE 8
[0350] This example described the synthesis of
##STR00110##
which was prepared in according to Scheme 7A and the procedure
below.
##STR00111##
[0351] a) A three-neck flask containing 32 mmol of LiCl was flamed
with a gas lamp in vacuo, followed by flushing with N.sub.2. This
sequence was repeated for 3 times in order to get dry LiCl. To the
flask was added 10 mmol of (R,R)-(-)-pseudoephedrine glycinamide
hydrate (A. G. Myers et al J. Org. Chem. 64: 3322-3327 (1999)) and
30 mL of dry THF at room temperature under an atmosphere of
N.sub.2. The suspension was then treated with 31 mmol of LiHMDS
(1.0 M in THF) at 0.degree. C. with stirring for 1 hour, followed
by adding a solution of 10 mmol of 3-methylthiobenzyl chloride (S.
Laufer et al J. Med. Chem. 45: 2733-2740 (2002)) in 5 mL of dry
THF. The resulting mixture was stirred at 0.degree. C. overnight
and quenched by adding 10 mL of water. The solvent was removed, and
the residue was diluted with 50 mL of water. The mixture was
extracted with CH.sub.2Cl.sub.2 for 3 times. The organic extract
was combined and dried with anhydrous Na.sub.2SO.sub.4.
Subsequently, the solvent was removed, and the residue was purified
to give the desired alkylated intermediate in 70% yield. ESI-MS
(m/z): M+H.sup.+) 359.2.
[0352] A mixture of 5 mmol of the alkylated intermediate in 12 mL
of 10 N NaOH was refluxed until the starting material was consumed.
The mixture was diluted with 20 mL, of water and extracted with
CH.sub.2Cl.sub.2 for 3 times. The aqueous phase was then stirred
with 6 mmol of (Boc).sub.2O and 12 mmol of NaHCO.sub.3 in 30 mL of
1,4-dioxane for 15 hours. The organic solvent was removed, and the
residue was diluted with 30 mL of water and extracted with
CH.sub.2Cl.sub.2. The aqueous phase was subsequently treated with
solid citric acid to adjust the pH value to 4.0, flowed by
extracting with EtOAc for 3 times. The organic extract was dried
with anhydrous Na.sub.2SO.sub.4. The solvent was removed, and the
residue was dried in vacuo to give compound 8.2 in quantitative
yield. ESI-MS (m/z): (M+H.sup.+) 334.10.
[0353] b) A mixture of 5 mmol of compound 8.2 in 10 mL of
CH.sub.3OH and 10 mL of CH.sub.2Cl.sub.2 was added 10 mmol of
(trimethylsilyl)diazomethane (2.0 M in hexanes) at 0.degree. C.,
the resulting mixture was stirred at room temperature for 30
minutes. The solvent was removed, and the residue was dried in
vacuo to give the desired ester in quantitative yield. ESI-MS
(m/z): (M+H.sup.+) 348.10.
[0354] To a solution of the ester in 20 mL of CH.sub.3OH and 2 mL
of water was added 12 mmol of Oxone.RTM. at room temperature, and
the resulting suspension was stirred at room temperature for 15
hours. The reaction mixture was concentrated and diluted with 50 mL
of EtOAc, washed with water, and dried with anhydrous
Na.sub.2SO.sub.4. The solvent was removed and the residue was dried
in vacuo to give compound 8.3 in quantitative yield. .sup.1H NMR
(400 MHz, CD.sub.3Cl): .delta. 7.82 (m, 1H), 7.69 (s, 1H), 7.50 (m,
1H), 7.43 (m, 1H), 5.03 (m, 1H), 4.62 (m, 1H), 3.74 (s, 3H), 3.26
(m, 1H), 3.09 (m, 1H), 3.03 (s, 3H), 1.39 (s, 9H), ppm; ESI-MS
(m/z): (M-tBoc+H.sup.+) 258.1.
[0355] c) A mixture of 2 mmol of compound 8.3 in 10 mL of 4.0 N HCl
in dioxane was stirred at room temperature for 15 hours. The
solvent was removed, and the residue was dried in vacuo to give
compound 8.4 in quantitative yield as an HCl salt. .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 7.95 (m, 1H), 7.87 (s, 1H), 7.64 (m, 2H),
4.44 (t, J=6.85 Hz, 1H), 3.82 (s, 3H), 3.41 (m, 1H), 3.29 (m, 1H),
3.13 (s, 3H) ppm; ESI-MS (m/z): (M+H.sup.+) 258.10.
[0356] d) Compound 8 was made according to Example 3g except that
compound 4.1 was used instead of compound 3.7 and compound 8.4 was
used instead of compound 3.4. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 7.92 (s, 1H), 7.81 (d, J=7.92 Hz, 1H), 7.68 (d, J=7.83 Hz),
7.56 (t, J=7.83 Hz, 1H), 7.30-7.49 (m, 5H), 5.06 (m, 1H), 4.60 and
4.83 (m, 2H), 3.95 and 3.66 (m, 2H), 3.44 (d, J=13.44 Hz, 1H), 3.14
(m, 1H), 3.08 (s, 3H), 2.85 (m, 2H) ppm; ESI-MS (m/z): (M+H.sup.+)
609.05.
[0357] c) Compound 8.4 can also be prepared according to Scheme 7B
and the procedure below.
##STR00112##
[0358] A mixture of 8.5 (1.0 mL), methyl iodide (1.2 mmoL) and
potassium carbonate (2 mmoL) in 20 mL of acetone was heated at
50.degree. C. for 3 hours. The solvent of the reaction mixture was
removed under reduced pressure. The residue was partitioned between
EtOAc and water. The aqueous solution was extracted with EtOAc, and
combined organic solution was washed with brine, dried over
Na.sub.2SO.sub.4, filtered, concentrated. The crude product as a
white solid (yield 98%) was used for next step without
purification.
[0359] To a solution of the compound (1 mmoL) made above in 4 mL of
THF at 0.degree. C. was added LiAlH.sub.4 (1.1 mmoL) slowly. The
reaction mixture was allowed to warm to room temperature and
stirred for 1 hour. The reaction was added consecutively with
water, 15% aqueous NaOH and water with strong stirring. The
filtration and evaporation of filtrate provided the crude product
8.6 (yield 92%). No purification was needed. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 3.05 (s, 3H), 4.75 (s, 2H), 7.53 (t, J=7.58 Hz,
1H), 7.62 (d, J=7.34 Hz, 1H), 7.81 (d, J=7.83 Hz, 1H), 7.93 (s,
1H).
[0360] Solid tetraproplyammonium perruthenate ("TPAP", 0.05 mmol)
was added in one portion to a stirred mixture of compound 8.6 (1
mmoL), 4-methylmorpholine N-oxide ("NMO"; 1.5 mmoL) and powdered 4A
molecular sieve (equal weight to that of NMO) in 5 mL of DCM at
room temperature under N.sub.2. The reaction mixture was stirred at
room temperature, for 1 hour, and then filtered through a short pad
of silica gel, eluting with mixture of DCM and AcOEt (1:1). The
filtrate was concentrated and the residue was purified with
chromatography (SiO2, AcOEt/hexane2:1) to afford compound 8.7
(yield 72%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 3.14 (s,
3H), 7.81 (t, J=7.58 Hz, 1H), 8.21 (t, J=9.05 Hz, 2H), 8.46 (s,
1H), 10.12 (s, 1H), ppm.
[0361] The N,N,N',N',-tetramethylguanidine ("TMG"; 1.05 mmole) was
added slowly to a solution of (d,l)-Cbz-.alpha.-phosphonoglycine
trimethylester (1.1 mmole) in 4 ml of DCM at room temperature.
After 15 minutes, the mixture was cooled to -30.degree. C. and
compound 8.7 (1 mmole) added dropwise. The mixture was kept at
-30.degree. C. for 20 minutes and slowly allowed to warm to
0.degree. C. The solution was diluted with AcOEt and washed
consecutively with 1 N NaHSO.sub.4 and brine. The solution was
dried (Na.sub.2SO.sub.4), and solvent evaporated to provide crude
product. Purification of the crude product on chromatography (SiO2,
AcOEt/hexanes/DCM 3:3:1) to give product 8.8 (yield 72%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 2.97 (s, 3H), 3.86 (s, 3H), 5.08
(s, 2H), 6.78 (s, 1H), 7.34 (d, J=6.36 Hz, 5H), 7.50 (t, J=7.83 Hz,
1H), 7.72 (d, J=7.34 Hz, 1H), 7.85 (d, J=7.34 Hz, 1H), 8.04 (s,
1H). Olefinic proton in the minor trans isomer at 7.19 ppm (s, 1H),
ESI-MS (m/z): (M+H.sup.+) 346.
[0362] To the solution of 8.8 (1 mmole) in MeOH (20 mL, presparged
with nitrogen gas) in a glass pressure vessel was added chiral
catalyst
(+)-bis(2S,5S)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(1)t-
etrafluoroborate (0.01 mmole). The reactor was then pressurized
with H.sub.2 to 40 psi and shaking was continued at room
temperature for 17 hours. The solvent was evaporated. The residue
was dissolved in AcOEt and filtered through a plug of SiO.sub.2
with AcOEt. The filtrate was evaporated to provide the crude
product 8.9 (yield, 72%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
2.98 (s, 3H), 3.13 (dd, J=13.69, 6.36 Hz, 1H), 3.29 (m, 1H), 3.76
(s, 3H), 4.69 (m, 1H), 5.06 (m, 2H), 5.44 (d, J=6.85 Hz, 1H), 7.31
m, 5H), 7.41 (d, J=7.34 Hz, 1H, 7.47 (t, J=7.83 Hz, 1H), 7.72 (s,
1H), 7.82 (d, J=7.34 Hz, 1H), ESI-MS (m/z): (M+H.sup.+) 348.
[0363] The compound 8.9 was hydrogenated (Pd/C, MeOH,) with a
hydrogen balloon to afford compound 8.4 (yield 98%). ESI-MS (m/z):
(M+H.sup.+) 258.
EXAMPLE 9
[0364] This example describes the synthesis of
##STR00113##
which was prepared in according to Scheme 8 and the procedure
below.
##STR00114##
[0365] a) Compound 9.1 was made according to Example 1d-e except
that compound 8.4 was used instead of compound 1.3.
[0366] b) Compound 9 was made according to Example 3g except that
compound 9.1 was used instead of comported 3.7 and
2-hydroxycinnamic acid was used instead of compound 3.4. .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 7.92 (m, 2H), 7.81 (m, 1H), 7.68
(s, 1H) 7.58 (m, 2H), 7.28 (m, 2H), 7.18 (m, 1H), 6.84 (m, 2H),
5.07 (m, 1H), 4.80 and 4.88 (m, 2H), 3.96 (m, 2H), 3.42 (m, 1H),
3.15 (m, 1H), 3.08 (s, 3H), 2.71-2.91 (m, 2H) ppm; ESI-MS (m/z):
(M+H.sup.+) 617.10.
EXAMPLE E10
[0367] This example describes the synthesis of
##STR00115##
which was prepared according to Example 3g except that compound 9.1
was used instead of compound 3.7 and 2-fluorocinnamic acid was used
instead of compound 3.4. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
7.92 (s, 1H), 7.81 (m, 3H), 7.68 (m, 1H), 7.57 (m, 1H), 7.42 (m,
1H), 7.29 (m, 2H), 7.23 (m, 1H), 7.16 (m, 1H), 5.06 (m, 1H), 4.81
and 4.88 (m, 2H), 3.82 and 3.97 (m, 2H), 3.44 (m, 1H), 3.16 (m,
1H), 3.08 (s, 3H), 2.86 and 2.93 (m, 2H) ppm; ESI-MS (m/z):
(M+H.sup.+) 619.10.
EXAMPLE 11
[0368] This example describes the synthesis of
##STR00116##
which was prepared according to Example 3g except that compound 9.1
was used instead of compound 3.7 and 6-indazolecarboxylic acid was
used instead of compound 3.4. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.13 (s, 1H), 7.93 (m, 3H), 7.83 (m, 1H), 7.70 (m, 1H),
7.60 (m, 1H), 7.20 and 7.34 (m, 1H), 5.06 (m, 1H), 4.64 and 4.88
(m, 2H), 3.69 and 3.98 (m, 2H), 3.40 (m, 1H), 3.15 (m, 1H), 3.08
(s, 3H), 2.88 (m, 2H) ppm; ESI-MS (m/z): (M+H.sup.+) 615.15.
EXAMPLE 12
[0369] This example describes the synthesis of
##STR00117##
which was prepared according to Example 3g except for compound 9.1
was used instead of compound 3.7 and 2-indolecarboxylic acid was
used instead of compound 3.4. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 7.93 (s, 1H), 7.83 (m, 2H), 7.72 (m, 1H), 7.83 (m, 1H),
7.57 (m, 1H), 7.45 (m, 1H), 7.27 (s, 1H), 7.20 (m, 1H), 7.07 (m,
1H), 6.93 (s, 1H), 5.08 (m, 1H), 4.88 (m, 2H), 4.07 (m 2H), 3.46
(m, 1H), 3.15 (m, 1H), 3.08 (s, 3H), 2.96 (m, 2H) ppm; ESI-MS
(m/z): (M+H.sup.+) 614.10.
EXAMPLE 13
[0370] This example describes the synthesis of
##STR00118##
which was prepared according to Example 3g except that compound 9.1
was used instead of compound 3.7 and 2-quinolinecarboxylic acid was
used instead of compound 3.4. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.51 (m, 1H), 8.08 (m, 1H), 8.01 (m, 1H), 7.94 (m, 1H),
7.84 (m, 2H), 7.70 (m, 3H), 7.58 (m, 1H), 7.36 and 7.04 (m, 1H),
5.07 (m, 1H), 4.78 and 4.95 (m, 2H), 3.79 and 4.08 (m, 2H), 3.45
(m, 1H), 3.17 (m, 1H), 3.09 (s, 3H), 2.97 (m, 2H) ppm; ESI-MS
(m/z): (M+H.sup.+) 626.10.
EXAMPLE 14
[0371] This example describes the synthesis of
##STR00119##
which was prepared according to Scheme 9 and the procedure
below.
##STR00120##
[0372] a) To a solution of 3-carboxylbenzenesulfonyl chloride (3.54
g, 16 mmol) in ethyl acetate (50 mL) at 0.degree. C. was added
concentrated ammonia (2.5 mL). The residue was neutralized with HCl
in dioance (20 mL), diluted with ethyl acetate (100 mL), dried with
anhydrous sodium sulfate and filtered. Concentration of the
filtrate yielded the title compound, which was used without
purification.
[0373] b) Crude compound 14.1 was dissolved in THF (50 mL), to it
was added borane (1.0 M in THF, 50 mL) over 20 minute period. After
the reaction was stirred at room temperature for 15 hours, the
reaction was diluted with brine (20 mL) and water (10 mL),
extracted with ethyl acetate (100 mL). The organic extract was
dried ever anhydrous sodium sulfate and filtered. Concentration of
the filtrate yielded the title compound, which was used without
further purification.
[0374] c) To crude compound 14.2 solution in DCM (100 mL) was added
activated 4A molecular sieve powder (8 g), pyridinium dichromate
(7.55 g, 20 mmol). After the reaction was stirred at room
temperature for 2 hours, the reaction mixture was filtered through
silica gel (50 g), rinsed with ethyl acetate. The residue after
concentration of the filtrate was purified by silca gel column with
30-50% ethyl acetate in hexane to give compound 14.3 (477 mg, 16% 3
steps). ESI-MS (m/z): (M+H.sup.+) 186.
[0375] d) Compound 14.4 was made according to Example 8e except
that compound 14.3 was used instead of compound 8.7. MS (ESI.sup.+)
m/z: 260 (M+H.sup.+).
[0376] e) Compound 14 was made according to Example 3g except that
compound 14.4 was used instead of compound 3.4. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 7.89 (s, 1H), 7.80 (s, 1H), 7.75 (m, 2H),
7.64 (s, 1H), 7.57 (d, 1H), 7.34 (d, 2H), 6.93 9s, 1H), 5.00 (m,
1H), 3.99 (m, 1H), 3.73 (m, 1H), 3.40 (dd, 1H), 3.12 (dd, 1H), 2.89
(m, 2H) ppm; ESI-MS (m/z): 616 (M+H.sup.+).
EXAMPLE 15
[0377] This example describes the synthesis of
##STR00121##
which was prepared according to Scheme 10 and the procedure
below.
##STR00122##
[0378] a) To a solution of 0.2 mol of furan in 200 mL of dry THF
was added 0.2 mol of n-BuLi (1.6 M in hexanes) at -78.degree. C.,
the resulting solution was stirred at room temperature for 4 hours.
Subsequently, the mixture was cooled to -78.degree. C. and treated
with 0.21 mol of dimethyl disulfide, and the mixture was stirred at
room temperature overnight, followed by adding 10 mL of saturated
aqueous NH4Cl. The mixture was concentrated at room temperature,
and the residue was diluted with 200 mL of saturated aqueous NH4Cl
and extracted with ether. The extract was then washed with brine
and dried with anhydrous Na2SO4. The solvent was removed, and the
residue was distilled to collect the fraction at 135-140.degree.
C./760 mmHg to give compound 15.1 in 55% yield. .sup.1H NMR (400
MHz, CD.sub.3Cl): .delta. 7.50 (s, 1H), 6.45 (m, 1H), 6.39 (s, 1H),
2.42 (s, 3H) ppm.
[0379] b) To a solution of 0.1 mol of compound 15.1 in 100 mL of
dry THF was added 0.1 mol of n-BuLi (1.6 M in hexanes) at
-78.degree. C., the resulting solution was stirred at room
temperature for 4 hours. Subsequently, the mixture was cooled to
-78.degree. C. and treated with 0.12 mol of dry DMF, and the
mixture was stirred at room temperature overnight. The reaction was
quenched by adding 10 mL of saturated aqueous NH.sub.4Cl, and the
mixture was concentrated. The residue was diluted with 100 mL of
brine and extracted with EtOAC. The extract was washed with brine
and dried with anhydrous Na.sub.2SO.sub.4. The solvent was removed
and the residue was purified to give the title compound in 65%
yield. .sup.1H NMR (400 MHz, CD.sub.3Cl): .delta. 9.52 (s, 1H),
7.24 (d, J=3.4 Hz, 1H), 6.42 (d, J=3.4 Hz, 1H), 2.60 (s, 3H) ppm;
ESI-MS (m/z): (M+H.sup.+) 143.1.
[0380] c) A mixture of 50 mmol of compound 15.2 and 120 mmol of
m-CPBA in 100 mL of CH.sub.2Cl.sub.2 was stirred at room
temperature overnight. The mixture was diluted with 150 mL of
CH.sub.2Cl.sub.2, and the mixture was washed with saturated aqueous
NaHCO.sub.3 for several times. The solution was then dried with
anhydrous Na.sub.2SO.sub.4 and concentrated. The residue was
purified to give compound 15.3 in 70% yield. .sup.1H NMR (400 MHz,
CD.sub.3Cl): .delta. 9.83 (s, 1H), 7.33 (m, 2H), 3.27 (s, 3H) ppm;
ESI-MS (m/z): (M+H.sup.+) 175.0.
[0381] d) Compound 15.4 was made according to Example 8e except
that compound 15.3 was used instead of 8.7. ESI-MS (m/z):
(M+H.sup.+) 248.1.
[0382] e) Compound 15 was made according to Example except that
compound 15.4 was used instead of 3.4. .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 7.92 (s, 1H), 7.76 (m, 1H), 7.67 (s, 1H), 7.34
(m, 1H), 7.13 (s, 1H), 6.69 (s, 1H), 6.49 (s, 1H), 5.11 (m, 1H),
4.73 and 4.88 (m, 2H), 3.76 and 4.02 (m, 2H), 3.46 (m, 1H), 3.30
(m, 1H), 3.17 (s, 3H), 2.94 (m, 2H) ppm; ESI-MS (m/z): (M+H.sup.+)
605.05.
EXAMPLE 16
[0383] This example describes the synthesis of
##STR00123##
which was prepared according to the procedure below.
[0384] To a solution of 0.2 mmol of compound 8.4 (Example 8c or 8e)
in 1 mmol of Et.sub.3N and 5 mL of dry CH.sub.2Cl.sub.2 was added
0.22 mmol of 2,6-dichlorobenzoyl chloride at 0.degree. C., the
resulting mixture was stirred at room temperature for 12 hours. The
solvent was removed and the residue was dried in vacuo.
Subsequently, the residue was treated with 0.8 mmol of
LiOH.H.sub.2O in 2 mL of THF and 0.5 mL of H.sub.2O. After stirring
at room temperature for 30 minutes, the reaction mixture was added
1.0 mL of 1.0N aq. HCl. The organic solvent was removed, and the
residue was diluted with 10 mL of brine. The mixture was extracted
with EtOAc and the extract was dried with anhydrous
Na.sub.2SO.sub.4. The solvent was removed and the residue was dried
in vacuo to give the desired compound in 65% yield. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 7.92 (s, 1H), 7.82 (d, J=6.85 Hz,
1H), 7.71 (d, J=6.85 Hz, 1H), 7.56 (t, J=7.82 Hz, 1H), 7.34 (m,
3H), 5.08 (dd, J=9.78, 4.89 Hz, 1H), 3.45 (dd, J=14.67, 4.89 Hz, 1
H), 3.14 (dd, J=14.67, 9.78 Hz, 1H), 3.08 (s, 3H) ppm; ESI-MS
(m/z): (M+H.sup.+) 416.00.
EXAMPLE 17
[0385] This example describes the synthesis of
##STR00124##
which was prepared according to the procedure basis.
[0386] Compound 6.1 (Example 6a, 0.2 mmol) in DCM (1 mL) was
treated with HCl in dioxane (4.0 M, 1 mL). After 1 hour, the
solvent was evaporated. The residue and 1 mmol of Et.sub.3N and 5
mL of dry CH.sub.2Cl.sub.2 was added 0.22 mmol of
2,6-dichlorobenzoyl chloride at 0.degree. C., the resulting mixture
was stirred at room temperature for 15 hours. The solvent was
removed and the residue was dried in vacuo. Subsequently, the
residue was treated with 0.8 mmol of LiOH.H.sub.2O in 2 mL of THF
and 0.5 mL of H.sub.2O. After stirring at room temperature for 30
minutes, the reaction mixture was added 1.0 mL of 1.0 N aqueous
HCl. The organic solvent was removed, and the residue was diluted
with 10 mL of brine. The mixture was extracted with EtOAc and the
extract was dried with anhydrous Na.sub.2SO.sub.4. The solvent was
removed and the residue was dried in vacuo to give the desired
compound.
EXAMPLE 18
[0387] This example describes the synthesis of
##STR00125##
which is prepared according to Scheme 11 and the procedure
below.
##STR00126## ##STR00127##
[0388] a) 1 equivalent of LiAlH.sub.4 (1.0M in THF) was added to a
0.degree. C. solution of 1 equivalent of composed ethyl
6-indazolecarboxylate (Batt, D. G., J. Med. Chem. 43; 41-58 (2000))
at -78.degree. C. The reaction was stirred at -78.degree. C. for
another 30 minutes, and then warmed to 0.degree. C. An aqueous
solution of 1 equivalent of 1M NaOH was added slowly. The resulting
slurry was filtered thru a plug of Celite and washed with a copious
amount of ethyl acetate. The combined organics were dried with
MgSO.sub.4 and concentrated in vacuo to provide the alcohol 18.1 in
high enough purity to be used without further purification.
[0389] 1.1 equivalent of Dess-Martin periodinane was added to 1
equivalent of 18.1 in dichloromethane. After stirring the reaction
for 3 hours at room temperature, the resulting precipitate was
removed by filtering thru a plug of celite. The celite plug was
washed with dichloromethane. The combined organics were
concentrated to provide the aldehyde 18.2 in high enough purity to
be used without further purification.
[0390] c) 2.1 equivalents of ethyl magnesium bromide (0.5M in THF)
were added to a pre-cooled solution containing 18.2 in THF at
0.degree. C. After 30 minutes, the reaction was warmed to room
temperature and stirred for an additional 2 hours. The resulting
reaction mixture was diluted with ethyl acetate and washed with
water. The organic layer was then dried with MgSO.sub.4, filtered,
and concentrated in vacuo. The residue was then purified on silica
gel column chromatography (gradient elution using ethyl acetate and
hexanes) to provide pure compound 18.3.
[0391] d) To a mixture of 4-amino-2,6-dichlorophenol (1 equivalent)
in 3:2 THF/H.sub.2O was added NaHCO.sub.3 (1.1 equivalent) and
Boc.sub.2O (1.1 equivalent), after stirring overnight, the reaction
was extracted with ether, and dried with MgSO.sub.4, filtered, and
concentrated in vacuo. The residue 18.4 was used without
purification.
[0392] e) To a solution of phenol 18.4 (1 equivalent) and
2,6-lutidine (2.2 equivalent) in DCM at -78.degree. C. was added
triflic anhydride (1.2 equivalent). After the reaction mixture was
gradually warmed to room temperature overnight, the reaction
mixture was diluted with ether, washed with water, dried with
MgSO.sub.4, filtered, and concentrated in vacuo. The residue was
then purified on silica gel column (gradient elution using ethyl
acetate and hexanes) to provide pure compound 18.5.
[0393] f) A mixture of 10 mmol of the triflate 18.5, 1.0 mmol of
dppp and 40 mmol of DIEA (in 100 mL of dry DMF and 50 mL of
anhydrous CH.sub.3OH was flushed with CO for 15 minutes, and then
1.0 mmol of Pd(OAc).sub.2 was added under the atmosphere of CO.
Subsequently, the resulting mixture was stirred at 70.degree. C.
overnight under an atmosphere of CO. The solvent was removed and
the residue was purified by column chromatography with 10-30% EtOAc
in hexane to give compound 18.6.
[0394] g) 1 equivalent of Boc-aniline 18.6 was dissolved carefully
in 6 M aqueous H.sub.2SO.sub.4, and the mixture was then cooled to
0.degree. C. To it was added slowly with vigorous stirring sodium
nitrite (1.1 equivalent in water), followed by sodium iodide (5
equivalent) in 1.5 hours. After the reaction was stirred at room
temperature for overnight, the reaction was diluted with ether,
washed with water, dried with MgSO.sub.4, filtered, and
concentrated in vacuo. The residue was then purified on silica gel
column (gradient elution using ethyl acetate and hexanes) to
provide pure compound 18.7.
[0395] h) 1 equivalent of iodide 18.7, 1 equivalent of alkyne 18.3,
0.05 equivalent of CuI, and 5 equivalents of triethylamine were
dissolved in benzene and the solution degassed by bubbling N.sub.2
thru a syringe needle and into the solution for 15 minutes. 0.05
equivalent of PdCl.sub.2 (dppf). DCM was added. After 4 hours, the
reaction was diluted with ethyl acetate and washed with water,
brine. The organic layer was then dried with MgSO.sub.4, filtered,
and concentrated in vacuo. The residue was then purified on silica
gel column chromatography (gradient elution using ethyl acetate and
hexanes) to provide pure compound 18.8.
[0396] i) 1 equivalent of 18.8 was dissolved in MeOH and 5%
Rh/Al.sub.2O.sub.3 (20 weight %) was added. Under reduced pressure,
oxygen was removed from the flask. The internal pressure was
restored by the addition of hydrogen gas delivered using a hydrogen
filled balloon. The reaction was stirred under an atmosphere of
hydrogen gas for 14 hours. The reaction was filtered thru a pad of
celite and concentrated in vacuo. The residue was then purified on
silica gel column chromatography (gradient elution using ethyl
acetate and hexanes) to provide pure compound 18.9.
[0397] j) 4 equivalents of LiI was added to 1 equivalent of
compound 18.9 in pyridine. The reaction was refluxed for 14 hours,
then allowed to cool to room temperature. The reaction was
concentrated and the resulting residue was partitioned between
ethyl acetate and water. The aqueous layer was extracted with ethyl
acetate. The combined organic layers were dried over MgSO.sub.4,
filtered, and concentrated. The residue was then purified on silica
gel column chromatography (gradient elution using ethyl acetate and
methanol) to provide pure compound 18.10.
[0398] 1 equivalent of compound 18.10, 1 equivalent of compound 8.4
(Example 8c or 8e), and 3 equivalents of DIEA were dissolved in
DMF. 1.1. equivalent of HATU was added. The reaction was stirred at
room temperature for 14 hours. The reaction mixture was diluted
with ethyl acetate and washed with water, brine. The combined
organics were dried with MgSO.sub.4, filtered, and concentrated.
The residue was then purified on silica gel column chromatography
(gradient elution using ethyl acetate and hexanes) to provide pure
intermediate ester. The ester was dissolved in methanol followed by
addition of 2 equivalents of 1M LiOH (aq). Upon completion, the
excess solvents were removed under reduced pressure and the
resulting acid was then purified by reverse phase HPLC to give pure
compound 18.
EXAMPLE 19
[0399] This example describes the synthesis of
##STR00128##
which was prepared by treating a solution of compound 18 (Example
18) in DCM/TFA (1:1 ratio) with triethylsilane (10 equivalent).
After LC-MS showed that the starting material was completely
consumed, the reaction was concentrated, and the residue was
purified by reverse phase HPLC to give the title compound.
EXAMPLE 20
[0400] This example describes the synthesis of
##STR00129##
which was prepared according to Scheme 12 and the procedure
below.
##STR00130## ##STR00131##
[0401] a) A solution of 1 equivalent of compound 18.7 (Example 18g)
in THF at -40.degree. C. was treated with 1.0 equivalent of
isopropylmagnesium bromide. After 0.5 hour, DMF (5 equivalents) was
added, and the reaction was warmed to room temperature over night.
The reaction mixture was diluted with ethyl acetate and washed with
water, brine. The organic layer was then dried with MgSO.sub.4,
filtered, and concentrated in vacuo. The residue was then purified
on silica gel column chromatography (gradient elution using ethyl
acetate and hexanes) to provide pure compound 20.1.
[0402] b) To a solution of aldehyde 20.1 (1 equivalent) in THF at
-78.degree. C. was added 2.1 equivalents of ethnyl magnesium
bromide (0.5 M in THF). After the reaction was warmed to room
temperature and stirred for an additional 2 hours. The resulting
reaction mixture was diluted with ethyl acetate and washed with
water. The organic layer was then dried with MgSO.sub.4, filtered,
and concentrated in vacuo. The residue was then purified on silica
gel column chromatography (gradient elution using ethyl acetate and
hexanes) to provide pure compound 20.2.
[0403] c) 1 equivalent of compound 20.2, 1 equivalent of
1-chloro-4-iodobenzene, 0.05 equivalent of CuI, and 5 equivalents
of triethylamine were dissolved in benzene and the solution
degassed by bubbling N.sub.2 thru a syringe needle and into the
solution for 15 minutes. 0.05 equivalent of PdCl.sub.2 (dppf). DCM
was added. After 4 hours, the reaction was diluted with ethyl
acetate and washed with water, brine. The organic layer was then
dried with MgSO.sub.4, filtered, and concentrated in vacuo. The
residue was then purified on silica gel column chromatography
(gradient elution using ethyl acetate and hexanes) to provide pure
compound 20.3.
[0404] d) 1 equivalent of compound 20.3 was dissolved in MeOH. 5%
Rh/Al.sub.2O.sub.3 was added. Under reduced pressure, oxygen was
removed from the flask. The internal pressure was restored by the
addition of hydrogen gas delivered using a hydrogen filled balloon.
The reaction was stirred under an atmosphere of hydrogen gas for 14
hours. The reaction was filtered thru a pad of celite and
concentrated in vacuo. The residue was then purified on silica gel
column chromatography (gradient elution using ethyl acetate and
hexanes) to provide pure compound 20.4.
[0405] 4 equivalents of LiI was added to 1 equivalent of compound
20.4 in pyridine. The reaction was refluxed for 14 hours, then
allowed to cool to room temperature. The reaction was concentrated
and the resulting residue was partitioned between ethyl acetate and
water. The aqueous layer was extracted with ethyl acetate. The
combined organic layers were dried over MgSO.sub.4, filtered, and
concentrated. The residue was then purified on silica gel column
chromatography (gradient elution using ethyl acetate and methanol)
to provide pure compound 20.5.
[0406] f) 1 equivalent of compound 20.5, 1 equivalent of compound
8.4 (Example 8c or 8e), and 3 equivalents of DIEA were dissolved in
DMF. 1.1 equivalent of HATU was added. The reaction was stirred at
room temperature for 14 hours. The reaction mixture was diluted
with ethyl acetate and washed with water, brine. The combined
organics were dried with MgSO.sub.4, filtered, and concentrated.
The residue was then purified on silica gel column chromatography
(gradient elution using ethyl acetate and hexanes) to provide pure
compound 20.6.
[0407] g) 1 equivalent of compound 20.6 was dissolved in methanol
followed by 2 equivalents of 1M LiOH (aq). Upon completion, the
excess solvents were removed under reduced pressure and the
resulting acid was then purified by reverse phase HPLC and
lyophilized to a pure powder compound 20.
EXAMPLE 21
[0408] This example describes the synthesis of
##STR00132##
which was prepared according to Scheme 13 and the procedure
below.
##STR00133##
[0409] a) A solution of bromine (461 .mu.L, 9.00 mmol) in methanol
(6.0 mL) was prepared at -78.degree. C. The cold solution was added
dropwise to a mixture of KCN (1.85 g, 19.0 mmol) in methanol (6.0
mL) under nitrogen at -78.degree. C. After 20 minutes, a solution
of pyrrole (0.624 mL, 9.00 mmol) in methanol (20 mL) was added. The
mixture was allowed to reach -40.degree. C. and stirred for 0.5
hour. It was then poured into ice-water and extracted with ether
(3.times.). The organic layers were combined and washed with
saturated sodium thiosulfate and brine. The organic phase was then
dried (Na.sub.2SO.sub.4) and concentrated. The crude residue was
purified by flash chromatography (0-50% ethyl acetate in hexane) to
yield 734 mg (66%) of compound 21.1 as a clear oil, R.sub.f 0.24
(10% ethyl acetate in hexane). .sup.1H NMR (CDCl.sub.3) .delta.
8.68 (br s, 1H), 7.03 (s, 1H), 6.69 (s, 1H), 6.32 (s, 1H), ES (+)
MS m/e=125 (M+H).sup.+.
[0410] b) To a solution of 21.1 (614 mg, 4.95 mmol) and iodomethane
(0.340 mL, 5.45 mmol) in methanol (40 mL) under nitrogen at
-10.degree. c. was added dropwise aqueous sodium hydroxide (9.90
mL, 1 M, 9.90 mmol). The mixture is warmed to ambient temperature
and stirred for 0.5 h. Excess sodium hydroxide is then quenched by
the addition of dry ice. The mixture is tiluted with brine and
extracted with dichloromethane (3.times.). The combined organic
layers are dried (Na.sub.2SO.sub.4) and concentrated to yield 504
mg (90%) of compound 21.2 as a dark oil. R.sub.f 0.35 (10% ethyl
acetate in hexane). .sup.1H NMR (CDCl.sub.3) .delta. 8.31 (br s,
1H), 6.84 (s, 1H), 6.38 (s, 1H), 6.24 (s, 1H), 2.36 (s, 3H).
[0411] c) To a 0.degree. C. solution of compound 21.2 (100 mg,
0.884 mmol) in methanol (4.0 mL) was added dropwise sodium
periodate (208 mg, 0.972 mmol) in water (4.0 mL). The mixture is
allowed to reach room temperature and after 15 minutes LC/MS and
TLC indicated complete disappearance of compound 21.2. The mixture
was then filtered, concentrated, and the residue was partitioned
between ethyl acetate and water. The aqueous layer was extracted
twice with ethyl acetate and the combined organic phases were
washed with brine, dried (Na.sub.2SO.sub.4) and concentrated to
yield 63 mg (55%) of compound 21.3 as a dark oil, R.sub.f 0.25
(ethyl acetate). .sup.1H NMR (CDCl.sub.3) .delta. 11.74 (br s, 1H),
7.00 (s, 1H), 6.65 (s, 1H), 6.20 (s, 1H), 3.03 (s, 3H), ES (+) MS
m/e=130 (M+H).sup.+.
[0412] d) To a solution of compound 21.3 (60 mg, 0.464 mmol) in
dichloromethane (2.0 mL) was added trifluoroacetic acid (1.0 mL).
After 15 minutes, LC/MS and TLC indicated complete consumption of
compound 21.3. The solvent was removed in vacuo and the residue was
dried under high vacuum to yield 60 mg (100%) of compound 21.4 as
an oil. R.sub.f 0.11 (ethyl acetate). .sup.1H NMR (CDCl.sub.3)
.delta. 9.16 (br s, 1H), 7.28 (s, 1H), 6.94 (s, 1H), 6.66 (s, 1H),
3.02 (s, 3H). ES (+) MS m/e=130 (M+H).sup.+.
[0413] c) To a mixture of compound 21.4 (60 mg, 0.464 mmol) and
Cs.sub.2CO.sub.3 (378 mg, 1.16 mmol) was added a solution of
compound 21.5 (Ferreira et al, Tetrahedon Letters, 39: 9575 (1998);
140 mg, 0.464 mmol) in acetonitrile. The resulting mixture was
stirred at 60.degree. C. until LC/MS and TLC indicated complete
consumption of the starting material (.about.1 hour). The mixture
was cooled to room temperature, diluted with ethyl acetate and
washed with water and brine. The organic layer was dried
(Na.sub.2SO.sub.4) and concentrated. The crude residue was purified
by flash chromatography (0-100% ethyl acetate in hexane) to yield
114 mg (57%) of compound 21.6 as a viscous oil, R.sub.f 0.31 (ethyl
acetate). .sup.1H NMR (CDCl.sub.3) .delta. 7.05 (s, 1H), 6.75 (s,
1H), 6.50 (s, 1H), 5.25 (m, 1H), 4.65 (m, 1H), 4.40 (m, 1H), 3.79
(s, 3H), 2.79 (s, 3H), 1.47 (s, 18H), ES (+) MS m/e=275
(M-Boc-t-Bu+2H).sup.+.
[0414] f) To a solution of compound 21.6 (114 mg, 0.265 mmol) in
dichloromethane (1.00 mL) is added mCPBA (89.0 mg, 0.397 mmol)
portionwise. After 5 minutes at room temperature, LC/MS and TLC
indicated complete disappearance of compound 21.6. The mixture was
filtered and concentrated. The crude residue was purified by flash
chromatography (0-50% ethyl acetate in hexane) to yield 89.0 mg
(75%) of compound 21.7 as a clear oil, R.sub.f 0.45 (50% ethyl
acetate in hexane). .sup.1H NMR (CDCl.sub.3) .delta. 7.22 (s, 1H),
6.69 (s, 1H), 6.50 (s, 1H), 5.27 (m, 1H), 4.65 (m, 1H), 4.45 (m,
1H), 3.79 (s, 3H), 305 (s, 3H), 1.48 (s, 18H). ES (+) MS m/e=247
(m-2 Boc+3H).sup.+.
[0415] g) To a solution of compound 21.7 (89.0 mg, 0.0.199 mmol) in
dichloromethane (0.50 mL) was added HCl (4.00 mL, 4.0 M in
dioxane). The resulting mixture was stirred at ambient temperature
until LC/MS indicated complete deprotection (.about.1 hour). The
mixture was concentrated and the residue was dried under
high-vacuum to yield 53 mg (100%) of compound 21.8 as white powder,
ES (+) MS m/e=247 (M+H).sup.+.
[0416] h) A mixture of compound 21.8 (53.0 mg, 0.199 mmol),
compound 4.1 (Example 4a, 77.0 mg, 0.199 mmol), HATU (79.0 mg,
0.209 mmol), and triethyl amine (0.111 mL, 0.796 mmol) in DMF (1.00
mL) was stirred at room temperature over night. The mixture was
then diluted with ethyl acetate and washed with 1.0 M aqueous HCl,
saturated NaHCO.sub.3, and brine. The organic layer was dried
(Na.sub.2SO.sub.4) and concentrated. The crude residue was purified
by flash chromatography (0-100% ethyl acetate in hexane) to yield
70.3 mg (58%) of compound 21.9 as a white solid, R.sub.f 0.16 (75%
ethyl acetate in hexane). .sup.1H NMR (CDCl.sub.3) .delta.
7.46-7.39 (m, 5H), 7.28 (s, 1H), 6.73 (s, 1H), 6.69 (br s, 1H),
6.48 (s, 1H), 5.13 (m, 1H), 4.83 (br s, 1H), 4.56 (m, 1H), 3.85 (s,
3H), 3.70 (m, 1H), 3.04 (s, 3H), 2.91 (br s, 2H), 2.81 (s, 2H). ES
(+) MS m/e=614 (M+H).sup.+.
[0417] i) To a solution of 21.9 (70.3 mg, 0.115 mmol) in THF (1.00
mL) was added LiOH (aqueous 1.0 M, 0.360 mL, 0.360 mmol). The
resulting mixture was stirred at room temperature until TLC and
LC/MS indicated complete hydrolysis (.about.0.5 hour). The reaction
was then quenched by the addition of 1.0 M aqueous HCl (0.400 mL)
and concentrated to dryness. The residue was taken up in
dimethylsulfoxide ("DMSO"; 4.0 mL) and purified by preparative
RP-HPLC. The fractions containing pure compound were consolidated
and concentrated. The residue was lyophilized under high-vacuum for
48 hours to yield 33.8 mg (49%) of compound 21 as a white powder.
.sup.1H NMR (CDCl.sub.3) .delta. 7.46-7.39 (m, 4H), 7.28 (m, 2H),
7.15 (br s, 1H), 6.77 (s, 1H), 6.38 (s, 1H), 5.74 br s, 2H), 5.04
(m, 1H), 4.83 (br s, 1H), 4.53 (m, 3H), 3.69 (m, 1H), 3.00 (s, 3H),
2.85 (br s, 2H). ES (+) MS m/e=600 (M+H).sup.+.
EXAMPLE 22
[0418] This example describes the synthesis of
##STR00134##
which was prepared according to Scheme 14 and the procedure
below.
##STR00135##
[0419] a) A solution of 5.0 g (28.2 mmol) of compound 22.1 (Plobeck
et al., J. Med. Chem. 43:3878-3894 (2000)) and sulfuryl chloride
(100 mmol each, added at the beginning of the reaction and after 15
hours) in acetic acid (50 mL) was refluxed for 36 hours. The off
white solid after concentration of the reaction mixture was rinsed
with ether, and to the resulting crude product was added DCM (50
mL), followed by BBr3 (1.0 M in DCM, 100 mL). After 6 hours, the
reaction mixture is concentrated, and water (50 mL) was carefully
added. The resulting precipitate is collected by suction filtration
and dried to give crude compound 22.2 in quantitative yield.
[0420] b) The crude compound 22.2 was dissolved in DCM/pyridine (50
mL/50 mL) and cooled to 0.degree. C. To it was slowly added triflic
anhydride (42.3 mmol), and the reaction was then stirred at room
temperature for 6 hours. The reaction mixture was partitioned
between ethyl acetate (200 mL) and water (50 mL), and the organic
layer was washed with water (30 mL, twice) and brine, dried over
anhydrous sodium sulfate and filtered. The residue after
concentration of the filtrate was purified by silica gel column
chromatography to give compound compound 22.3 (3.16 g, 32%). ESI-MS
(m/z): (M+H.sup.+) 364/366.
[0421] c) Carbon monoxide gas was bubbled through a mixture of
compound 22.3 (581 mg, 1.6 mmol), BiNAP (0.2 mmol), palladium
acetate (0.2 mmol), triethylamine (1 mL), anhydrous methanol (3 mL)
and anhydrous DMF (3 mL) for 10 min, then the reaction was heated
at 65.degree. C. under a carbon monoxide balloon for 15 hours. The
reaction mixture was partitioned between ethyl acetate (100 mL) and
water (25 mL), and the organic layer was washed with water (25 mL,
twice) and brine, dried over anhydrous magnesium sulfate and
filtered. The residue after concentration of the filtrate was
purified by silica gel column to give compound 22.4 (213 mg, 49%).
ESI-MS (m/z): (M+H.sup.+) 274/276.
[0422] d) To a suspension of sodium hydride (24 mg, 1.0 mmol) in
THF (2 mL) was added compound 22.4 (63 mg, 0.23 mmol),
4-chlorobenzyl chloride (55 mg, 0.34 mmol) and tetrabutylammonium
iodide (10 mg). After 6 hours, the reaction was diluted with ether
and filtered through silica gel, rinsed with ether. The residue
after concentration of the filtrate was purified by silica gel
column to give compound 22.5 (50 mg, 55%). ESI-MS (m/z):
(M+H.sup.+) 398/400.
[0423] e) A mixture of compound 22.5 (50 mg) and 1 mmol of LiI in 2
mL of pyridine was reflux overnight. The reaction was concentrated
in vacuo and the residue was further dried by high vacuum for 2
hours. The resulting crude compound 22.6 was used without further
purification. ESI-MS (m/z): (M+1), 384.
[0424] f) Compound 22 was prepared according to Example 3g except
that compound 22.6 was used instead of compound 3.7 (yield: 82%).
.sup.1H NMR (400 MHz, dmso-d.sub.6): 9.12 (d, 1H), 8.54 (t, 1H),
7.90 (s, 1H), 7.77 (dd, 1H), 7.72 (dd, 1H), 7.42 (d, 2H), 7.35 (d,
2H), 7.16 (dd, 1H), 4.77 (m, 1H), 4.70 (s, 2H), 3.64 (m, 2H), 3.53
(t, 2H), 3.01 (t, 2H) ppm. ESI-MS (m/z): (M+H.sup.+) 580.
EXAMPLE 23
[0425] This example describes the synthesis of
##STR00136##
which was prepared according to Scheme 15 and the procedure
below.
##STR00137##
[0426] a) To a solution of Trit-Ser-Ome (compound 23.1, 10 mmol)
and triethylaminie in DCM (40 mL) was added slowly methanesulfonyl
chloride (11 mml), after 12 hours, the reaction was extracted with
ether (100 mL), washed with water, dried over anhydrous magnesium
sulfate and filtered. Concentration of the filtrate gave compound
23.2, which was used without further purification.
[0427] b) Solution of the crude compound 23.2, sodium azide (20
mmol) in DMF was stirred for 15 hours. The reaction was extracted
with ether (100 mL), washed with water, dried over anhydrous
magnesium sulfate and filtered. The residue after concentration of
the filtrate was purified by column, eluting with 0-20% ethyl
acetate in hexane to give compound 23.3.
[0428] A mixture of 1 mmol of compound 23.3, 1.5 mmol of
cyclopropylacetylene, 0.02 mmol of CuI, and 0.02 mmol of Et3N in 6
mL of CH.sub.3CN was stirred at room temperature overnight. The
solvent was removed and the residue was purified to give compound
23.4 in 65% yield. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 7.80
(s, 1H), 7.29-7.31 (m, 6H), 7.15-7.23 (m, 9H), 4.49 (m, 2H), 3.73
(m, 1H), 3.16 (s, 3H), 1.99 (m, 1H), 0.99 (m, 2H), 0.80 (m, 2H),
ppm; ESI-MS (m/z): (M+H.sup.+) 453.15.
[0429] d) A mixture of 0.5 mmol of compound 23.4 in 2 mL of 4.0 N
HCl in dioxane was stirred at room temperature for 1 hours. The
solvent was removed and the residue was diluted with 10 mL of
water. The mixture was extracted with ether for 3 times, and the
aqueous phase was dried with lyophilizer to give compound 23.5 in
quantitative yield. ESI-MS (m/z): (M+H.sup.+) 212.15.
[0430] e) Compound 23 was prepared according to Example 3g except
that compound 4.4 was used instead of compound 3.7 and compound
23.5 was used instead of compound 3.4 .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 7.74 (s, 1H), 7.33 and 7.49 (m, 5H), 5.25 (m,
1H), 4.63-4.92 (m, 4H), 3.99 and 3.68 (m, 2H), 2.89 (m, 2H), 1.91
(m, 1H), 0.95 (m, 2H), 0.75 (m, 2H), ppm; ESI-MS (m/z): (M+H.sup.+)
562.10.
EXAMPLE 24
[0431] This example describes the synthesis of
##STR00138##
which was prepared according to Scheme 16 and the procedure
below.
##STR00139##
[0432] a) To a solution of 50 mmol of 1-bromo-3,5-difluorobenzene
in 100 mL of dry DMF was added 50 mmol of NaSCH3 at 0.degree. C.,
the resulting mixture was stirred at room temperature overnight and
treated with 10 mL of saturated aqueous NH.sub.4Cl. The mixture was
diluted with 1 L of water, extracted with hexane for several times.
The extract was washed with water and dried with anhydrous
Na.sub.2SO.sub.4. The solvent was removed and the residue was
purified to give compound 24.2 in 90% yield. .sup.1H NMR (400 MHz,
CD.sub.3Cl): .delta. 7.15 (s, 1H), 7.02 (d, J=8.3 Hz, 1H), 6.89 (d,
J=9.2 Hz, 1H), 2.50 (s, 3H) ppm.
[0433] b) A mixture of 40 mmol of compound 24.2 and 42 mmol of CuCN
in 100 mL of dry DMF was stirred at 150.degree. C. overnight. The
mixture was diluted with 500 mL of water, extracted with ether for
several times. The mixture was then washed with diluted aqueous
NH.sub.4OH and water and dried with anhydrous Na.sub.2SO.sub.4. The
solvent was removed; the residue was purified to give compound 24.3
in 50% yield. .sup.1H NMR (400 MHz, CD.sub.3Cl): .delta. 7.28 (s,
1H), 7.17 (d, J=9.2 Hz, 1H), 7.11 (d, J=6.8 Hz, 1H), 2.53 (s, 3H)
ppm; ESI-MS (m/z): (M+H.sup.+) 168.0.
[0434] c) A mixture of 20 mmol of compound 24.3 and 22 mmol of KOH
in 25 mL of EtOH and 25 mL of H.sub.2O was stirred at 60.degree. C.
for 30 minutes. The mixture was concentrated, the residue was
diluted with 100 mL of water, extracted with EtOAc for several
time. The extract was dried with anhydrous Na.sub.2SO.sub.4. The
solvent was removed and the residue was dried in vacuo to give a
crude product of compound 24.4. The crude was carried on the next
step without further purification. ESI-MS (m/z): (M+H.sup.-)
187.0.
[0435] d) To a solution of 20 mmol of compound 24.4 in 60 mL of dry
THF was added 24 mmol of LiAlH.sub.4 (1.0 M in THF) at 0.degree. C.
After stirring at room temperature overnight, the reaction mixture
was carefully added saturated aqueous NH.sub.4O. The resulting
suspension was then concentrated. The residue was dissolved in 200
mL of 1.0 N HCl and extracted with EtOAc for several times. The
extract was dried with anhydrous Na.sub.2SO.sub.4 and concentrated.
Subsequently, the residue was purified to give
5-fluoro-3-methylmercapto-1-benzeyl alcohol in 81% yield. .sup.1H
NMR (400 MHz, CD.sub.3Cl): .delta. 7.03 (s, 1H), 6.86 (m, 2H), 4.69
(s, 2H), 2.51 (s, 3H) ppm; ESI-MS (m/z): (M+H4H.sup.+) 173.1.
[0436] A mixture of 15 mmol of 5-fluoro-3-methylmercapto-1-benzeyl
alcohol and 20 mmol of SOCl.sub.2 in 30 mL of dry CH.sub.2Cl.sub.2
was refluxed for several hours. The mixture was then diluted with
100 mL of CH.sub.2Cl.sub.2, washed with saturated aqueous
NaHCO.sub.3, saturated aqueous NH.sub.4Cl, and brine and dried with
anhydrous Na.sub.2SO.sub.4. The solvent was removed and the residue
was purified to give compound 24.5 in 85% yield.
[0437] e) Compound 24.6 was prepared according to Example 3a-c
except that compound 24.5 was used instead of 3-methylthiobenzyl
chloride.
[0438] Compound 24 was prepared according to Example 3g except that
compound 24.6 was used instead of compound 3.7. .sup.1H NMR (400
MHz, Cd.sub.3OD): .delta. 7.92 (s, 1H), 7.80 (s, 1H), 7.75 (d,
J=7.83 Hz, 1H), 7.74 (s, 1H), 7.59 (d, J=7.34 Hz, 1H), 7.49 (d,
J=9.29 Hz, 1H), 7.07 and 7.35 (m, 2H), 6.96 (s, 1H), 5.10 (dd,
J=9.78, 4.40 Hz, 1H), 4.72 and 4.91 (m, 2H), 3.77 and 4.00 (m, 2H),
3.50 (dd, J=14.18, 4.40 Hz, 1H), 3.20 (m, 1H), 2.91 (m, 2H) ppm;
ESI-MS (m/z): (M+H.sup.+) 633.10.
EXAMPLE 25
[0439] This example describes the synthesis of
##STR00140##
which was prepared according to Scheme 17 and the procedure
below.
##STR00141##
[0440] a) To a solution of 5.0 mmol of compound 3.2 (Example 3a),
0.25 mmol of Pd(PPh.sub.2).sub.2Cl.sub.2, and 0.25 mmol of CuI in
15 mmol of degassed Et.sub.2N and 40 mL of degassed toluene was
added 5.5 mmol of isobutyryl chloride at 0.degree. C. The resulting
mixture was stirred at room temperature overnight and treated with
20 mL of saturated aqueous NaHCO.sub.3. The organic layer was
separated and dried with anhydrous Na.sub.2SO.sub.4. The solvent
was removed and the residue was purified by column chromatography
to give compound 25.1 in 80% yield. .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 4.38 (m, 1H), 3.74 (s, 3H), 2.91 (m, 2H), 2.61
(m, 1H), 1.44 (s, 9H), 1.14 (d, J=6.85 Hz, 6H) ppm; ESI-MS (m/z):
(M+H.sup.+) 320.1.
[0441] b) To a solution of 1.0 mmol of compound 25.1 in 3 mL of
CH.sub.3OH was added 1.0 mmol of NH.sub.2NH.sub.2 at 0.degree. C.,
the resulting mixture was stirred for another 30 minutes. The
solvent was removed, and the residue was purified give compound
25.2 in 65% yield.
[0442] .sup.1H NMR (400 MHz, CD.sub.3OD): 6.28 and 5.95 (s, s, 1H),
4.39 and 4.19 (m, 1H), 3.73 (s, 3H), 2.91 (m, 2H), 2.70 and 2.98
(m, 1H), 1.43 and 1.45 (s,s, 9H), 1.12 and 1.27 (m, 6H), ppm;
ESI-MS (m/z): (M+H.sup.+) 312.20.
[0443] c) A mixture of 0.5 mmol of compound 25.2 in 4 mL of 4.0 N
HCl in dioxane was stirred at room temperature for 12 hours. The
solvent was removed and the residue was dried in vacuo to give
compound 25.3. ESI-MS (m/z): (M+H.sup.+) 212.10.
[0444] d) Compound 25 was prepared according to Example 3g except
that compound 4.4 was used instead of compound 3.7 and compound
25.3 was used instead of compound 3.4.
[0445] .sup.1H NMR (400 MHz, CD.sub.3OD): 7.15-7.54 (m, 5H), 6.38
(s, 1H), 5.06 (dd, J=9.78, 4.89 Hz, 1H), 4.66 and 4.88 (m, 2H),
4.01 and 3.71 (m, 2H), 3.41 (dd, J=15.41, 4.65 Hz, 1H), 3.18 (dd,
J=15.16, 4.65 Hz, 1H), 3.07 (m, 1H), 2.92 (m, 2H), 1.32 (d, J=7.34
Hz, 6H) ppm; ESI-MS (m/z): (M+H.sup.+) 563.10.
EXAMPLE 26
[0446] This example describes the synthesis of
##STR00142##
which was synthesized according Scheme 18 and the procedure
below.
##STR00143##
[0447] a) A solution of compound 26.1 (12.4 g, 75 mmol) and
NH.sub.4BF.sub.4 (10.5 g, 100 mmol) in water (85 mL) was treated
with concentrated HCl (15 mL), cooled to 3.degree. C., and treated
dropwise over 25 minutes with a solution of NaNO.sub.2 (5.18 g, 75
mmol) in water (12 mL). The resulting thick slurry was stirred for
35 minutes, and the solid was collected by filtration, rinsed with
water, methanol, and ether, and dried under N.sub.2. The solid was
added in one portion to a stirred mixture of KOAc (8.1 g, 82.5
mmol) and 19-crown-6 (0.5 g, 1.9 mmol) in chloroform (170 mL).
After 70 minutes, water (170 mL) was added, and the layers were
separated. The aqueous phase was extracted with chloroform, and the
combined organic layers were rinsed with water, dried, and
concentrated. The residue was triturated with hexane and the
resulting solid isolated by filtration to provide 8.85 g (67%
yield) of compound 26.2 as a dull yellow powder. .sup.1H NMR
(CDCl.sub.3) .delta. 3.96 (s, 3H), 7.80-7.85 (m, 2H), 8.14 (s, 1H),
8.27 (s, 1H); ES (+) MS m/e=177 (M+1).
[0448] b) A solution of compound 26.2 (5.0 g, 28.4 mmol) in THF (56
mL) was treated with LiOH (21 mL of a 2M aqueous solution, 42
mmol), and the reaction mixture is stirred at 50.degree. C. After 4
hours, the reaction mixture was cooled to room temperature and
diluted with water. The basic aqueous layer was rinsed with diethyl
ether, acidified to pH 3-4 by the addition of 1 M HCl, and
extracted with ethyl acetate. The aqueous layer was extracted
further with ethyl acetate, and the combined organic layers were
rinsed with brine, dried over MgSO.sub.4, and concentrated to
afford 4.0 g (87% yield) of compound 26.3. .sup.1H NMR (CD.sub.3OD)
.delta. 7.79-7.87 (m, 2H), 8.14 (s, 1H), 8.29 (s, 1H); ES (+) MS
m/e=163 (M+1).
[0449] c) A solution of compound 1.1 (7.5 g, 20.8 mmol) in DCM (30
mL) was treated with TFA (10 mL). After 1 hour, the reaction
mixture was concentrated to afford 7.8 g (100% yield) of compound
26.4. ES (+) MS m/e=261 (M+1).
[0450] d) A solution of compound 36.3 (7.8 g, 20.8 mmol), compound
26.4 (3.4 g, 20.8 mmol), 1-hydroxybenzotriazole hydrate ("HOBt",
3.5 g, 22.3 mmol), and diisopropylethylamine ("DIEA", 14 mL, 83.3
mmol) in DMF (100 mL) was treated with EDCI (4.4 g, 22.3 mmol).
After 2 h, the reaction mixture was treated with 1 M HCl and
extracted with ethyl acetate. The combined organic extracts were
rinsed with NaHCO3 (sat'd), rinsed with brine, rinsed with water,
dried over MgSO.sub.4, and concentrated to afford 8.4 g (99% yield)
of the title compound. ES (+) MS m/e=404 (M+1).
[0451] e) A solution of compound 26.5 (8.4 g, 20.8 mmol) in
pyridine (70 mL) was treated with lithium iodide (11.1 g, 83.1
mmol), and the reaction mixture was heated to 100.degree. C. After
16 hours, the reaction mixture was cooled to room temperature and
diluted with 1 M NaOH (aq). The basic aqueous layer was rinsed with
diethyl ether to remove most of the pyridine. The aqueous portion
was then carefully acidified with concentrated HCl to pH 3-4. The
resulting slurry was filtered. The precipitate was collected and
dissolved in THF, while the filtrate was extracted with ethyl
acetate. The THF and ethyl acetate solutions were combined, rinsed
with brine, dried over MgSO.sub.4, and concentrated to afford 7.1 g
(88% yield) of compound 26.6. ES (+) MS m/e=390 (M+1).
[0452] f) A solution of compound 26.6 (3.06 g, 7.83 mmol) and DIEA
(4/6 mL, 25.4 mmol) in dimethylformamide ("DMF") was treated with
HATU (3.06 g, 8.06 mmol), and the resulting mixture was stirred at
room temperature. After 20 minutes, the reaction mixture was
treated sequentially with HCl.H-DAP(Boc)-OMe (2.18 g, 8.59 mmol)
and N,N-dimethylaminopyridine ("DMAP", 0.58 g, 4.65 mmol). After
2.5 hours, the reaction was diluted with ethyl acetate, washed with
three portions of water, washed with one portion of brine, dried
over MgSO.sub.4, and concentrated. Flash column chromatography
afforded 3.91 g (84% yield) of compound 26.7. .sup.1H NMR (400 MHz,
chloroform-d) .delta.: 1.42 (s, 9H), 2.81 (s, 2H), 3.70 (m, 2H),
3.75 (2H), 3.81 (s, 3H), 4.82 (m, 21H), 4.99 (m, 1H), 7.2 (d, 2H),
7.59 (s, 1H), 7.81 (d, 1H), 8.10 (s, 1H), MS (API-ES.sup.+) m/z:
590.2 (M+H.sup.+). 534.1 (M-tButyl+H.sup.+), 490.1
(M-Boc+H.sup.+).
[0453] g) A solution of compound 26.7 (3.91 g, 6.62 mmol) in DCM
was treated with HCl (8.3 mL of a 4 M dioxane soln, 33.2 mmol), and
the resulting mixture was stirred at room temperature. After 2
hours, the reaction mixture was concentrated to afford the HCl
salt, which was used without further purification. The HCl salt
(3.94 g, 6.99 mmol) and triethylamine ("TEA", 3.0 mL, 21.5 mmol) in
methanol was treated with N-cyanoimido-S,S-dimethyl-dithiocarbonate
(1.37 g, 8.43 mmol), and the reaction mixture was stirred at
50.degree. C. After 3.5 hours, the reaction mixture was
concentrated to remove most of the methanol, diluted with ethyl
acetate, washed with two portions of water, washed with one portion
of brine, dried over MgSO.sub.4, and concentrated. Flash column
chromatography afforded 3.27 g (80% yield) of compound 26.8 (MS
(API-ES.sup.+), m/z: 588.2 (M+H.sup.+). A solution of compound 26.8
(0.10 mmol) was made in 4:1 methanol/dichloroethane ("DCE", 2.5
mL), and treated sequentially with 2 M methanolic ammonia (0.25
mmol) and silver nitrate (0.10 mmol). Use reaction mixture was
stirred as 50.degree. C. until complete conversion is observed
through monitoring by LCMS. The reaction mixture was then filtered
through celite, and KOH (0.1 mL of a 2 M methanolic soln, 0.2 mmol)
was added. The reaction mixture was stirred once again at
50.degree. C. After 2-4 hours the reaction mixture was directly
subjected to preparatory HPLC purification to afford compound
26.
EXAMPLE 27
[0454] This example describes the synthesis of
##STR00144##
where R.sup.A and R.sup.B are each independently hydrogen,
aliphatic, aromatic, heteroaromatic, or together form a cyclic
moiety. These compounds are made according to the procedure of
Example 26 except that a substituted amine of the formula
HNR.sup.AR.sup.B is used instead of ammonia in step g. Illustrative
examples of substituted amines and the resulting compounds are
shown in Table 1.
TABLE-US-00001 TABLE 1 HNR.sup.AR.sup.B Compound ##STR00145##
##STR00146## ##STR00147## ##STR00148## ##STR00149## ##STR00150##
##STR00151## ##STR00152## ##STR00153## ##STR00154## ##STR00155##
##STR00156## ##STR00157## ##STR00158## ##STR00159## ##STR00160##
##STR00161## ##STR00162## ##STR00163## ##STR00164## ##STR00165##
##STR00166##
EXAMPLE 28
[0455] This example describes the synthesis of
##STR00167##
which is made according to Scheme 19 and the procedure below.
##STR00168##
[0456] a) Compound 28.4 is prepared from 28.1 in three chemical
steps, following the procedure published in Okada, T. et al Chem.
Phar. Bull. 1993, 41(1), 126-131; Frigola, J. et al J. Med. Chem.
1993, 36(7), 801-810 as shown above. A solution of commercially
available 28.1 in DCM is treated with trifluoromethanesulfonyl
chloride in the presence of base to provide 36.2. Next, this
product is dissolved in dimethoxyethane ("DME"), and the mesylate
moiety is displaced by dimethylamine. Finally, Pd/C-catalyzed
hydrogenolysis in MeOH at 45 PSI H.sub.2 (g) affords compound
28.4.
[0457] b) Compound 28 is synthesized according to the procedure of
Example 26 except 3-(dimethylamino)cyclobutanol (35.1) is used
instead of ammoniua in step g.
EXAMPLE 29
[0458] This example describes the synthesis of
##STR00169##
which is made according to Scheme 20 and the procedure below.
##STR00170##
[0459] a) To a solution of benzyl-3-pyrroline-1-carboxylate
(compound 29.1, 10 mmol) in THF (15 mL) was added N-methyl
morphline (22 mmol) and O.sub.8O.sub.4 (2 mL of a 2.5 wt % in
t-BuOH), and the resulting mixture was stirred at room temperature
overnight. The solvent was removed; the residue was dissolved in
EtOAc (100 mL), washed with dilute aq. Na.sub.2SO.sub.3, sat, aq.
NH.sub.4Cl, and brine, and dried with anhydrous Na.sub.2SO.sub.4.
The solvent was removed and the residue was purified by column
chromatography to give compound 29.2 in 55% yield. EIMS (m/z):
calcd. for C.sub.12H.sub.13NO.sub.4 (M.sup.+)+Na 260.1, found
260.1; .sup.1H NMR (CD.sub.3OD, 400 MHz): .delta. 7.31-7.38 (m,
5H), 5.13 (s, 2H), 4.17 (m, 2H), 3.58 (m, 2H), 3.34 (m, 2H)
ppm.
[0460] b) A mixture of compound 29.2 (1.0 mmol) and 10% Pd/C (0.1
mmol) in methanol (5 mL) is stirred at room temperature for several
hours under an atmosphere of H.sub.2. The reaction mixture is
filtered, the filtrate is concentrated, and the residue is dried in
vacuo to give compound 29.3.
[0461] c) Compound 29 is synthesized according to the procedure of
Example 26 except that (3R, 4S)-(dihydroxy)pyrrolidine (29.3) is
used instead of ammonia in step g.
EXAMPLE 30
[0462] This example describes the synthesis of
##STR00171##
which was prepared according to Scheme 21 and the procedure
below.
##STR00172##
[0463] a) A mixture of (3R, 4R)-benzyl-3,4-pyrrolidindiol (compound
30.1, 1 mmol) and 20% Pd(OH).sub.2/C (0.1 mmol) in methanol (10 mL)
is shaken at room temperature for several hours under 45 psi of
H.sub.2. (g). The reaction mixture is filtered, the filtrate is
concentrated, and the residue is dried in vacuo to give compound
30.2.
[0464] b) Compound 30 is synthesized according to the procedure of
Example 26 except that compound 30.2 is used instead of ammonia in
step g.
EXAMPLE 31
[0465] This example describes the synthesis of
##STR00173##
which was prepared according to Scheme 22 and the procedure
below.
##STR00174##
[0466] a) A mixture of commercially available benzyl
3-pyrroline-1-carboxylate (compound 28.1, 10 mmol) and m.CPBA (12
mmol) in DCM (50 mL) was stirred at room temperature overnight. The
reaction mixture was diluted with DCM (100 mL) and washed
sequentially with sat. aq. Na.sub.2SO.sub.3, and brine. The organic
layer was dried with anhydrous Na.sub.2SO.sub.4 and then
concentrated. The residue was purified by chromatography to give
compound 31.1 in 80% yield. EIMS (m/z): calcd. for
C.sub.12H.sub.13NO.sub.3 (M.sup.+)+Na 242.1, found 242.1; .sup.1H
NMR (CDCl.sub.3, 400 MHz): .delta. 7.36-7.37 (m, 5H), 5.13 (s, 2H),
3.89 (m, 2H), 3.70 (m, 2H), 3.41 (m, 2H), ppm.
[0467] b) A mixture of compound 31.1 (5 mmol) in conc. aq. NH.sub.3
(20 mL) is stirred at 65.degree. C. overnight. The reaction mixture
was concentrated and dried in vacuo to give compound 31.2. This
material is used without further purification.
[0468] c) A solution of compound 31.2 (10 mmol) and Et.sub.3N (20
mmol) in dry THF (100 mL) at -20.degree. C. is treated dropwise
with TFAA (10 mmol) over 1 hour. After 1 h, the reaction mixture is
quenched with sat. aq. NH.sub.4Cl (1 mL). The solvent is removed
and the residue is dissolved in DCM (100 mL). The mixture is
subsequently washed sequentially with sat. aq. NH.sub.4Cl, sat. aq.
NaHCO.sub.3, and brine. The organic layer is dried with anhydrous
Na.sub.2SO.sub.4, the solvent was removed, and the residue is
purified by chromatography to afford compound 31.3.
[0469] d) A solution of compound 31.3 (5 mmol) and Et.sub.3N (10
mmol) dry DCM (20 mL) at 0.degree. C. is treated dropwise with MsCl
(5.5 mmol), and the mixture is allowed to come gradually to room
temperature. After 1 hour at room temperature, the reaction mixture
containing in situ generated 31.4 is treated with DBU (30 mmol),
and the resulting mixture is stirred at for several hours. The
solvent is removed, and the residue is purified by chromatography
to afford compound 31.5
[0470] e) A mixture of compound 31.5 (3 mmol) and K.sub.2CO.sub.3
(6 mmol) in 2/1 (v/v) MeOH/H.sub.2O (15 mL) is stirred at room
temperature. After 24 h, the solvent is removed; the residue is
treated with sat aq. NaHCO.sub.3 (20 mL), and the mixture is
extracted with DCM several times. The extract is dried with
Na.sub.2CO.sub.3-x, the solvent is removed, and the residue is
purified by chromatography to afford compound 31.6.
[0471] f) A mixture of compound 31.6 (2 mmol), NaHCO.sub.3 (3
mmol), and Boc.sub.2O (2.2 mmol) in 1:1 1,4-dioxane/water (20 mL)
is stirred at room temperature for several hours. The mixture is
diluted with brine (50 mL) and extracted with EtOAc several times.
The combined extracts are washed with brine, dried with anhydrous
Na.sub.2SO.sub.4, and concentrated. The residue is purified by
chromatography to give the N-Boc protected intermediate. A mixture
of this intermediate (1 mmol) and 10% Pd/C (0.1 mmol) in MeOH (5
mL) is stirred at room temperature for several hours under an
atmosphere of H.sub.2 (g). The reaction mixture is filtered, the
filtrate is concentrated, and the residue is dried in vacuo to
afford compound 31.7.
[0472] g) Compound 31 is prepared according to Example 26g except
that compound 31.7 is used instead of ammonia.
EXAMPLE 32
[0473] This example describes the synthesis of
##STR00175##
which is prepared according to Scheme 23 and the procedure
below.
##STR00176##
[0474] a) A mixture of compound 31.2 (2 mmol), NaHCO.sub.3 (3
mmol), and Boc.sub.2O (2.2 mmol) in 1:1 1,4-dioxane/water (20 mL)
is stirred at room temperature for several hours. The mixture is
diluted with brine (50 mL) and extracted with EtOAc several times.
The combined extracts are washed with brine, dried with anhydrous
Na.sub.2SO.sub.4, and concentrated. The residue is purified by
chromatography to afford compound 32.3.
[0475] b) A mixture of compound 32.3 (1 mmol) and 10% Pd/C (0.1
mmol) in MeOH (5 mL) is stirred at room temperature for several
hours under an atmosphere of H.sub.2 (g). The reaction mixture is
filtered, the filtrate is concentrated, and the residue is dried in
vacuo to afford compound 32.4.
[0476] c) Compound 32 is prepared according to Example 26g except
that compound 32.4 is used instead of ammonia.
EXAMPLE 33
[0477] This example describes the synthesis of
##STR00177##
which is prepared according to Scheme 24 and the procedure
below.
##STR00178##
[0478] a) A solution of compound 33.1 (10 mmol) and DIEA (25 mmol)
in DCM (20 mL) at 0.degree. C. is treated dropwise with benzyl
chloroformate (10 mmol), and the reaction mixture is allowed to
come to room temperature. After 2 h at RT, the reaction mixture is
diluted with ethyl acetate (100 mL), rinsed with 1 M HCl (50 mL),
rinsed with brine, dried over MgSO.sub.4, and concentrated to
afford compound 33.2.
[0479] b) A solution of compound 33.2 (10 mmol) and N-methyl
morpholine (22 mmol) in THF (15 mL) is treated with O.sub.8O.sub.4
(2 mL of a 2.5 wt % in t-BuOH), and the resulting mixture is
stirred at room temperature overnight. The solvent is removed. The
residue is dissolved in EtOAc (10 mL), washed with dilute aq.
Na.sub.2SO.sub.3, sat. aq. NH.sub.4Cl, and brine, and then dried
over anhydrous Na.sub.2SO.sub.4. The solvent is removed, and the
residue is purified by column chromatography to give the title
compound.
[0480] c) A mixture of compound 33.3 (1.0 mmol) and 10% Pd/C (0.1
mmol) in methanol (5 mL) is stirred at room temperature for several
hours under an atmosphere of H.sub.2. The reaction mixture is
filtered, the filtrate is concentrated, and the residue is dried in
vacuo to give compound 33.4.
[0481] d) Compound 33 is prepared according to Example 26g except
that compound 33.4 is used instead of ammonia.
EXAMPLE 34
[0482] This example describes the synthesis of
##STR00179##
which is prepared according to Scheme 25 and the procedure
below.
##STR00180##
[0483] a) A mixture of Tl(OAc) (17.6 g, 54.5 mmol) in dried acetic
acid (40 mL) is refluxed with stirring for 1 hour and then cooled
to room temperature. Compound 32.2 (34.6 mmol) and iodine (8.46 g,
33.3 mmol) are added, and the resulting suspension is heated to
reflux. After 9 hours, the reaction mixture is cooled to room
temperature, and the yellow TlI precipitate is removed by
filtration with ether rinses. The filtrate is concentrated, and the
residue is dissolved in ethyl acetate, dried ever MgSO.sub.4, and
reconcentrated to afford compound 34.1.
[0484] b) A mixture of 34.1 (1.0 mmol) and 10% Pd/C (0.1 mmol) in
methanol (5 mL) is stirred at room temperature for several hours
under an atmosphere of H.sub.2. The reaction mixture is filtered,
the filtrate is concentrated, and the residue is dried in vacuo to
give compound 34.2.
[0485] c) Compound 34 is prepared according to Example 26g except
that compound 34.2 is used instead of ammonia.
EXAMPLE 35
[0486] This example describes the synthesis of
##STR00181##
which is prepared according to Scheme 26 and the procedure
below.
##STR00182##
[0487] a) A mixture of compound 35.1 (10 mmol) in ethanol (20 mL)
is saturated with HCl (g) and stirred at room temperature
overnight. The solvent is removed, the residue is dissolved in DCM
(100 mL), the resulting solution is treated sequentially with TEA
(30 mmol) and BnBr (11 mmol), and the reaction mixture is heated to
reflux. After 12 h, the reaction mixture is cooled to room
temperature and concentrated. The residue is dissolved in EtOAc
(150 mL), washed with brine, and dried over anhydrous
Na.sub.2SO.sub.4. The solvent is removed and the residue is
purified by chromatography to afford compound 35.2.
[0488] b) A solution of LiBH.sub.4 (20 mmol) in dry THF (20 mL) at
room temperature is treated in a dropwise fashion with a solution
of compound 35.2 (5 mmol) in THF (5 mL). After stirring overnight,
the reaction mixture is quenched by adding several drops of water.
The mixture is concentrated, diluted with brine (50 mL), and
extracted several times with 9/1 (v/v) EtOAc/i-PrOH. The combined
extracts are dried over anhydrous Na.sub.2SO.sub.4, the solvent is
removed, and the residue is purified by chromatography to afford
compound 35.3.
[0489] c) A solution of compound 35.3 (2 mmol) and TEA (2.2 mmol)
in dry THF (10 mL) at -78.degree. C. is treated dropwise with
trifluoroacetic anhydride ("TFAA", 2.2 mmol). After several hours,
the mixture is treated with TEA (6 mmol), and the reaction mixture
is heated to reflux. The mixture then is concentrated, and the
residue is dissolved in THF (10 mL) and treated with water (2.5
mL). This mixture is treated with NaOH (10 mmol) with vigorous
stirring at room temperature for several hours. The solvent is
removed, and the residue is treated with sat. aq. NaHCO.sub.3 (20
mL) and extracted several times with 9/1 (v/v) EtOAc/i-PrOH. The
combined extracts are dried over anhydrous Na.sub.2SO.sub.4, the
solvent is removed, and the residue is purified by chromatography
to afford compound 35.4.
[0490] d) A mixture of compound 35.4 (1 mmol) and 20%
Pd(OH).sub.2/C (0.1 mmol) in methanol (10 mL) is shaken at room
temperature for several hours under 45 psi of H.sub.2. (g). The
reaction mixture is filtered, the filtrate is concentrated, and the
residue is dried in vacuo to give compound 35.5.
[0491] e) Compound 35 is prepared according to Example 26g except
that compound 35.5 is used instead of ammonia.
EXAMPLE 36
[0492] This example describes the synthesis of
##STR00183##
which was prepared according to Example 35 except that (2R,
4S)-4-hydroxyproline (trans-D-Hyp-OH) was used instead of compound
35.1.
EXAMPLE 37
[0493] This example describes the synthesis of
##STR00184##
which was prepared according to Example 35 except that (2S,
4R)-4-hydroxyproline (trans-L-Hyp-OH) was used instead of compound
35.1.
EXAMPLE 38
##STR00185##
[0494] which is prepared in according to Scheme 27 and the
procedure below.
##STR00186##
[0495] a) A solution of HCl-H-DAP(Boc)-OMe (10 mmol) and DIEA (11
mmol) in DCM (50 mL) at 0.degree. C. is treated dropwise with
benzoyl chloride (11 mmol). Over 3 h the reaction mixture is
allowed to warm to room temperature. The reaction mixture is
concentrated, and the residue is purified by chromatography. This
intermediate is treated with a solution of 4 M HCl in dioxane, and
the resulting mixture is stirred at room temperature. After 1 h,
the solvent is removed to afford compound 38.1, which is used
without further purification.
[0496] b) A solution of compound 38.1 (10 mmol) and DIEA (12 mmol)
in DCM (50 mL) at 0.degree. C. is treated dropwise with
p-nitrophenyl chloroformate (11 mmol), and the reaction mixture is
allowed to warm to room temperature. After 2 hours, the reaction
mixture is concentrated, and the residue is purified by
chromatography to afford compound 38.2.
[0497] c) A solution of compound 38.2 (10 mmol) and TEA (25 mmol)
in 1:1 DCE/DMF (10 mL) is treated with 2 M methanolic ammonia (18
mmol), and the mixture is heated to 40.degree. C. After 15 hours,
the reaction mixture is concentrated, and the residue is purified
by chromatography to afford compound 38.3.
[0498] d) A mixture of compound 38.3 (1.0 mmol) and 10% Pd/C (0.1
mmol) in methanol (10 mL) is taken at room temperature for several
hours under 45 psi of H.sub.2. (g). The reaction mixture is
filtered, the filtrate is concentrated, and the residue is dried in
vacuo to give compound 38.4.
[0499] e) A solution of compound 26.6 (8.0 mmol) and DIEA (25 mmol)
in DMF is treated with HATU (8.0 mmol), and the resulting mixture
was stirred at room temperature. After 20 minutes, the reaction
mixture is treated sequentially with compound 38.4 (8.6 mmol) and
DMAP (0.5 mmol), and the mixture is then heated to 60.degree. C.
After 2.5 hours, the reaction is diluted with ethyl acetate, washed
with three portions of water, washed with one portion of brine,
dried over MgSO.sub.4, and concentrated. Flash column
chromatography affords compound 38.5
[0500] f) A solution of compound 38.5 (0.15 mmol) in methanol (1
mL) was treated with 2 M methanolic KOH (0.45 mmol), and the
reaction mixture is heated to 50.degree. C. After 3 hours, the
reaction mixture is concentrated to dryness and the residue is
subjected to preparatory HPLC purification to afford compound
38.
EXAMPLE 39
[0501] This example described the synthesis of
##STR00187##
where R.sup.A and R.sup.B are each independently hydrogen,
aliphatic, aromatic, heteroaromatic, or together form a cyclic
moiety. These compounds are made according to the procedure in
Example 38 except that a substituted amine of the formula
HNR.sup.AR.sup.B is used instead of ammonia in step c. Illustrative
examples of substituted amines and the resulting compounds are
shown in Table 2.
TABLE-US-00002 TABLE 2 HNR.sup.AR.sup.B Compound ##STR00188##
##STR00189## ##STR00190## ##STR00191## ##STR00192## ##STR00193##
##STR00194## ##STR00195## ##STR00196## ##STR00197## ##STR00198##
##STR00199## ##STR00200## ##STR00201## ##STR00202## ##STR00203##
##STR00204## ##STR00205## ##STR00206## ##STR00207##
EXAMPLE 40
[0502] This example describes the synthesis of
##STR00208##
which is prepared according to Scheme 28 and the procedure
below.
##STR00209## ##STR00210##
[0503] a) Commercially available compound 40.1 (10 mmol) in THF (50
mL) is treated with sodium hydrosulfite (50 mmol) in water (20 mL).
After 8 hours at room temperature, the reaction is extracted with
ethyl acetate (100 mL), and the organic extract is washed with
water and brine, dried over anhydrous magnesium sulfate and
filtered to give the crude compound 40.2.
[0504] b) To a slurry of compound 40.2 (10 mmol), ammonium
tetrafluoroborate (12.5 mmol) in water (12 mL) is added
concentrated HCl (2 mL). The reaction is cooled to 0.degree. C.,
and to it is added sodium nitrite (10 mmol), After the reaction is
stirred for 1 hour at 0.degree. C., the solid is collected by
filtration, rinsed with methol, ether and dried under vacuum. The
resulting solid is added to a stirring solutionof HOAc (3 mL),
18-crown-6 (0.3 mmol) in chloroform (20 mL). After 1 hour, water
(10 mL) and DCM (20 mL) are added. The organic layer is separated,
dried by magnesium sulfate and filtered. The residue after
concentration of the filtrate is triturated with hexane to give
product 40.3.
[0505] c) Compound 40.4 was made according to the procedure for the
preparation of compound 6.1 except that R-3-(+)-pyrrolidinol was
used instead of pyrrolidine.
[0506] d) Compound 40.4 is desolved in DCM, and is treated with
triethylamine (1.5 eq) and acetic anhydride (1.2 eq). The resulting
solution is filtered through silica gel, concentrated. The residue
is then purified by silica gel column chromagraphy to yield
compound 40.5.
[0507] e) Compound 40.5 in DCM is treated with anhydrous 4 N HCl in
dioxane (2.0 eq). After starting material disappears, the reaction
is concentrated to give compound 40.6.
[0508] f) Compound 40.7 is made according to the procedure for the
preparation of compound 1.5 except that compound 40.6 is used
instead of 1.3.
[0509] g) Compound 40.8 is made according to the procedure for the
preparation of compound 1.6 except that compounds 40.7 and 40.3 are
used instead of compounds 1.5 and 1.11.
[0510] Compound 40 is made according to the procedure for the
preparation of compound 1 except that compound 40.8 is used instead
of 1.6.
EXAMPLE 41
[0511] This example describes the synthesis of
##STR00211##
which is prepared according to Scheme 29 and the procedure
below.
##STR00212##
[0512] Compound 41 is made according to the procedure for the
preparation of compound 3 except that compounds 18.10 and 40.6 are
used instead of 3.4 and 3.7. The enantiomerically pure compounds
are isolated using chiral column chromatography.
EXAMPLE 42
[0513] This example describes the synthesis of
##STR00213##
which is prepared according to Scheme 30 and the procedure
below.
##STR00214##
[0514] a) A solution of compound 18.7 (10 mmol),
1-ethoxy-1-ethenyltributyltin (10.5 mmol), Pd(PPh).sub.4 (0.5 mmol)
in dimethoxyethane (DME, 50 mL) is heated as 80.degree. C. until
compound 18.7 disappears. The reaction is cooled to room
temperature, and to it is added 4N aqueous HCl (5 mL). The reaction
is stirred for 3 hours and extracted with ether (80 mL). The
organic extract is washed with brine, dried with anhydrous
magnesium sulfate, filtered and concentrated. The residue is
purified by column chromatography to give compound 42.1.
[0515] b) A solution of compound 42.1 in THF at -78.degree. C. is
treated with LDA (2.0 eq). After 1 hour, a solution of compound
18.2 (1.0 eq) in THF is added to the dry ice cooled reaction. After
another 3 hours, saturated aqueous NH.sub.4Cl is added to the
reaction and the mixture is allowed to warm to room temperature.
The reaction mixture is partitioned between ethyl acetate and
water, and the organic layer is washed with water and brine, dried
with anhydrous magnesium sulfate and filtered. The residue after
concentration of the filtrate is purified by silica gel column to
give compound 42.2.
[0516] c) A solution of compound 42.2 in ethanol is treated with
sodium borohydride (2.0 eq). After 1 hour, the reaction mixture is
partitioned between ethyl acetate and water, and the organic layer
is washed brine, dried with anhydrous magnesium sulfate and
filtered. The residue after concentration of the filtrate is
purified by silica gel column to give compound 42.3.
[0517] d) A mixture of 42.3 LiI (3 eq) in pyridine is reflux
overnight. The solvent is removed and the residue is dissolved in
EtOAc. The resulting solution is then washed with saturated aqueous
NH.sub.4Cl and dried with anhydrous Na.sub.2SO.sub.4. The solvent
is removed and the residue is dried in vacuo to give a quantitative
yield of compound 42.4. The crude product was carried on the next
step without further purification.
[0518] e) Compound 42 is made according to the procedure for the
preparation of compound 3 except that compounds 42.4 and 40.6 are
used instead of 3.4 and 3.7. The enantiomerically pure compounds
are isolated using chiral column chromatography.
EXAMPLE 43
[0519] This example describes the synthesis of
##STR00215##
which is prepared according to Scheme 31 and the procedure
below.
##STR00216##
[0520] a) A solution of compound 18.2 in ethanol is treated with
hydroxylamine )1.05 eq). After 10 hours, the reaction is
concentrated and the residue is dried under vacuum to give compound
43.1.
[0521] b) A solution of 43.1 is hydrogenated with 20%
Pd(OH).sub.2/C as a catalyst at 45 psi of hydrogen to give compound
43.2.
[0522] c) A solution of commercially available 43.3 in carbon
tetrachloride is treated with N-chlorosuccinimide (NCS, 3 eq). The
reaction mixture is then diluted with ethyl acetate, washed with 1N
NaOH, water and brine, dried over anhydrous MgSO.sub.4 and
filtered. The crude product is recrystalized from hot ethanol to
give compound 43.4.
[0523] d) A solution of 43.4 in THF is treated with LiOH (2 eq, 2.0
N aqueous). After most starting material is consumed, the mixture
is then diluted with ethyl acetate, washed with saturated ammonium
chloride, water and brine, dried over anhydrous MgSO.sub.4 and
filtered. The crude product is recrystalized from hot ethanol to
give compound 43.5.
[0524] e) A solution of 43.5, 43.2 (1.1 eq) and EDC (1.0 eq) in DMF
is stirred for 10 hours at room temperature. The mixture is t hen
diluted with ethyl acetate, washed with saturated ammonium
chloride, water and brine, dried over anhydrous MgSO.sub.4 and
filtered. The crude product is then refluxed with formic acid until
LC-MS indicates the reaction is completed. Solvent is evaporated,
and the crude product is purified by silica gel column to give
compound 43.6.
[0525] f) A mixture of 43.6 LiI (3 eq) in pyridine is reflux
overnight. The solvent is removed and the residue is dissolved in
EtOAc. The resulting solution is then washed with saturated aqueous
NH.sub.4Cl and dried with anhydrous Na.sub.2SO.sub.4. The solvent
is removed and the residue is dried in vacuo to give a quantitative
yield of compound 43.7. The crude product was carried on the next
step without further purification.
[0526] g) Compound 43 is made according to the procedure for the
preparation of compound 3 except that compounds 43.7 and 40.6 are
used instead of 3.4 and 3.7.
[0527] Diversification
[0528] It will also be appreciated that each of the components used
in the synthesis of inventive compounds can be diversified either
before synthesis or alternatively after the construction of the
core structure of formula (I). As used herein, the term
"diversifying" or "diversify" means reacting an inventive compound
(I) or any of the precursor fragments (or any classes or subclasses
thereof) at one or more reactive sites to modify a functional
moiety or to add a functional moiety (e.g., nucleophilic addition
of a substrate). Described generally herein are a variety of
schemes to assist the reader in the synthesis of a variety of
compounds, either by diversification of the intermediate components
or by diversification of the core structures as described herein,
and classes and subclasses thereof. It will be appreciated that a
variety of diversification reactions can be employed to generate
compounds other than those described in the Exemplification herein.
As but a few examples, where a double bond is present in the
compound structure, epoxidation and aziridation can be conducted to
generate epoxide and aziridine derivatives of compounds described
herein. For additional guidance available in the art, the
practitioner is directed to "Advanced Organic Chemistry", March, J.
John Wiley & Sons, 2001, 5.sup.th ed., the entire contents of
which are hereby incorporated by reference.
[0529] 2) Biological Data:
[0530] As discussed below, LFA-ICAM interactions have been directly
implicated in numerous inflammatory disease states including, but
not limited to graft rejection, dermatitis, psoriasis, asthma and
rheumatoid arthritis. Thus, compounds capable of modulating
adhesion between intracellular adhesion molecules (e.g., ICAM-1, -2
and -3) and the leukocyte integrin family of receptors would be
useful in the development of novel therapeutics. Described below
are certain assays used for the determination of ICAM-1:LFA
Receptor binding, Human T-Cell Adhesion, and T-Cell proliferation
which are described in published PCT applications WO 99/49856 and
WO 02/05114, the entire contents of which are hereby incorporated
by reference. WO 99/49856 also describes the preparation and
purification of full-length LFA-1 from 293 cells, the preparation
of a plasmid for expression of a human ICAM-1 immunoadhesion, and
the generation of ICAM-1 immunoadhesion expressing 293 cell
line.
[0531] ICAM-1:LFA Receptor Binding Assay (Protein/Protein
Assay):
[0532] Competitive inhibition of the CD11a/CD18-ICAM-1 interaction
is quantitated by adding known amounts of inhibitors according to
the two protein/protein assay systems described below:
[0533] Forward Format LFA-1:ICAM-1 Assay (PPFF):
[0534] Purified full length recombinant human LFA-1 protein is
diluted to 2.5 .mu.g/ml in 0.02 M Hepes, 0.15M NaCl, and 1 mM
MnCl.sub.2 and 96-well plates (50 .mu.l/well) are coated overnight
at 4.degree. C. The plates are washed with wash buffer (0.05% Tween
in PBS) and blocked for 1 h at room temperature with 1% BSA in
0.02M Hepes, 0.15 M NaCl, and 1 mM MnCl.sub.2. Plates are washed.
50 .mu.l/well inhibitors, appropriately diluted in assay buffer
(0.5% BSA in 0.02M Hepes, 0.15M NaCl, and 1 mM MnCl.sub.2), are
added to a 2.times. final concentration and incubated for 1 h at
room temperature. 50 .mu.l/well of purified recombinant human 5
domain ICAM-1g, diluted to 50 ng/ml in assay buffer, is added and
incubated 2 h at room temperature. Plates are washed and bound
ICAM-1g is detected with Goat anti-HuIgG(Fc)-HRP for 1 h at room
temperature. Plates are washed and developed with 100 .mu.l/well
TMB substrate for 10-30' at room temperature. Colorimetric
development is stopped with 100 ul/well 1M H.sub.2PO.sub.4 and read
at 450 nM on a platereader.
[0535] An alternative protein/protein assay system below also
quantitates competitive inhibition of the CD11a/CD18-ICAM-1
interaction.
[0536] PLM2 Antibody Capture LFA-1:ICAM-1 Assay (PLM2)
[0537] A non-function blocking monoclonal antibody against human
CD18, PLM-2 (as described by Hildreth, et al., Molecular
Immunology, Vol. 26, No. 9, pp. 883-895, 1989), is diluted to 5
.mu.g/ml in PBS and 96-well flat-bottomed plates are coated with
100 .mu.l/well overnight at 4.degree. C. The plates are blocked
with 0.5% BSA in assay buffer (0.02 M Hepes, 0.15 M NaCl, and 1 mM
MnCl.sub.2) 1 h at room temperature. Plates are washed with 50 mM
Tris pH 7.50, 0.1M NaCl, 0.05% Tween 20 and 1 mM MnCl.sub.2.
Purified full-length recombinant human LFA-1 protein is diluted to
2 .mu.g/ml in assay buffer and 100 ml/well is added to plates and
incubated at 1 h at 37.degree. C. Plates are washed 3.times., 50
.mu.l/well inhibitors, appropriately diluted in assay buffer, are
added to a 2.times.final concentration and incubated for 30.degree.
C. at 37.degree. C. 50 .mu.l/well of purified recombinant human 5
domain ICAM-Ig, diluted to 161 ng/ml (for a final concentration of
80 ng/ml) in assay buffer, is added and incubated 2 h at 37.degree.
C. Plates are washed and bound ICAM-Ig is detected with Goat
anti-HuIgG(Fc)-HRP for 1 h at room temperature. Plates are washed
and developed with 100 .mu.l/well TMB substrate for 5-10' at room
temperature. Colorimetric development is stopped with 100
.mu.l/well 1M H.sub.3PO.sub.4 and read at 450 nM on a
platereader.
[0538] Human T-Cell Adhesion Assay (Cell Attachment Assay)
[0539] The T-cell adhesion assay is performed using a human
T-lymphoid cell line HuT 78. Goat anti-HuIgG(Fc) is diluted to 2
.mu.g/ml in PBS and 96-well plates are coated with 50 .mu.l/well at
37.degree. C. for 1 h. Plates are washed with PBS and blocked for 1
h at room temperature with 1% BSA in PBS. 5 domain ICAM-Ig is
diluted to 100 ng/ml in PBS and 50 .mu.l/well was added to the
plates O/N at 4.degree. C. HuT 78 cells are centrifuged at 100 g
and the cell pellet is treated with 5 mM EDTA for .about.5' at
37.degree. C. in a 5% CO.sub.2 incubator. Cells are washed in 0.14
M NaCl, 0.02 M Hepes, 0.2% glucose and 0.1 mM MnCl.sub.2 (assay
buffer) and centrifuged. The cells are resuspended in assay buffer
to 3.0.times.10.sup.6 c/ml. Inhibitors are diluted in assay buffer
to a 2.times.final concentration and pre-incubated with HuT78 cells
for 30.degree. at room temperature. 100 .mu.l/well of cells and
inihibitors are added to the plates and incubated at room
temperature for 1 h. 100 .mu.l/well PBS is added and the plates are
sealed and centrifuged inverted at 100 g for 5'. Unattached cells
are flicked out of the plate and excess PBS is blotted on a paper
towel. 60 .mu.l/well p-nitrophenyl n-acetyl-.beta.-D-glucosaminide
(0.257 g to 100 ml citrate buffer) is added to the plate and
incubated for 1.5 h at 37.degree. C. The enzyme reaction is stopped
with 90 .mu.l/well 50 mM glycine/5 mM EDTA and read on a
platereader at 405 nM. HUT 78 cell adhesion to 5dICAM-Ig is
measured using the p-nitrophenyl n-acetyl-.beta.-D-glucosaminide
method of Landegren, U. (1984), J. Immunol. Methods 57,
379-388.
[0540] T-Cell Proliferation Assay:
[0541] This assay is an in vitro model of lymphocyte proliferation
resulting from activation, induced by engagement of the T-cell
receptor and LFA-1, upon interaction with antigen presenting cells
(Springer, Nature 346: 425 (1990)).
[0542] Microtiter plates (Nunc 96 well ELISA certified) are
pre-coated overnight at 4.degree. C. with 50 .mu.l of 2 .mu.g/ml of
goat anti-human Fc(Caltag H10700) and 50 .mu.l of 0.07 .mu.g/ml
monoclonal antibody to CD3 (Immunotech 0178) in sterile PBS. The
next day coat solutions are aspirated. Plates are then washed twice
with PBS and 100 .mu.l of 17 ng/ml 5d-ICAM-1-IgG is added for 4
hours at 37.degree. C. Plates are washed twice with PBS prior to
addition of CD4+ T cells. Lymphocytes from peripheral blood are
separated from heparinized whole blood drawn from healthy donors.
An alternative method is to obtain whole blood from healthy donors
through leukophoresis. Blood is diluted 1:1 with saline, layered
and centrifuged 2500.times.g for 30 minutes on LSM (6.2 g Ficoll
and 9.4 g sodium diztrizoate per 100 ml) (Organon Technica, NJ).
Monocytes are depleted using a myeloid cell depletion reagent
method (Myeloclear, Cedarlane Labs, Hornby, Ontario, Canada). PBLs
are resuspended in 90% heat-inactivated Fetal Bovine serum and 10%
DMSO, aliquoted, and stored in liquid nitrogen. After thawing,
cells are resuspended in RPMI 1640 medium (Gibco, Grand Island,
N.Y.) supplemented with 10% heat-inactivated Fetal Bovine serum
(Intergen, Purchase, N.Y.), 1 mM sodium pyruvate, 3 mM L-glutamine,
1 mM nonessential amino acids, 500 .mu.g/ml penicillin, 50 .mu.g/ml
streptomycin, 50 .mu.g/ml gentamycin (Gibco).
[0543] Purification of CD4+ T cells are obtained by negative
selection method (Human CD4 Cell Recovery Column Kit #CL 110-5
Accurate). 100,000 purified CD4+ T cells (90% purity) per
microtiter plate well are cultured for 72 hours at 37.degree. C. in
5% CO.sub.2 in 100 ml of culture medium (RPMI 1640 (Gibco)
supplemented with 10% heat inactivated FBS (Intergen), 0.1 mM
non-essential amino acids, 1 nM Sodium Pyruvate, 100 units/ml
Penicillin, 100 .mu.g/ml Streptomycin, 50 .mu.g/ml Gentamicin, 10
mM Hepes and 2 mM Glutamine). Inhibitors are added to the plate at
the initiation of culture. Proliferative responds in these cultures
are measured by addition of 1 .mu.Ci/well titrated thymidine during
the last 6 hours before harvesting of cells. Incorporation of
radioactive label is measured by liquid scintillation counting
(Packard 96 well harvester and counter). Results are expressed in
counts per minute (cpm).
[0544] In Vitro Mixed Lymphocyte Culture Model:
[0545] The mixed lymphocyte culture model, which is an in vitro
model of transplantation (A. J. Cunningham, "Understanding
Immunology, Transplantation Immunology" pages 157-159 (1978)
examines the effects of various LFA-1 antagonists in both the
proliferative and effector arms of the human mixed lymphocyte
response.
[0546] Isolation of Cells: Mononuclear cells from peripheral blood
(PBMC) are separated from heparanized whole blood drawn from
healthy donors. Blood is diluted 1:1 with saline, layered, and
centrifuged at 2500.times.g for 30 minutes on LSM (6.2 g Ficoll and
9.4 g sodium diztrizoate per 100 ml) (Organon Technica, NJ). An
alternative method is to obtain whole blood from healthy donors
through leukophoresis. PBMCs are separated as above, resuspended in
90% heat inactivated Fetal Bovine serum and 10% DMSO, aliquoted and
stored in liquid nitrogen. After thawing, cells are resuspended in
RPMI 1640 medium (Gibco, Grand Island, N.Y.) supplemented with 10%
heat-inactivated Fetal Bovine serum (Intergen, Purchase, N.Y.), 1
mM sodium pyruvate, 3 mM L-glutamine, 1 mM nonessential amino
acids, 500 .mu.g/ml penicillin, 50 .mu.g/ml streptomycin, 50
.mu.g/ml gentamycin (Gibco).
[0547] Mixed Lymphocyte Response (MLR): One way human mixed
lymphocyte cultures are established are in 96-well flat-bottomed
microtiter plates. 1.5.times.10.sup.5 responder PBMCs are
co-cultured with an equal number of allogeneic irradiated (3000
rads for 3 minutes, 52 seconds stimulator PBMSc in 200 .mu.l of
complete medium. LFA-1 antagonists are added at the initiation of
cultures. Cultures are incubated at 37.degree. C. in 5% CO.sub.2
for 6 days, then pushed with 1 .mu.Ci/well of 3H-thymidine (6.7
Ci/mmol, NEN, Boston, Mass.) for 6 hours. Cultures are harvested on
a Packard cell harvester (Packard, Canberra, Canada). [.sup.3H] TdR
incorporation is measured by liquid scintillation counting. Results
are expressed as counts per minute (cpm).
* * * * *